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ABSTRACT 
 
 The methylcitrate cycle and glyoxylate bypass are two critical pathways of the 
central carbon metabolism of the human pathogen Mycobacterium tuberculosis (Mtb). 
Transcription of the key enzymes in these pathways is controlled by two paralogous 
local regulators, MtPrpR and MtRamB. No structure is available for these regulators or 
their homologs and the regulatory mechanisms are not well understood. In this study, we 
present the crystal structures of different forms of MtPrpR including two domains of 
unknown function. Our studies showed that MtPrpR is an iron-sulfur protein that binds 
to coenzyme A (CoA) and its derivatives. A single amino acid polymorphism in the CoA 
binding pocket enables the protein homologs to distinguish among different CoA 
derivatives. Our study suggested the methylcitrate cycle and glyoxylate bypass are 
regulated through a combination of feedforward and feedback mechanisms based on the 
CoA pool composition. 
 The ubiquitin-proteasome pathway plays a pivotal role in cellular protein 
breakdown. Dysregulation of proteolysis leads to various human diseases including 
cancer. Inhibiting the proteasome is a promising approach in cancer treatment. Several 
inhibitors targeting the 20S proteasome have been tested on humans and approved by the 
FDA as antitumor drugs. In this study, we characterized a fungal derived natural product 
compound with a [M+H]
+
 m/z value of 721.33 (designated Mz721). Mz721 
preferentially targets the trypsin- and chymotrypsin-like sites of the yeast 20S 
proteasome. The IC50 value for the trypsin-like site in particular is below five nanomolar. 
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The crystal structure of the yeast 20S proteasome in complex with Mz721 revealed that 
the inhibitor is structurally similar to the previously reported TMC-95 series natural 
products. It binds to all active sites in a non-covalent mode. Being cytotoxic against 
cancer cells, Mz721 is much less toxic than bortezomib, a first-in-class agent for 
multiple myeloma treatment, on the human dermal fibroblasts. As a result, Mz721 can 
act as a lead molecule to develop drugs that target the trypsin-like site of the 20S 
proteasome. 
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Da dalton 
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igr intracellular growth  
INF-γ interferon-γ 
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MCM methylmalonyl-CoA mutase 
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MM multiple myeloma 
MMCE methylmalonyl-CoA epimerase 
MMP methylmalonyl pathway 
MS mass spectrometry 
mtb Mycobacterium tuberculosis 
NAD nicotinamide adenine dinucleotide 
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NBD nucleotide-binding domain 
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PCC propionyl-CoA carboxylase 
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CHAPTER I  
INTRODUCTION: CHOLESTEROL METABOLISM IN MYCOBACTERIUM 
TUBERCULOSIS 
 
I.1 Cholesterol utilization by microorganisms 
I.1.1 Role of cholesterol in microorganism infection 
Composed of a rigid tetracyclic hydrocarbon core and an eight-carbon side-chain, 
cholesterol is very hydrophobic in general (Fig. 1). The solubility of cholesterol in water 
is only 1.8±0.8 µg/mL, and the molecule tends to self-associate (1). But the 3β-hydroxyl 
group makes cholesterol slightly amphiphilic, and, thereby, a crucial component of the 
cell membrane. More than 90% of cellular cholesterol is located in the plasma 
membrane (2), and cholesterol accounts for 10 to 45 molar percentage (mol%) of the 
plasma membrane (3). The heterogeneous distribution of the plasma membrane results in 
cholesterol-rich subdomains known as “lipid rafts”, which are actively involved in 
multiple cellular signaling processes. However, lipid rafts are also utilized by some 
intracellular microorganisms, including Escherichia coli, Chlamydia trachomatis, 
Helicobacter pylori, Plasmodium falciparum (2). The internalization of these 
microorganisms involves attachment to the lipid rafts, although cholesterol per se may 
not be absolutely required (2).  
Nevertheless, cholesterol is essential in mycobacteria internalization by 
macrophages, a process known as the phagocytosis. Cholesterol is accumulated at the 
mycobacterial entry site of macrophages. Depletion of the plasma membrane cholesterol 
  
2 
 
inhibits the uptake of Mycobacterium tuberculosis (Mtb) and M. bovis Bacille Calmette-
Guérin (BCG) by macrophages (4). In addition to phagocytosis, cholesterol is also 
required for Mtb persistence. For a common intracellular pathogen in a macrophage, the 
fusion of a lysosome to a pathogen-containing phagosome can lead to the digestion of 
the pathogen and disinfection. However, Mtb can recruit a membrane attached protein 
TACO (tryptophane aspartate–containing coat protein) to the surface of a phagosome, 
which prevents the fusion between a lysosome and a phagosome (5). The attachment of 
TACO to the phagosome membrane is also cholesterol-dependent (4). 
 
I.1.2 Microorganisms using cholesterol as a carbon source 
Cholesterol utilization by microorganisms was first documented in 1913 when 
Söhngen showed that soil microorganisms could grow on cholesterol medium (6). The 
degradation of cholesterol by actinomycetes, including multiple species of fast-growing 
mycobacteria, was reported in the 1940s by Tak (7) and Turfitt (8, 9). Several side 
chain-degraded and ring-cleaved metabolic intermediates were detected in 
Proactinomycetes erythropolis, Pseudomonas spp., and Nocardia restrictus (10-13).  
 M. smegmatis, a fast-growing non-pathogenic saprophytic actinobacterium, is 
also able to degrade cholesterol (14). Slow-growing mycobacteria such as Mtb and M. 
bovis BCG were observed to uptake and accumulate cholesterol, but the degradation 
intermediates were claimed undetectable (14). Therefore, for a long time, Mtb had been 
considered not being able to use cholesterol as a carbon source. 
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I.1.3 The in vivo carbon source conundrum of Mtb 
After being inhaled through aerosol droplets, Mtb will pass through the human 
airway and reach the alveoli where the bacilli get phagocytosed by macrophages. Mtb 
rapidly proliferate in the macrophages until the onset of acquired immune response. The 
infected macrophages are surrounded by numerous immune cells including monocytes 
and lymphocytes. Together they form a tissue known as a granuloma (15). Further 
development of cellular immunity leads to the necrosis of Mtb infected macrophages and 
the formation of a caseum center of a granuloma where Mtb can persist for decades with 
little or no replication. The caseum center is hypoxic, low in pH, iron limited, nutrient 
depleted, but rich in lipids. (16-21). Mtb has successfully evolved many features in order 
to adapt this habitat. A significant feature of this adaptation is a carbon source switch. 
(22-25).  
First observed by Segal and Bloch in 1956, Mtb freshly isolated from infected 
lungs behaved quite differently from that grown on culture media (22). The former had a 
much lower metabolic activity as measured by its weak ability to reduce the redox 
indicator tetrazolium chloride. Moreover, the respiratory rate of the former increased 
only in response to a few substrates including fatty acids but not glucose. These 
observations led to a hypothesis that Mtb shifted its carbon source from carbohydrate-
based to lipid-based nutrients during infection. The hypothesis was supported by Mtb 
whole genome sequencing and preliminary annotation in 1998. Its genome encodes more 
than 250 lipid metabolic genes (26). Fatty acids were initially regarded as the sole lipid 
carbon source in vivo. This was because the glyoxylate shunt, which assimilates the fatty 
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acid degradation product acetyl-CoA (27, 28), was demonstrated essential for Mtb 
growth in vivo. The glyoxylate shunt enzyme isocitrate lyase 1 (Icl1) was not only 
required for bacterial persistence (23, 27, 29) but also upregulated during infection (30). 
Although very profound, this discovery could not explain why Mtb needs so many lipid 
metabolic genes. Moreover, many of these genes did not have functionally characterized 
orthologs. 
During a study of Rhodococcus jostii, a cluster of 51 genes was linked to 
cholesterol utilization (31) (see Section I.2). Homologs of the genes were also found 
clustered in the Mtb genome (31). The gene cluster was renamed “Cho region” for 
cholesterol utilization. This breakthrough shed light on a large number of the previously 
uncharacterized lipid metabolic genes and paved the way for the subsequent studies on 
cholesterol metabolism by Mtb. 
 
I.2 Cholesterol uptake by Mtb 
The discovery of the cholesterol transport system was an outcome of genome-
wide identification of in vivo essential genes in Mtb. Sassetti et al. generated a 
transposon insertion mutant library of Mtb (32). By comparing the in vitro and in vivo 
growth of the mutant library (32), they identified genes that were only required for Mtb 
survival during infection in mice (29). Apart from a panel of functionally characterized 
genes, they discovered two gene operons (rv0166-0178, and rv3494c-3501c) that “have 
no obvious homologs outside of mycobacteria and closely related species” (29). These 
gene operons had been previously demonstrated to allow Mtb or even nonpathogenic E. 
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coli, when carrying these genes, to enter mammalian cells. Thereby, the gene operons 
were renamed the mammalian cell entry (mce) family (33). The two gene operons, 
designated mce1 and mce4 (32), were required during different stages of infection. 
Specifically, mce1 was used during initial infection, while mce4 was essential for 
maintaining a chronic infection (29, 34).  
A bioinformatics study suggested that the mce operons encoded multisubunit 
transport systems. The YrbEA and YrbEB subunits in both Mce systems showed 
sequence homology to the transmembrane permease subunits of ATP-binding cassette 
(ABC) transporters (29, 35). However, both mce operons lack a nucleotide-binding 
domain (NBD) subunit which is an essential component of an ABC transporter. Genetic 
interaction mapping suggested rv0655 outside the mce operon as the putative NBD 
subunit of both mce operons, and the gene was renamed mceG (35). Double deletion of 
mceG and mce4 (or mceG and mce1) had less than an additive effect because they 
participated in the same pathway. MceG is homologous to the NBD subunits of ABC 
transporters (29, 35). Besides mceG, a host of putative lipid metabolic genes also 
appeared in the mce genetic interaction map (29, 35), indicating that Mce systems might 
be lipid transporters.  
A breakthrough occurred in 2006. Differential gene expression in response to 
carbon sources was carried out on a steroid-degrading soil actinomycete R. jostii RHA1 
strain. Van der Geize et al. (31) showed that 51 genes within a 235-kb region of the 
rhodococcal genome were specifically expressed under cholesterol exposure. 
Mutagenesis and biochemical assays confirmed that many of these genes participated in 
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cholesterol catabolism, specifically, the degradation of the side chain and the A/B-ring 
(Fig. 1). Twenty-eight out of 51 genes were functionally annotated.  Moreover, these 51 
genes were mapped onto a cluster of 83 genes in the Mtb genome (rv3492c-rv3574), 
which is the aforementioned Cho region (many of the gene functions will be covered in 
Section I.4). The mce4 operon, which contains eight genes, belongs to the Cho region. 
This significant discovery elucidated the function of the mce4 operon and additionally 
suggested that Mtb might catabolize cholesterol. In agreement with this discovery, many 
of these genes in Mtb had been previously shown to be essential (36) and upregulated 
(30) during the bacterial growth in INF-γ activated macrophages (A summary of 
cholesterol utilization related genes are listed in Table 1. The data are exclusively from 
those unbiased high throughput experiments without a particular target of interest).  
 
 
Figure 1. Structure and numbering of cholesterol  
Cholesterol contains A/B/C/D rings and an aliphatic side-chain including C21-C27 
carbons. The 
14
C-isotope-labeled carbons are indicated with asterisks.
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Table 1. Summary of cholesterol utilization related genes 
Locus Gene name Annotation 
Essential for 
growth on 
cholesterol 
Essential for 
growth in 
macrophage 
Essential for 
growth in 
mice 
Essential in 
vitro 
(glycerol) 
Upregulated 
in 
macrophage 
Upregulated 
in  
cholesterol 
rv0467 icl1 isocitrate lyase     y n/a 
rv0655 mceG/mkl NBD of Mce transporters y y y   n/a 
rv1106c 3β-hsd 3β-hydroxysteroid 
dehydrogenase 
     n/a 
rv1130 prpD methylcitrate dehydratase y    y n/a 
rv1131 prpC methylcitrate synthase y    y n/a 
rv1143 mcr methyl acyl-CoA racemase      n/a 
rv1322A  putative Methylmalonyl-CoA 
epimerase 
     n/a 
rv1410c  P55 efflux pump  y    n/a 
rv1492 mutA methylmalonyl-CoA mutase 
β-subunit 
     n/a 
rv1493 mutB methylmalonyl-CoA mutase 
α-subunit 
     n/a 
rv3280 accD5 acyl-CoA carboxylase β      n/a 
rv3281 accE5 acyl-CoA carboxylase ε    y  n/a 
rv3285 accA3 acyl-CoA carboxylase α    y  n/a 
rv3409 choD cholesterol oxidase      n/a 
rv3494c mceF Mce4 y      
rv3495c lprN Mce4 y  y    
rv3496c mce4D Mce4 y      
rv3497c mce4C Mce4 y  y    
rv3498c mce4B Mce4 y      
rv3499c mce4A Mce4 y  y    
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Table 1. Continued 
Locus Gene name Annotation 
essential for 
growth on 
cholesterol 
Essential for 
growth in 
macrophage 
Essential for 
growth in 
mice 
Essential in 
vitro 
(glycerol) 
Upregulated 
in 
macrophage 
Upregulated 
in  
cholesterol 
rv3500c yrbe4B Mce4 y      
rv3501c yrbe4A Mce4 y  y    
rv3502c hsd4A dehydrogenase y  y   y 
rv3503c fdxD feredoxin      y 
rv3504 chsE4 acyl-CoA dehydrogenase      y 
rv3505 chsE5 acyl-CoA dehydrogenase     y y 
rv3506 fadD17 acyl-CoA synthetase       
rv3513c fadD18 probable acyl-CoA ligase       
rv3515c fadD19 acyl-CoA synthetase y    y y 
rv3516 echA19 Enoyl-CoA hydratase     y y 
rv3518c cyp142 cytochrome P450      y 
rv3520c        y 
rv3521        y 
rv3522 ltp4 ketoacyl-CoA thiolase      y 
rv3523 ltp3 ketoacyl-CoA thiolase   y   y 
rv3526 kshA monooxygenase y    y y 
rv3534c hsaF aldolase y  y  y y 
rv3535c hsaG aldehyde dehydrogenase     y y 
rv3536c hsaE HHD hydratase y    y y 
rv3537 kstD dehydrogenase y y   y y 
rv3538 hsd4B 2-enoyl acyl-CoA hydratase    y y y 
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Table 1. Continued 
Locus Gene name Annotation 
essential for 
growth on 
cholesterol 
Essential for 
growth in 
macrophage 
Essential for 
growth in 
mice 
Essential in 
vitro 
(glycerol) 
Upregulated 
in 
macrophage 
Upregulated 
in 
 cholesterol 
rv3540c ltp2 β-hydroxyl-CoA aldolase y  y  y y 
rv3541c chsH1 acyl-CoA hydratase  y y  y y 
rv3542c chsH2 acyl-CoA hydratase y y y  y y 
rv3543c chsE2 acyl-CoA dehydrogenase y    y y 
rv3544c chsE1 acyl-CoA dehydrogenase y y y  y y 
rv3545c cyp125 cytochrome P450 y  y  y y 
rv3546 fadA5 ketoacyl-CoA thiolase y    y y 
rv3548c   y     y 
rv3549c   y     y 
rv3550 echA20 enoy-CoA hydratase      y 
rv3551 ipdA hydrolase y y y   y 
rv3552 ipdB hydrolase  y   y y 
rv3553 ipdC acyl-CoA reductase y     y 
rv3556c fadA6 ketoacyl-CoA thiolase  y y  y y 
rv3557c kstR2 Tet-R type regulator     y y 
rv3559c ipdF ketoacyl-CoA reductase y   y  y 
rv3560c fadE30 acyl-CoA dehydrogenase y y y   y 
rv3561 fadD3 acyl-CoA synthetase y    y y 
rv3562 fadE31 acyl-CoA dehydrogenase     y y 
rv3563 fadE32 acyl-CoA dehydrogenase y y y   y 
rv3564 fadE33 acyl-CoA dehydrogenase y   y  y 
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Table 1. Continued 
Locus Gene name Annotation 
essential for 
growth on 
cholesterol 
Essential for 
growth in 
macrophage 
Essential for 
growth in 
mice 
Essential in 
vitro 
(glycerol) 
Upregulated 
in 
macrophage 
Upregulated 
in 
 cholesterol 
rv3565 aspB       y 
rv3567c hsaB monooxygenase       y 
rv3568c hsaC DHSA dioxygenase y     y 
rv3569c hsaD DSHA hydrolase y y   y y 
rv3570c hsaA monooxygenase y y   y y 
rv3571 kshB monooxygenase y    y y 
rv3573c chsE3 acyl-CoA dehydrogenase y     y 
rv3574 kstR Tet-R type regulator   y  y y 
rv3723 lucA lipid transport coordinator  y y   n/a 
Essentiality for growth on cholesterol data are from (37) 
Essentiality for growth in macrophage data are from (36) 
Essentiality for growth in mice data are from (29) 
Essentiality for growth in glycerol data are from (29) 
Upregulation in macrophage data are from (30) 
Upregulation in cholesterol data are from (38), n/a: not assessed.
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Soon after the discovery of the Cho region, Mtb was confirmed to be able to use 
cholesterol (34, 39), and the identity of the mce4 operon as a cholesterol transporter was 
also confirmed (34, 40). Tracking radioisotope-labeled cholesterol suggested the fate of 
two carbon atoms, C4 and C26 (Fig. 1, labeled with asterisks), that were catabolized into 
CO2 or assimilated into mycobacterial lipids, respectively (see Section I.4). As 
mentioned before, mce4 was required for Mtb persistence, while mce1 was crucial for 
initial infection. In addition, the Δmce4 strain could grow normally on the resting 
macrophages but was highly attenuated in INF-γ stimulated macrophages (34). These 
indicated that the bacilli switch their nutrient source during different stages of infection, 
and the switch is probably an adaptation to the immune response of the host (34). Mce1 
operon was later demonstrated to encode a multisubunit fatty acid transporter (41), 
suggesting the crucial role of fatty acids during early infection.  
In the aforementioned mce operon genetic interaction study, there were a group 
of genes besides mceG that showed positive genetic interactions with mce4 operon. 
While most of these genes participate in the lipid degradation, two of them were 
demonstrated to be part of the transport system. Rv1410c encodes a transmembrane 
protein known as the P55 multidrug efflux pump. Besides conferring drug resistance in 
Mtb, Rv1410c was suggested to be part of the Mce4 transport system (42). Deleting P55 
encoding gene in M. bovis BCG strain caused severe growth defect on cholesterol 
containing media or in vivo. Another gene associated with the Mce4 transport system is 
rv3723. This gene was renamed lipid uptake coordinator A (lucA) (43). In a synthetic 
lethal screening, lucA mutants were able to rescue the growth inhibition of Δicl1 Mtb in 
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cholesterol-containing medium, because blocking cholesterol import could stop the 
production and accumulation of toxic catabolic intermediates that required detoxification 
by Icl1 (41) (see Section I.4.3 for Icl1 detoxification). ΔlucA Mtb imported 70% less 
cholesterol than did the wildtype strain (41). LucA was also shown to interact directly 
with the subunits of Mce1 and Mce4, indicating it is part of the Mce lipid transport 
systems (41). 
To date, all of the reported cholesterol import processes have been associated 
with the Mce4 transport system. However, Δmce4 Mtb mutants still retained a low level 
of cholesterol uptake and metabolism, suggesting the existence of other complementary, 
although less efficient, cholesterol import approaches (34). These approaches remain to 
be identified. 
 
I.3 Regulation of cholesterol uptake and utilization 
I.3.1 The kstR regulon 
As mentioned above, the Cho region containing the mce4 operon could be 
upregulated on cholesterol exposure or during macrophage infection. The upregulation is 
mediated by a TetR-type transcriptional regulator KstR which is also encoded in the R. 
jostii or Mtb Cho region (31). In fact, years before the discovery of the Cho region, 
Kendall et al. had been aware of the importance of kstR when they compared the results 
of three earlier experiments (29, 30, 44, 45). They noticed that among all the Mtb genes, 
kstR was the only gene upregulated during macrophage infection, induced by immunity, 
  
13 
 
and essential in mice infection. This indicated the pivotal role of kstR for Mtb 
pathogenicity (44). 
A follow-up study by Kendall et al. (46) showed that M. smegmatis KstR 
repressed the expression of 83 genes, namely the kstR regulon. Deletion of kstR elevated 
the transcription of these genes by one to two orders of magnitude, including the mce4 
operon (46) (the relationship between kstR and cholesterol was not known when their 
experiments commenced). Notably, the kstR regulon in M. smegmatis is the counterpart 
of the Mtb Cho region. 
The recognition DNA sequence of KstR was predicted to contain a 14-bp 
palindrome TnnAACnnGTTnnA (n denotes A/T/C/G) which is located upstream of the 
gene operons in the kstR regulon (46). The dissociation constant (Kd) between Mtb KstR 
and a 28-bp DNA segment harboring the predicted sequence was below 10 nM (47). The 
binding site was substantiated by DNase I footprinting of the promoter region of M. 
smegmatis msmeg_5228 gene (48). This gene encodes 3β-hydroxy-steroid 
dehydrogenase (HSD) in cholesterol degradation (49) (see Section I.4.1 for enzyme 
function). Msmeg_5228 gene is outside the Cho region, but its transcription was 
activated by a hundred-fold in kstR deleted M. smegmatis (48). Interestingly, the 
transcription of Mtb hsd (rv1106c) was not elevated in cholesterol medium or during 
macrophage infection due to a lack of the palindromic recognition DNA sequence in the 
promoter region (48, 50, 51). It is likely that Mtb hsd co-expresses with the xseAB 
exonuclease in the same operon, and the expression is constitutive. Mtb may have gained 
some benefit during evolution when HSD is constantly expressed (48).  
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In order to identify the ligand of KstR, Garcia-Fernandez et al. tested a panel of 
cholesterol catabolic intermediates and several fatty acids using a combination of 
thermostability assay, electromobility shift assay (EMSA), and in vitro transcription 
assay (52). They showed that an early cholesterol degradation intermediate 3-oxo-4-
cholestenoic acid (3OChA, Fig. 2) was the ligand of KstR. However, cholesterol per se 
did not show any effect possibly due to its poor solubility in aqueous solution (47). This 
result was challenged by Ho et al. (47), who showed that 3OChA did not affect the 
interaction between KstR and the DNA probe. Instead, two CoA-ester intermediates, 3-
oxocholest-4-en-26-oyl-CoA (3-OCS-CoA, Fig. 2) and 3-oxo-4-pregnene-20-carboxyl-
CoA (3-OPC-CoA), were able to release DNA from KstR (compounds in the original 
literature were termed 3-OChA-CoA and 4-BNC-CoA, but the nomenclature will be 
consistent throughout this review). The Kd values for each effector against KstR were 
around 60 and 280 nM, respectively. Interestingly, in the crystal structure of KstR in 
complex with 3OCS-CoA or 3-OPC-CoA, the CoA moiety beyond the sulfur atom in 
either structure was invisible, indicating that CoA was not directly involved in the 
binding but might improve the solubility of the effector (47). Both 3OCS-CoA and 3-
OPC-CoA were able to induce a conformational change of KstR (47). 
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Figure 2. The signal molecules of kstR and kstR2 regulons 
 
 
I.3.2 The kstR2 regulon 
Kendall et al. later found a 15-gene sub-region (rv3548c-rv3553, rv3556-rv3557, 
rv3559-rv3565) inside the kstR regulon that was regulated by a second TetR-type of 
regulator KstR2 (Rv3557) (53). Those 15 genes in the kstR2 regulon distributed in three 
operons each containing a 14-bp palindrome AnCAAGnnCTTGnT in the promoter 
region. DNA probe containing the palindrome could be specifically shifted by KstR2 in 
EMSA (53). Similar to the kstR regulon, deleting M. smegmatis kstR2 de-repressed the 
transcription of those 15 gene orthologs in M. smegmatis. Interestingly, the regulation by 
KstR and KstR2 were independent (53).  
Casabon et al. observed that kstR2 regulon could be activated by carbon sources 
including cholesterol or 3aα-H-4α(3′-propanoate)-7aβ-methylhexahydro-1,5-
indanedione (HIP, Fig. 2) (54). The latter is a catabolic intermediate of the cholesterol 
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C/D-ring degradation (see Section I.4.3). In addition, deletion of fadD3 (rv3561) inside 
the kstR2 regulon abolished the regulon activation. The authors further demonstrated that 
HIP-CoA (Fig. 2), the product of FadD3, was the effector of the KstR2 (54, 55). This 
naturally led them to the prediction that the role of the kstR2 regulon was to catabolize 
the C/D-ring of cholesterol, and that Mtb was able to degrade cholesterol completely 
(48). 
 
I. 4 Cholesterol degradation pathway in Mtb 
Cholesterol degradation has been observed to occur concurrently from both the 
aliphatic side-chain and the A-ring in some cholesterol-degrading bacteria. But the exact 
order of the two is not clear and may be organism various (56, 57). Mtb and M. bovis 
BCG cannot process the A/B-ring when the side-chain is intact (58, 59). Cholesterol 
catabolism will be reviewed in the order of side-chain, the A/B-ring and, lastly, the C/D-
ring degradation. 
 
I.4.1 β-oxidation of cholesterol aliphatic side-chain  
I.4.1.1 HSD oxidizes the 3-OH and isomerizes cholesterol 
HSD, an NAD
+
-dependent dehydrogenase/isomerase, is largely considered to 
catalyze the initial step in cholesterol degradation (48, 49, 59). HSD converts the 3β-
hydroxy to 3-oxo on the A-ring and then isomerizes the de-saturated position from Δ5 to 
Δ4 (50) The resultant product is an enone-containing molecule cholest-4-en-3-one (Fig. 
3). This step may not be absolutely required before side-chain degradation, because hsd-
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deleted Mtb laboratory strain H37Rv could survive on cholesterol medium. As 
mentioned in I.3.1, hsd is outside the Mtb Cho region, and its transcription is not 
regulated by KstR due to the lack of recognition DNA in the promoter region (46, 48, 
53).  
Besides the NAD
+
/NADP
+
-dependent dehydrogenases, some cholesterol-
degrading microorganisms use a FAD-dependent cholesterol oxidase (ChOx) to catalyze 
the same transformation via a different mechanism. Mtb genome encodes a ChOx type 
of enzyme, ChoD (Rv3409c) (51), (60). However, ChoD appeared not being able to 
catalyze the transformation of cholesterol to cholest-4-en-3-one, nor was it essential for 
cholesterol utilization (49). Moreover, hsd was required for Mtb clinical strain CDC1551 
to grow on the medium using cholesterol as the sole carbon source (61), indicating the 
non-redundant function of HSD in Mtb CDC1551. The in vivo essentiality of hsd was 
paradoxical. Hsd was not essential for Mtb to infect mice macrophages or guinea pigs. 
This might because during the experimental conditions, Mtb had access to multiple 
carbon sources  (50).  
 
I.4.1.2 Cytochrome P450 enzymes activate the aliphatic side chain 
 In order to subject the aliphatic side chain into β-oxidation cycles, the terminal 
methyl groups must be first oxidized to carboxylic acid form. An operon containing six 
genes (rv3540c-rv3545c) was previously shown by Chang et al. to be essential for Mtb 
growth in macrophage and in mice, and the operon was renamed the intracellular growth 
(igr) operon (62). The igr operon contains a cytochrome P450 enzyme CYP125 
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(Rv3545c). CYP125 catalyzes sequential oxidation on the C26 of cholest-4-en-3-one 
(58, 59, 63-65) (Fig. 3). It is worth mentioning that C25 of cholesterol is a prochiral 
carbon which is turned into a chiral center after asymmetric modification on either C26 
or C27 terminal methyl group. CYP125 stereospecifically generates the (25S)- form. 
Another cytochrome P450 enzyme CYP142 (Rv3518), on the other hand, produces the 
(25R)- form (66) (Fig. 3). These two enzymes successively oxidize cholest-4-en-3-one 
all the way to carboxylic acid form, each maintaining their own stereospecificity. 
FadD19 (Rv3515c), a fatty acyl CoA ligase, can take both chiral forms as substrates and 
ligate them with a coenzyme A molecule while still maintaining the chiral configuration 
of C25 (67, 68). However, only the (25S)- form of the resultant product 3-OCS-CoA is 
the substrate of β-oxidation enzymes (69). Mtb genome encodes an α-methyl acyl CoA 
racemase (MCR, Rv1143) which interconverts the (25R)- and (25S)-3-OCS-CoA (69). 
FadD19 and MCR together make CYP125 and CYP142 partially redundant in Mtb 
H37Rv strain, and either CYP is nonessential in the presence of the other. The clinical 
Mtb strain CDC1551, however, does not encode CYP142 in the genome, which makes 
CYP125 indispensable (66). 
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Figure 3. Cholesterol aliphatic side chain activation 
Pathway drawn in blue indicates the intermediates with (25R)- configuration. 
 
I.4.1.3 β-oxidation of the side chain 
Each cycle of lipid β-oxidation typically involves an acyl-CoA dehydrogenase 
(FadE), an (S)-enoyl-CoA hydratase (EchA), a β-hydroxy-acyl-CoA dehydrogenase 
(FadB), and a β-ketoacyl-CoA thiolase (FadA). However, Mtb genome, including the 
Cho region, is highly redundant in each type of these enzymes. As a result, a specific 
reaction may be catalyzed by multiple enzymes or enzyme complexes. On the other 
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hand, some of these enzymes may catalyze multiple reactions. It is difficult to annotate 
the gene functions precisely. 
ChsE4-ChsE5 (formerly FadE26-FadE27, Rv3504-Rv3505) dehydrogenase 
complex has been shown to catalyze the first round of β-oxidation of 3-OCS-CoA (70) 
(Fig. 4). ChsE4-ChsE5 only recognizes the (25S)- form of 3-OCS-CoA. Crystal structure 
of ChsE4-ChsE5 complex revealed that the two proteins were structurally similar to each 
other and formed an α2β2-type of heterotetramer (70). Notably, ChsE4-ChsE5 was the 
first structure of α2β2-type of acyl-CoA dehydrogenase. Unlike the typical 
homotetrameric acyl-CoA dehydrogenases where each polypeptide chain binds to one 
FAD cofactor, ChsE4-ChsE5 heterotetramer only binds to two FAD molecules. Each 
FAD was located on the interface of an αβ-heterodimer (70). ChsE4-ChsE5 complex 
was shown to be very versatile. It exhibited high specific activity not only for 3-OCS-
CoA, but also for the CoA-esters of the second and third rounds of β-oxidation. This 
potentially explains why the downstream acyl-CoA dehydrogenases ChsE3 and ChsE1-
ChsE2 are not absolutely essential (70).  
The echA, fadB and fadA genes involved in the first round β-oxidation are not 
clear. Since there are only two echA genes, echA19 and echA20, in the Cho region, and 
echA20 is involved in C/D-ring degradation (71), it is possible that EchA19 catalyzes the 
hydration of multiple enoyl-CoA intermediates. Another possibility is the involvement 
of EchAs outside the Cho region (51).  There is no fadB gene in the Cho region. This 
step may be catalyzed by genes elsewhere in the genome (51). Similar to echA, the Cho 
region encodes two fadA genes, fadA5 and fadA6. The latter participates in the C/D-ring 
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degradation (71, 72), which indicates the potential versatility of fadA5 in the side chain 
degradation. FadA5 was shown to be required to generate the side-chain-removed 
product 4-androstene-3,17-dione (AD) (38), but the exact substrate specificity of FadA5 
has not been investigated. 
At the end of the first round of β-oxidation, a propionyl-CoA molecule 
containing the C25 to C27 of cholesterol is released. As mentioned in Section I.2.1, the 
radioactivity of 
14
C26-labeled cholesterol was detected in mycobacterial lipids (34). This 
was because propionyl-CoA could be converted to methylmalonyl-CoA and 
incorporated into the methyl-branched lipids (MBLs) (see Section I.4.2). 
The second round of β-oxidation may be catalyzed by an acyl-CoA 
dehydrogenase ChsE3 (formerly FadE34, Rv3573c) (70). Unlike ChsE4-ChsE5, ChsE3 
showed substrate specificity for 3-OCO-CoA (70). At the end of the second round β-
oxidation, an acetyl-CoA molecule containing C23 and C24 of cholesterol may be 
released by FadA5 (38) (Fig. 4).  
The third round of β-oxidation is non-cannonical, and it is well-studied. The 
genes involved are clustered in the aforementioned igr operon. ChsE1-ChsE2 (formerly 
FadE28-FadE29, Rv3543c-Rv3544c) (73, 74) specifically catalyze the conversion of 3-
OPC-CoA into 3-oxo-4,17-pregnadiene-20-carboxyl-CoA (3-OPDC-CoA, kcat/Km = 2.5 
× 105 M–1 s–1) (74) ChsE1-ChsE2 complex is also a heterotetramer with two FAD 
molecules bound (74). The β-hydroxylation at C17 of 3-OPDC-CoA is catalyzed by a 
MaoC-like (R)-enoyl-CoA hydratase complex ChsH1-ChsH2 (Rv3541c-Rv3542c). This 
reaction generates 17-hydroxy-3-oxo-4-pregnene-20-carboxyl-CoA (17-OHPC-CoA) 
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(73, 75). Notably, after β-hydroxylation, C17 becomes a tertiary carbon with no 
hydrogen atom attached (Fig. 4, labeled with an asterisk). Dehydrogenation cannot occur 
on this carbon to produce β-ketoacyl-CoA as a substrate of a thiolase. As a result, an 
aldolase Ltp2 (lipid transfer protein, Rv3540c) is employed to cleave a propionyl-CoA 
directly from17-OHPC-CoA (75, 76). The retro-aldol cleavage by Ltp2 required the 
presence of ChsH1-ChsH2 (76). Notably, ChsH2 contains a C-terminal domain of 
unknown function DUF35 that could be pulled down by Ltp2 (75, 76). The aldolase 
activity could be reproduced simply by Ltp2-DUF35 complex against 17-OHPC-CoA. 
The specific activity for this reaction was quite high with a kcat/Km value of around 2.4 × 
10
7
 M
-1
 s
-1 
(76). 
After three rounds of β-oxidation, the aliphatic side-chain of cholesterol is 
catabolized into two molecules of propionyl-CoA and one molecule of acetyl-CoA (Fig. 
4). The remaining compound AD contains only the A/B and C/D rings. 
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Figure 4. Degradation of aliphatic side-chain 
C17 in 17-OHPC-CoA is labeled with an asterisk. 
 
 
I.4.2 Degradation of the A/B-Ring 
I.4.2.1 KstD catalyzes the 1,2-desaturation 
In order to open the A/B-ring, multiple oxidation reactions have to occur on the 
rings. The first step is to desaturate the C1-C2 single bond of AD to generate 1,4-
androstadiene-3,17-dione (ADD) (Fig. 5a). This reaction is catalyzed by a FAD-
dependent ketosteroid dehydrogenase Δ1 KstD (Rv3537). In vitro enzyme assay of Mtb 
KstD showed that it recognized a narrow range of substrates which need to be side-chain 
completely degraded (77). Disrupting kstD resulted in the accumulation of a downstream 
  
24 
 
intermediate 9-hydroxy-1,4-androstadiene-3,17-dione (9-OHADD) in Mtb (39). This 
indicates that the downstream hydroxylase KSH can share the substrate of KstD. In fact, 
the order of 1,2-desaturation and 9-hydroxylation in R.jostii is not critical because 
rhodococci have three KstD enzymes and they can accept a wide range of steroid 
substrates (77, 78). However, Mtb genome only encodes one Δ1 KstD, and it did not 
show in vitro activity against 9-OHAD (77), which means desaturation has to occur prior 
to hydroxylation. This raises the query of how this order is controlled in Mtb (see 
below).  
 
I.4.2.2 KSH catalyzes the 9α-hydroxylation 
The hydroxylation at C9 of ADD is catalyzed by a two-component enzyme 3-
ketosteroid 9α-hydroxylase (64, 79) (Fig. 5a). The α-subunit KshA (Rv3526) is an 
oxygenase containing a Rieske-type [Fe2S2Cys2His2] cluster and a non-heme 
mononuclear Fe
2+
 center. The β-subunit KshB (Rv3571) is a reductase containing a 
plant-type [Fe2S2Cys4] cluster and a FAD cofactor. During the catalysis, the electron 
from an NADH in the solution is first transferred to FAD in the KshB reductase subunit 
(Fig. 5b). Relayed by the iron-sulfur clusters in KshB and KshA, the electron reaches the 
mononuclear ferrous center of KshA oxygenase subunit. The C9 hydroxylation is 
accomplished by consuming an oxygen molecule as the terminal electron acceptor (64, 
79). The reported specific activity of Mtb KshA-KshB was only twice for ADD than for 
AD (79). However, when scrutinizing the global fitting curve of the steady-state kinetics 
data for AD, one would notice that the standard deviation of the replicates was large, and 
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the fitting was not accurate. In addition, the maximum velocity for ADD was 
approximately ten-fold higher than for AD (79). These data indicate that KSH in Mtb 
prefers Δ1,4 dual desaturated substrates, and explains the previous question of how Mtb 
ensures that KstD is upstream of KSH. 
 
 
Figure 5. Activation of A/B-ring by desaturation and hydroxylation 
a, The catalytic order of Mtb KstD and KSH is strict (black), but that of R. jostii 
homologs is flexible (both black and blue). b, Schematic of the catalytic mechanism 
of KSH. 
 
 
I.4.2.3 HsaA-HsaB catalyzes the 4-hydroxylation 
The Δ1 de-saturation and 9α-hydroxylation will lead to the spontaneous open of 
the B-ring and aromatization of the A-ring (57) to produce 3-hydroxy-9,10-
seconandrost-1,3,5(10)-triene-9,17-dione (3-HSA). In order to open the A-ring, another 
hydroxyl group is introduced at C4- position (Fig. 6a, colored in blue) to generate a 
catechol-containing derivative 3,4-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-
dione (3,4-DHSA) (14, 31, 80). This step in Mtb is catalyzed by HsaA-HsaB (Rv3570c 
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and Rv3567c) (81) which are encoded in the hsa operon containing hsaABCD genes. 
HsaA-HsaB enzymes belong to the two-component flavin-dependent monooxygenases 
(TC-FDMs) (81) where the oxidized and reduced flavin is shuttled between the 
reductase and oxygenase subunits during catalysis (82) (Fig. 6b). Specifically, HsaB 
reductase subunit reduces a flavin using an NADH. The reduced flavin is transferred to 
HsaA oxygenase subunit, where the hydroxylation occurs on the C4 position of 3,4-
DHSA by consuming an oxygen molecule. The oxidized flavin is then shuttled back to 
HsaB for the next round of catalysis. Different monooxygenases have the preference to 
use either FAD or FMN as the flavin cofactor (83). Mtb HsaA-HsaB showed similar 
specific activity when using FAD (kcat/Km = 770 M
-1
 s
-1
) or FMN (kcat/Km = 1000 M
-1
 s
-
1
) as a cofactor, although both the kcat and Km were higher for FMN (81). 
 
I.4.2.4 HsaC opens A-ring 
The meta-cleavage between C4 and C5 of 3,4-DHSA is catalyzed by HsaC 
(Rv3568c), an iron-dependent extradiol dioxygenase. The reaction generates 4,5-9,10-
diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oic acid (4,9-DSHA). Unlike 
the intradiol dioxygenases which cleave the aromatic bond between two hydroxylated 
carbons, an extradiol dioxygenase cleaves an aromatic ring between a hydroxylated 
carbon and an adjacent non-hydroxylated carbon (84, 85). The meta-cleavage of a 
catechol requires a mononuclear non-heme ferrous iron (Fig. 7). The crystal structure of 
HsaC confirmed that the ferrous iron was located at the active site and coordinated by 
two histidines and one glutamate (86). This type of coordination in extradiol 
  
27 
 
dioxygenases is known as the 2-His-1-carboxylate facial triad motif because the three 
residues only occupy one face of the octahedral coordination sphere (87) (Fig. 7). The 
other face of the sphere can be coordinated by three solvent molecules. During catalysis, 
the two hydroxyl groups of the catecholic substrate substitute two solvent molecules, and 
an oxygen molecule substitutes the third solvent molecule (Fig. 7). The reaction is 
featured by the formation of a peroxide bridge between the ferrous iron and the 
catecholic substrate, followed by homolytic O-O bond fission. Through a Criegee-type 
rearrangement to form a putative seven-membered lactone intermediate (85, 87), the C-C 
bond between C4 and C5 of 3,4-DHSA is cleaved.  
The physiological role of HsaC in cholesterol degradation was confirmed by a 
knockout experiment (86). Mtb ΔhsaC strain was not able to completely degrade 
cholesterol but accumulated catechols which could be oxidized to 1,2-benzoquinone 
derivatives. These compounds in turn gave the initial Mtb culture a pinkish color. The 
bacilli lost viability soon, likely because they could not further degrade the intermediates 
to produce enough energy and/or they accumulated toxic intermediates (86).  
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Figure 6. Degradation of A/B-ring (Part 1) 
a, Catabolic pathway and intermediates. The oxygen atoms are colored base on the 
catalytic steps. b, Schematic of HsaAB FAD-dependent monooxygenase. 
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Figure 7. Suggested catalytic cycle for extradiol dioxygenase, adapted from (85) 
with permission. 
Copyright (2004) American Chemical Society. 
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I.4.2.5 HsaD cleaves HHD off 4,9-DSHA 
The last gene in hsa operon encodes an α/β hydrolase HsaD (Rv3569c) (31, 88). 
HsaD is responsible for cleaving 2-hydroxy-hexa-2,4-dienoic acid (HHD) from 4,9-
DSHA (Fig. 6a). Interesting, Lack et al. reported that upon binding to HsaD, the 
maximal absorption of 4,9-DSHA underwent a redshift of 60 nm (88). The crystal 
structures of an inactive mutant HsaDS114A in complex with several catechol meta-
cleavage products showed that the torsion angle about C4-C5 double bond (Fig. 8a, 
labeled with asterisks) dramatically deviated from planarity (88). Therefore, they 
proposed that the enolate substrate tautomerized into the keto form, which made C4-C5 
a rotatable single bond. The keto form could also explain the redshift phenomenon. 
Based on the crystal structures and the optical phenomenon, Lack et al. tentatively 
proposed a general acid-base catalytic mechanism (Fig. 8a). It is still disputable of 
whether the catalytic serine uses a general base mechanism to de-protonate a water 
molecule (Fig. 8a) or it acts as a nucleophile to directly attack the carbonyl at C6 (89-91) 
(Fig. 8b). 
 
I.4.2.6 HsaEFG degrades HHD 
Bioinformatics analyses (31) suggested the enzymes responsible for the 
degradation of HHD (Fig. 6a, 8c) are encoded in the hsaEFG operon (rv3534c-rv3536c). 
The function of HsaE has not been characterized but was proposed based on other meta-
cleavage pathway intermediates (92) (Fig. 8c). 4-hydroxy-2-oxohexanate (HOH), the 
putative product of HsaE, could be catabolized by HsaF-HsaG complex with specific 
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activity of approximately 7.91 × 104 M-1 s-1(92). HsaF catalyzes a retro-aldol cleavage in 
the presence of a divalent metal ion to stabilize the enol pyruvate intermediate. Mn
2+
 
showed the highest activity for the enzyme. The retro-aldol reaction generates pyruvate 
and propionaldehyde (92).  
The crystal structure of HsaF-HsaG complex showed a tunnel linking the active 
sites of HsaF and HsaG (92). This structure along with a homologous protein complex 
DmpF-DmpG structure (93) implied a substrate channeling mechanism (92) (Fig. 8c). 
After the retro-aldol cleavage, propionaldehyde would be channeled to the active site of 
HsaG for CoA-dependent dehydrogenation (92) (Fig. 8d). HsaG produces the third 
molecule of propionyl-CoA in cholesterol degradation. 
As mentioned in section I.2, Pandey and Sassetti showed that the radioactivity of 
14
C4 labeled cholesterol was detected in 
14
CO2 (34). Based on the retro-aldol cleavage 
by HsaF, the C4 carbon of cholesterol is turned into the carboxyl group of pyruvate (Fig. 
8c, indicated by red arrowhead). To enter the tricarboxylic acid cycle, pyruvate 
undergoes oxidative decarboxylation catalyzed by puruvate dehydrogease to form 
acetyl-CoA. Therefore, the carboxyl group ends up as CO2. This eventually explains the 
fate of C4 carbon of cholesterol. 
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Figure 8. Degradation of A/B-ring (Part 2) 
a, A simplified general base mechanism of HsaD as proposed in (88). Carbons C4 
and C5 that undergo a double bond shift are labeled with asterisks. b, An 
alternative nucleophile mechanism of HsaD analogous to other meta-cleavage 
product hydrolases as proposed in (89). c, Degradation of HHD. Dashed arrow 
indicates the reaction is hypothesized. Red arrowheads indicate C4 of cholesterol. 
d, Proposed catalytic mechanism of HsaG. 
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I.4.3 Degradation of the C/D-Ring 
Removing HHD from 4,9-DSHA yields the C/D-ring-contain compound 3aα-H-
4α(3’-propanoate)-7αβ-methylhexahydro-1,5-indanedione (HIP, Fig. 2, 6a, 9). Genetic 
studies suggested that the genes involved in HIP degradation are clustered in kstR2 
operon, but the catabolic pathway was unknown until very recently (71). Biochemical 
properties of most enzymes for C/D-ring degradation are still poorly understood.  
 
I.4.3.1 FadD3 initiates the degradation of C/D-ring 
FadD3 (Rv3561) is one of the predicted CoA ligases in the cholesterol 
degradation gene cluster and is the only CoA ligase in the kstR2 regulon (53, 54). The 
biochemical function of FadD3 was characterized by Casabon et al. in R. jostii RHA1 
strain through a comparative metabolism of wildtype and fadD3-deleted strains (55). R. 
jostii ΔfadD3 strain grew on cholesterol showed incomplete degradation of cholesterol 
and the accumulation of HIP. Mtb fadD3 was able to restore the full activity of 
cholesterol degradation in R. jostii ΔfadD3 strain (55). Steady-state kinetics of Mtb 
FadD3 showed that the enzyme could ligate CoA onto HIP with specific activity of 7.3 × 
10
5
 M
-1
 s
-1
 (55). 
As mentioned at the beginning of Section I.4, the cholesterol catabolism may be 
concurrent from the side-chain and the A/B-ring. While some A/B-ring catabolic 
enzymes are active against side chain partially degraded substrates, FadD3 is only active 
against the side chain fully removed substrates (55), indicating that the degradation of 
the C/D-ring is absolutely the last stage of the cholesterol catabolism. 
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I.4.3.2 Degradation of the C/D-ring yields acetyl- , propionyl- and succinyl-CoA 
The identities of the enzymes and intermediates during the C/D-ring degradation 
were elucidated in 2017 using a combination of bioinformatics, genetics and 
biochemical tools (71). Crowe et al. purified protein orthologs of the Mtb kstR2 regulon 
from several cholesterol degrading organisms, including Mtb, R. jostii RHA1, and 
Pseudomonas putida DOC21, and reconstituted the pathway in vitro. They further 
validated the in vivo functions of these enzymes by tracking the intermediates 
accumulated in the M. smegmatis mutants with these genes individually deleted (71). 
The catabolic pathway is shown in Fig. 9. Except for the IpdAB and FadA6 (72), the 
biochemical properties of these enzymes have not been characterized yet. The 
degradation includes ring-open steps coupled by several rounds of β-oxidation (71). The 
final products contain three molecules of acetyl-CoA, one molecule each of propionyl- 
and succinyl-CoA. 
Taking the side-chain and A/B-ring degradation together, the catabolism of 
cholesterol yields four molecules each of acetyl- and propionyl-CoA, one molecule of 
succinyl-CoA and one molecule of pyruvate. The acetyl-CoA, succinyl-CoA, and 
pyruvate can be readily fed into the TCA cycle and glyoxylate shunt for further 
catabolism or be used as synthetic blocks for anabolism. However, propionyl-CoA was 
considered as a potentially toxic molecule to Mtb and requires several pathways be 
assimilated. These pathways include the vitamin B12-dependent methylmalonyl pathway 
(MMP), the membrane-associated methyl-branched lipid (MBL) synthesis, and the 
methylcitrate cycle (MCC) (Fig. 10). 
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Figure 9. Degradation of C/D-ring, adapted and modified from (71).  
The acyl-CoAs that are sequentially removed from the C/D-ring are shown in 
different colors. 
 
 
 
  
36 
 
 
Figure 10. Overview of the propionyl-CoA assimilation pathways 
The propionyl-CoA assimilation pathways are shown along with the TCA cycle and 
glyoxylate shunt in the central carbon metabolism. 
 
I.5 Metabolism of the unique product propionyl-CoA in Mtb 
I.5.1 Methylmalonyl pathway (MMP) 
1.5.1.1 Mtb has a functional MMP 
MMP is a well-studied pathway that organisms use to metabolize propionyl-CoA. 
The pathway widely exists from prokaryotes to eukaryotes (26, 94-98). Enzymes 
involved in this pathway include propionyl-CoA carboxylase (PCC), methylmalonyl-
CoA epimerase (MMCE, also named methylmalonyl-CoA racemase) and 
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methylmalonyl-CoA mutase (MCM). Genes encoding these enzymes in Mtb have been 
identified or bioinformatically assigned. Mtb propionyl-CoA carboxylase complex (PCC) 
contains α, β and ε subunits which are encoded by three nearby genes rv3285, rv3280 
and rv3281, respectively (96, 99, 100). PCC carboxylates propionyl-CoA to generate 
(S)-methylmalonyl-CoA. This step is mediated by a biotin cofactor and consumes one 
ATP to activate a bicarbonate molecule. The conversion of (S)-methylmalonyl-CoA to 
(R)-methylmalonyl-CoA is catalyzed by MMCE. Bioinformatics study assigned 
Rv1322A as Mtb MMCE (96). But its biochemical function has not been experimentally 
validated. A critical and unique step in MMP is the reversible rearrangement between 
methyl-branched (R)-methylmalonyl-CoA and linear succinyl-CoA. This step is 
catalyzed by a vitamin B12-dependent enzyme MCM. Rv1492 (mutA) and rv1493 (mutB) 
in Mtb encode the β- and α-subunits of MCM, respectively (96). The α-subunit, MutB, 
binds to both B12 cofactor and the (R)-methylmalonyl-CoA substrate. Despite sharing a 
similar fold with the α-subunit, the β-subunit does not bind to B12 or acyl-CoA (101). A 
nearby gene rv1496 is likely to encode an MCM associated GTPase which is involved in 
assembling MCM-B12 complex and protecting MCM from inactivation (96, 102, 103). 
Savvi et al. (96) and others (104, 105) showed that MMP could partially compensate the 
disruption of MCC for Mtb survival on propionate media when vitamin B12 was 
supplemented into the media. Notably, for propionate utilization, bacteria need to 
activate this three-carbon molecule into the propionyl-CoA form. In Mtb, this reaction is 
presumably catalyzed by propionyl-CoA synthetase Rv3667 (105). These results 
together indicated that Mtb possesses a functional MCM pathway, although B12 must be 
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exogenously supplemented during in vitro growth. This raises the question of whether 
Mtb in vivo synthesizes B12 cofactor or acquires it via other approaches.  
 
I.5.1.2 Vitamin B12 acquisition in Mtb 
Vitamin B12 is one of the most complicated natural compounds. Its de novo 
synthesis is absent in eukaryotes and is limited to only a subset of archaea and eubacteria 
(106). The biosynthetic pathway involves around 25 genes starting from the last 
common precursor uroporphyrinogen-III (107) (Fig. 11). Different organisms use either 
the oxygen-dependent (aerobic) route or the oxygen-independent (anaerobic) route to 
synthesize B12 (106, 107). The major differences are that the latter incorporates cobalt 
before corrin synthesis while the former does it in the opposite order, and the former 
requires an oxygen molecule to hydroxylate precorrin 3A (106, 107) (Fig. 11). 
 Comparative genomics studies showed that Mtb seems to possess most of the 
gene homologs of the oxygen-dependent route except for cobF which is responsible for 
converting precorrin-5 into precorrin-6x (26, 107, 108) (Fig. 11). CobF is an S-
adenosylmethionine (SAM) dependent methyltransferase (106, 109). Although it was 
hypothesized that this step might be compensated by other methyltransferases in Mtb 
(108), the hypothesis has not been validated. As a result, it is still arguable whether Mtb 
is able to complete the B12 de novo synthesis. 
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Figure 11. Vitamin B12 biosynthesis 
Anaerobic pathways are colored green. The reaction catalyzed by CoF, which is 
missing in Mtb, is specified. 
 
 
Nevertheless, it is known that Mtb genome encodes a B12 transporter. Gopinath et 
al. screened the transposon insertion mutant library of Mtb (32) on the B12-containing 
culture media and found that mutating rv1819c abolished the B12 uptake. Sequence 
analysis suggested that rv1819c encodes an ABC transporter containing a 
transmembrane domain and a nucleotide-binding domain (NBD). Rv1819c was also 
crucial for the bacilli to use propionate when MCC was chemically inhibited (110). 
  
40 
 
I.5.1.3 Mtb may circumvent B12-dependent metabolic steps 
Although possessing the membrane-anchored B12-uptaking machinery, whether 
Mtb, especially the CDC1551 clinical strain, practically use B12-dependent MMP during 
infection and persistence is still not clear. Mtb laboratory strain H37Rv genome harbors 
two methionine synthase genes metH (rv2124c) and metE (rv1133c) (26). Both can 
synthesize methionine from homocysteine. The former is a B12-dependent 
methyltransferase, and the latter is B12-independent. However, compared to the H37Rv 
genome, the CDC1551 genome contains a deletion that resulted in a loss of 398 amino 
acids at the C-terminus of MetH. The deletion abolished the function of MetH and left 
the B12-independent MetE the only available methionine synthase for CDC1551 (111). 
Paradoxically, there is a B12 riboswitch upstream of the metE gene, which means that in 
the presence of B12 the metE mRNA will form an alternative structure and its 
transcription or translation should be attenuated. Warner et al. confirmed that 10 µg/mL 
(7.3 µM) of B12 supplementation to the culture medium was enough to inhibit the growth 
of CDC1551 strain by targeting the metE B12 riboswitch. Mutations at two adjacent 
positions of the metE riboswitch region conferred CDC1551 tolerance to B12 (111). 
These results together suggest that Mtb CDC1551 has to restrict the intracellular level of 
B12 in order to survive. Retaining the B12 riboswitch upstream of metE during evolution 
also indicates that CDC1551 can tolerate B12 starvation in vivo. 
Besides MutAB and MetE, Mtb genome potentially encodes a third B12-
dependent enzyme, the Class II ribonucleotide reductase (RNR) NrdZ (Rv0570). Similar 
to the case of MetE and MetH, there is also a B12-independent Class Ib RNR in Mtb 
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which contains the NrdE (Rv3051c) large subunit and NrdF2 (Rv3048c) small subunit. 
The presence of the Class Ib RNR makes Class II RNR nonessential both in vitro and 
during mice infection (112).  
All the genetic redundancy raises the conundrum of whether Mtb, not limited to 
CDC1551 strain, requires B12 and the B12-dependent pathways to survival in humans. 
Notably, the mutAB operon and rv1322A (MMCE) were neither essential in mice 
infection (29) nor upregulated during the infection of INF-γ activated macrophages (30). 
Therefore, it is unlikely that Mtb actively uses the B12-dependent MMP in vivo to 
assimilate propionyl-CoA, albeit the bacterium has a fully functional MMP.  
 
I.5.2 Methyl-branched lipid synthesis 
I.5.2.1 Mtb cell wall and the lipid-rich outer membrane 
The second pathway that propionyl-CoA can be fed into is the MBL synthesis. 
MBL synthesis uses (S)- and potentially (R)-methylmalonyl-CoA as building blocks. 
During MBL synthesis, propionyl-CoA is first converted by PCC to (S)-methylmalonyl-
CoA (100, 113), and thereby, this step is shared between MMP and MBL synthesis. 
Since Mtb synthesizes a large quantity of MBLs, they can act as a sink for propionyl-
CoA (25, 113). Although the MMP in Mtb is not essential and may not even be actively 
used in vivo, the genes encoding the PCC complex are essential (29, 100). This is likely 
because MBLs are critical for mycobacteria virulence (see below). 
The outer membrane of mycobacteria is rich in lipids (Fig. 12a). Besides the C60-
90 mycolic acids that could be covalently attached to the arabinogalactan layer to form 
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the mycolyl arabinogalactan-peptidoglycan (mAGP) complex, there are also free lipids 
and glycolipids that noncovalently anchor to the mAGP. Among these free lipids, 
phthiocerol dimycocerosates (PDIMs) and sulfolipid-1 (SL-1) contain methyl-branched 
fatty acyl chains (114). PDIMs are unique to the pathogenic mycobacteria including M. 
tuberculosis, M. marium, M. leprea, M. ulcerans, M. kansasii, etc. (115). Therefore, the 
PDIMs have been suggested to be associated with the bacterial virulence. Mtb mutants 
not being able to synthesize or transport PDIMs were highly attenuated in vivo. In 
addition, Mtb grown in vitro rapidly lost the PDIM due to mutations in the PDIM 
synthesis and transport genes. These results indicated that PDIM is related to in vivo 
activity (116). The SLs, on the other hand, are unique to Mtb (115). But they appeared to 
be dispensable for Mtb virulence in vivo (117).  
Since the MBL synthesis shares the intermediates (S)- and/or (R)-
methylmalonyl-CoA with MMP, given that MBL is essential to Mtb in vivo, it is 
important to understand why only the PCC in MMP is essential. We herein try to 
rationalize this question from the aspect of MBL biosynthesis. 
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Figure 12. Schematic of Mtb cell wall and biosyntheses of MBLs, a portion of the 
figure is adapted from (113) with permission 
a, Mtb cell wall structure and components. b and c, Structures and the key steps in 
PDIM (b) and SL-1 (c) syntheses, adapted from Jain et al. (2007) (113) with 
permission. Copyright (2007) National Academy of Sciences, U.S.A. TMM: 
trehalose monomycolate; TDM: trehalose dimycolate.  
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I.5.2.2 Stereochemistry in MBL biosynthesis and virulence of Mtb 
The genes responsible for PDIM biosynthesis are mainly clustered within a 50-kb 
region of the Mtb genome (26, 118).  The methyl-branches are introduced into the 
mycocerosate chains and the phthiocerol backbone of PDIM by three genes, all of which 
encode type-I polyketide synthases (PKSs). A giant protein complex was identified and 
characterized by Kolattukudy and colleagues in 1984 (119). The protein machinery was 
isolated the from M. bovis BCG cell lysate. This 490-kDa protein complex was a 
homodimer containing two polypeptide chains each of around 238-kDa. It elongates C18 
or C20 n-fatty acid primers with methylmalonyl-CoA to produce mycocerosic acids. 
Thus the protein was renamed mycocerosic acid synthase (MAS). MAS specifically uses 
methylmalonyl-CoA but not malonyl-CoA as a substrate. There are two biological 
epimers of methylmalonyl-CoA. Experiments showed that MAS could incorporate both 
the (S)- form and the (R,S)- racemic mixture into the methyl-branched chains (119). But 
whether the (R)- form in the racemic mixture was incorporated into the lipid was not 
validated. It is known that Mtb preferentially produces laevorotatory ((S)- form) lipids 
rather than dextrorotatory ((R)- form) ones (120, 121), and PCC complex is a 
stereospecific enzyme which only synthesizes the (S)-methylmalonyl-CoA (122). These 
results indicate why the PCC complex is essential in Mtb, but MMCE which 
interconverts the two methylmalonyl-CoA epimers is nonessential.  
In addition to mycocerosic acid chains, methylmalonyl-CoA is also incorporated 
into the phthiocerol backbone of PDIM by two type-I PKSs. Specifically, the phthiocerol 
backbone is elongated by five PKSs, PpsA-E, using a C22 n-fatty acid as a primer (Fig. 
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12b). The first three steps of the elongation are catalyzed by PpsA-C using malonyl-CoA. 
The fourth and fifth steps are catalyzed by PpsD and PpsE which introduce the methyl-
branches through the incorporation of methylmalonyl-CoA. After elongation, the 
product undergoes spontaneous decarboxylation (123) that renders the terminal 
methylmalonyl moiety non-chiral (Fig. 12b). Therefore, C4 carbon becomes the only 
methyl group-attached chiral center. It has been shown that in Mtb, this chiral center is 
strictly in the (S)- configuration (120), implicating the dispensability of the nonessential 
MMCE. 
The incorporation of methylmalonyl-CoA into SL-1 is catalyzed by another 
MAS-like type-I PKS, Pks2 (124). Pks2 elongates the C16 or C18 n-fatty acids with 
methylmalonyl-CoA, and the resultant product is known as phthioceranic acid (Fig. 12c). 
Pks2 can incorporate four to nine methyl-branches into phthioceranic acid, depending on 
the abundance of methylmalonyl-CoA (113). Genetically disrupting pks2 abolishes 
phthioceranic acid formation and consequently the SL-1 synthesis in Mtb. However, this 
did not affect the infection and persistence of Mtb in mice or guinea pigs, indicating that 
SL-1 per se is not an essential virulence factor (117, 125). The stereospecificity of Pks2 
has not been characterized. Since SL-1 appears nonessential for the survival and 
virulence of Mtb, the stereospecificity may not be a concern. 
It has been reported by Jain et al. that the dynamics of the MBL composition was 
affected by the level of methylmalonyl-CoA, and the MBL composition, in turn, 
influenced the virulence of Mtb in vivo (113). However, they also noticed that through 
two alternative ways of increasing the methylmalonyl-CoA level, the outcomes were 
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quite different. Specifically, when propionate was provided as the carbon source, both 
the molecular weight and abundance of MBLs increased. The increase in the molecular 
weight was due to an extension of the mycocerosate chain length by MAS. The lipid 
mass spectrometry showed that the PDIM pattern, in this case, was similar to that of the 
wildtype Mtb isolated from lung infection. Alternatively, if mutAB were overexpressed 
to convert more succinyl-CoA into (R)-methylmalonyl-CoA, the molecular weight of 
PDIM also increased. However, the abundance of methyl-branched lipids decreased by 
30% and 80% for PDIM and SL-1, respectively. Moreover, the bacteria growth was 
highly attenuated during mice infection (113). Although the author attributed the 
decreased viablity as a disturbance of the metabolism, it is also intriguing to consider the 
differences in stereochemistry. Propionate supplementation will lead to a direct increase 
of (S)-methylmalonyl-CoA synthesized by PCC. However, mutAB overexpression leads 
to direct production of (R)-methylmalonyl-CoA from succinyl-CoA. While the efficient 
incorporation of the (S)- form has been confirmed, the utilization of the (R)- form is not 
clear (119). Since Mtb is a laevorotatory ((S)- form) lipid-synthesizing bacterium (120, 
121), its preference of the (S)-methylmalonyl-CoA is likely to have physiological 
significance.  
In summary, propionyl-CoA is not only a nutrient and energy source of Mtb, but 
it is also indispensable for the virulence of the pathogen. The essentiality of PCC 
complex may be explained by its role in the MBL synthesis, but not in the MMP. It will 
be of great interest and significance to investigate the relationship between the virulence 
and stereochemistry of MBLs. 
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I.5.3 The methylcitrate cycle 
I.5.3.1 Enzymes of MCC in general and in Mtb 
The methylcitrate cycle (MCC) is a third pathway for Mtb to assimilate 
propionyl-CoA. MCC widely exists in prokaryotes but is absent in eukaryotes. The 
enzymes involved in the pathway are usually encoded within an operon, namely the 
propionate metabolic operon (prp operon). Typically, the operon contains a group of 
three genes prpB, prpC and prpD. Some organisms, i.e., Salmonella enteric, contain a 
fourth gene encoding a propionyl-CoA synthetase, PrpE, which prepares the substrate 
for MCC (126).  
The cycle starts with an aldol condensation reaction catalyzed by methylcitrate 
synthase (MCS, PrpC) (Fig. 13). Analogous to citrate synthase in the TCA cycle, MCS 
condenses propionyl-CoA with oxaloacetate and forms 2-methylcitrate (2-MC). In the 
second step, 2-MC is isomerized into 2-methylisocitrate (2-MIC). The isomerization 
could be catalyzed by a [4Fe4S] cluster-containing aconitase-like enzyme AcnD coupled 
with a hydratase PrpF. These two enzymes in some organisms, including Mtb, are 
substituted by a single enzyme methylcitrate dehydratase (MCD, PrpD) (126). PrpD is 
iron-sulfur-free and oxygen-tolerant. In the third step, 2-MIC is cleaved by 
methylisocitrate lyase (MCL, PrpB) via a retro-aldol reaction to form pyruvate and 
succinate. The two products can be used in anabolism or fed into the TCA cycle.  
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Figure 13. Consensus enzyme catalytic mechanisms of the methylcitrate cycle 
The residues are generalized as HA for a catalytic acid and B for a catalytic base. 
 
 
In Mtb, the prp operon only contains prpC (rv1131) and prpD (rv1130) without 
the methylisocitrate lyase gene prpB. This is because the isocitrate lyase 1 (Icl1, Rv0467) 
which commonly functions in the glyoxylate shunt also possesses MCL activity (127). 
Therefore, Icl1 is a bifunctional enzyme in Mtb. Notably, Mtb genome encodes a second 
copy of isocitrate lyase (Icl2). Deletion and complementation experiments suggested that 
the activity of Icl2 against 2-MIC was poor and Icl1 contributed to more than 90% of the 
MCL activity (25). 
 
I.5.3.2 Toxicity of propionyl-CoA and related metabolic intermediates 
Propionyl-CoA has been heavily documented to create cytotoxicity if it cannot be 
properly metabolized. Munoz-Elias et al. observed that propionyl-CoA accumulation 
could cause Mtb growth inhibition (25). They showed that Mtb deleting prpDC operon 
failed to grow on 0.1% propionate or valerate as the sole carbon source. Valerate 
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degradation could produce equal mole of propionyl-CoA and acetyl-CoA, and 
assimilation of the latter should not be impaired in the ΔprpDC bacilli. Therefore, the 
authors concluded that the accumulation of propionyl-CoA was the cause of growth 
inhibition (25), and the role of MCC was to detoxify propionyl-CoA (128). However, 
VanderVen et al. suggested that propionyl-CoA per se was not toxic. They showed that 
Mtb deleting both prpC and icl1 was able to grow on cholesterol or propionate-
containing rich media, where propionyl-CoA was produced and accumulated. However, 
if only icl1 was deleted, where propionayl-CoA could be converted into 2-MC or 2-MIC 
without further degradation, Mtb growth on the rich media was strongly inhibited. 
Therefore, they inferred that the metabolic intermediates, likely the 2-MC or 2-MIC, 
were toxic to Mtb (129). Eoh and Rhee applied metabolomics technique to potentially 
unravel a bigger picture of the propionate toxicity (130). They observed that the toxicity 
of propionate or propionyl-CoA was multifaceted. In icl1 deleted Mtb, propionyl-CoA 
could deplete the TCA cycle intermediate oxaloacetate and route the metabolism into a 
“dead-end” MCC pathway. This further resulted in the depletion of gluconeogenesis and 
TCA cycle substrates as well as amino acid synthesis precursors, accumulation of 
methylmalonyl-CoA, and shifting the NAD
+
/NADH ratio and membrane potential (130). 
However, the propionate or cholesterol inhibition was also observed in OADC-based 
rich media where nutrition and central carbon metabolic substrates are plenty, and 
substrate depletion should not be a concern (129). 
Propionyl-CoA-related toxicity has also been observed in other organisms. In E. 
coli, propionyl-CoA was shown to bind to the TCA cycle enzyme citrate synthase with 
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an affinity comparable to that of the true substrate acetyl-CoA. Nevertheless, E. coli 
citrate synthase had no detectable activity against propionyl-CoA, which made 
propionyl-CoA a potential inhibitor of E. coli citrate synthase (131). In addition, 
propionyl-CoA could inhibit several CoA-ester involved enzymes in fungi, among which 
pyruvate dehydrogenase was most strongly inhibited (132). Propionyl-CoA-related 
toxicity was probably best studied in S. enterica. Unlike E. coli citrate synthase, the S. 
enterica citrate synthase appeared to be able to synthesize 2-MC. However, the 2-MC 
synthesized by S. enterica citrate synthase was more toxic than synthesized by 
methylcitrate synthase PrpC (133, 134). Knocking down citrate synthase alleviated the 
cytotoxicity (133). Since citrate does not have a chiral center but 2-MC has two chiral 
centers, it is possible that citrate synthase may synthesize a mixture of 2-MC 
diastereomers, while PrpC may synthesize a stereospecific 2-MC. Further studies 
identified the enzyme target of the toxic 2-MC in S. enterica ΔprpC strain to be the 
gluconeogenesis enzyme fructose-1,6-bisphosphatase (FBPase) (134). Overexpression of 
FBPase relieved the toxicity. Moreover, a single mutation S123F in FBPase made the 
ΔprpC S. enterica resistant to propionate (134). 
The toxicity of 2-MC against Mtb FBPase was performed by Eoh and Rhee (130), 
who showed that 2-MC was a non-competitive inhibitor of FBPase with an IC50 value 
below 1 mM. But since the commercially available 2-MC is typically a racemic mixture 
of diastereomers, the true inhibitory constant was probably well below 1 mM. It will be 
very intriguing and necessary to find out the configuration of 2-MC produced by Mtb 
PrpC and the two citrate synthases (Rv0889c/CitA and Rv0896/GltA2). At present, the 
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reason of propionyl-CoA-related toxicity is unknown, and the toxicity of the 
intermediates appears to be the most satisfactory explanation. 
 
I.5.3.3 Role of MCC in vivo 
Paradoxically, although the prpDC operon was required for the in vitro growth of 
Mtb on propionate (25, 104, 135), odd-chain fatty acids (25) or cholesterol (104, 129) 
containing media and in murine bone marrow-derived macrophages (25, 104), the 
operon was dispensable for Mtb infection and persistence in mice (25). On the contrary, 
icl1 deleted Mtb was not viable in vivo or on the media containing acetate, propionate, 
fatty acids or cholesterol (25, 96, 105, 130). Since Icl1 is bifunctional which also 
participate in the glyoxylate shunt, it is conceivable that Icl1 performs a pivotal role in 
central carbon metabolism more than detoxifying MCC intermediates. Nevertheless, the 
role of Icl1 on the MCC is not negligible. Notably, prpDC and icl1 genes were highly 
upregulated during resting or INF-γ activated macrophage infections. (30) Therefore, it 
is likely that the overexpression of prpDC during infection is enforced regardless of its 
essentiality. A large amount of 2-MC and 2-MIC will consequently be generated, which 
requires an intact and fully functioning Icl1 to detoxify the MCC intermediates.  
MCC is a double-edged sword for Mtb growth in vivo. On the one hand, MCC is 
crucial for assimilating the high energy propionyl-CoA which is massively produced 
during cholesterol and odd-chain fatty acid degradation. On the other hand, MCC may 
lead to the production and accumulation of toxic intermediates. As a result, MCC needs 
to be precisely regulated. The regulation at the transcriptional level is achieved by two 
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local regulators, PrpR and RamB, which are encoded neighboring to the prpDC operon 
and icl1, respectively. In the next chapter, we will investigate the structure and 
biochemical properties of these regulators and unravel the regulatory mechanism of the 
MCC pathway. 
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CHAPTER II  
SHORT-CHAIN FATTY ACYL COENZYME A DERIVATIVES REGULATE 
MYCOBACTERIUM TUBERCULOSIS METHYLCITRATE CYCLE AND 
GLYOXYLATE SHUNT 
 
II.1 Introduction 
Mycobacterium tuberculosis (Mtb) remains a major global health problem. In 
2016, Mtb led to an estimated 1.3 million deaths among HIV-negative people, and 6.3 
million new tuberculosis (TB) cases were reported (136). It is well accepted that Mtb 
utilizes fatty acids and cholesterols as its primary source of nutrition when infecting 
humans (22, 34, 105). A common metabolite from the catabolism of both odd-chain fatty 
acids and cholesterols is propionyl coenzyme A (propionyl-CoA) (57, 71, 73, 96, 104).  
It has been shown that the accumulation and metabolism of propionyl CoA leads to the 
toxicity of the bacilli (128, 130).  
 There are several major pathways that utilize propionyl-CoA including the 
methylmalonyl pathway (MMP), methyl-branched chain fatty acids synthesis and the 
methylcitrate cycle (MCC) (Fig. 10). In the MMP, propionyl-CoA is sequentially 
converted to (S)- and (R)-methylmalonyl-CoA, which is then rearranged to the TCA 
cycle intermediate succinyl-CoA by a vitamin B12-dependent enzyme methylmalonyl-
CoA mutase (96). Since Mtb genome does not encode cobF, an essential enzyme in the 
de novo B12 synthesis (108, 137), it leads to the argument that the bacilli is not able to 
synthesize B12, and thus has to acquire B12 from the media (96) or scavenge from the 
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host (110). An alternative route to bypass the B12-dependent step is to incorporate 
methylmalonyl-CoA into the methyl-branched lipids pool (113). The other major 
pathway to catabolize propionyl-CoA is the MCC (25). Although MCC is dispensable in 
a mouse infection (25), it is essential for Mtb growth in the macrophage (25, 104), and 
thus is still considered as a candidate pathway for inhibitor development (129). The key 
enzymes of the MCC include methylcitrate synthase (MCS, also named PrpC), 
methylcitrate dehydratase (MCD, also named PrpD), and methylisocitrate lyase (MCL, 
also named PrpB in some organisms, i.e. M. smegmatis) (25, 128). In Mtb, the former 
two genes are encoded in the propionate (prp) metabolic operon. However, the Mtb 
genome does not encode a functionally unique MCL, instead its function is 
accomplished by isocitrate lyase 1 (Icl1), a well known enzyme in the anaplerotic 
glyoxylate shunt (25, 127, 130). 
 In Mtb, the transcription of the prp operon was proposed to be mediated by the 
master transcription sigma factor E (SigE) (138) and was stringently controlled by a 
local transcriptional regulator, PrpR (propionate regulator, Rv1129c, MtPrpR) (104, 135, 
138). The prpR gene is adjacent to, but in the opposite direction of, the prp operon (Fig. 
14). MtPrpR activates the transcription of both itself and the prp operon in response to 
propionate or cholesterol (104, 135). Deleting prpR from the Mtb genome made the 
bacterium unable to respond to propionate or cholesterol in vitro and fails to grow on 
media containing these molecules as sole carbon sources (104, 135). Interestingly, prpR 
deficient mutants have been found to be relatively prevalent in isoniazid resistant, as 
well as other drug resistant Mtb clinical isolates (139, 140), possibly because these 
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mutations slow down bacterial growth as a fitness cost of drug tolerance (140). These 
paradoxical phenomena intrigue us to understand the molecular characteristics and 
regulatory mechanism of this protein. 
 The regulatory mechanisms of MtPrpR and its homologs at the molecular level 
have not been resolved in any organism due to the paucity of structural information of 
these proteins. While we still do not understand how MtPrpR is stimulated, 2-
methylcitrate was suggested as a coactivator of PrpR in different organisms (141-143). 
cAMP has also been suggested to be indirectly involved in the response (129, 144). 
Conserved domain analysis (145) was only able to annotate the N-terminus of MtPrpR 
as the helix-turn-helix DNA binding domain (Fig. 15). The rest of the protein was 
previously annotated as two domains of unknown function, DUF955 and DUF2083 
(138). DUF955 was recently updated to be an IrrE N-terminal-like domain, which was 
reported as a Zn-dependent metaloprotease (146, 147). 
 
 
Figure 14. Genome organization of ramB-icl1 regulon and the prpR-prpDC regulon. 
Dashed lines indicate the presence of genes in between. The distances of the 
intergenic regions are indicated. The tandem repeats are zoomed in with the 
sequence spelled out. Lower case indicates the imperfect palindrome. 
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Figure 15. Domain organization of MtPrpR.  
Black blocks and the numbers above indicate the predicted domain borders; color-
filled blocks and the numbers below indicate the domains observed in the structure. 
The DII domain is colored in light yellow; GAF domain is colored in blue; C-
terminal region is colored in green. The HTH domain (hatched) was truncated 
from the protein construct. 
  
 
 Notably, in Mtb there is a prpR paralog, ramB (regulator of acetate metabolism 
B, rv0465c), located upstream of icl1 (Fig. 14). Unlike MtPrpR, which is largely 
accepted as a transcriptional activator (104, 135, 138), MtRamB is more likely to be a 
transcriptional repressor in the presence of a fermentable carbon source such as dextrose 
(138, 148). 
 A 17 bp length of DNA between prpR and prpD has been proposed as the 
primary recognition sequence of MtPrpR (135) (Fig. 14). It consists of a perfect 
(TTTGCAAA) and an imperfect (TTTGCgAA) palindrome separated by one base pair. 
The exact 17 bp DNA sequence also exists upstream of icl1 but nowhere else in the Mtb 
genome. In addition, very similar sequences have been mapped to MtRamB binding sites 
(148-150). This genome context may provide a precise regulatory mechanism, and cross-
regulation by MtPrpR and MtRamB might also exist. To unravel the potential structure-
function relationship of MtPrpR and its homologs, we solved the crystal structures of 
different forms of MtPrpR. The structure revealed that MtPrpR is an iron-sulfur protein 
that binds to Coenzyme A or its derivative molecules tightly, which may be a clue to its 
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regulatory mechanism. MtPrpR and MtRamB showed a concerted and carbon source 
dependent regulation upon icl1 transcription. 
 
II.2 Materials and Methods 
II.2.1 Bacterial strains, media, and growth conditions 
M. tuberculosis strains were maintained in complete 7H9 media (Middlebrook 
7H9 salts supplemented with 0.2% glycerol, 0.05% Tween-80 and 10% Middlebrook 
OADC). The prpR deletion mutant of M. tuberculosis H37Rv (H37RvΔprpR) was 
obtained from the Sassetti lab as described previously (104). PrpR deletion mutants 
carrying a rescuing wildtype or mutant allele were then constructed as described 
previously (140). Briefly, a kanamycin resistant plasmid carrying the prpR wildtype or 
mutant gene and 95 bp of the sequence upstream of the proposed translational start site 
was integrated at the L5 phage integration site of the prpR deletion strain. 
Knockdown of ramB was performed using the CRISPR interference (CRISPRi) 
system optimized for M. tuberculosis (151) targeting the 
sequence GCGGGCAGGTGCCGCCGCTGGA within the ramB ORF. The anhydrous 
tetracycline (ATc) inducible ramB knockdown vector was transformed into both 
wildtype H37Rv and the H37RvΔprpR mutant strains. 
 
II.2.2 Cloning, protein expression, and purification 
The gene Rv1129c (prpR) encoding the full-length PrpR protein (MtPrpR_M1) 
was cloned as previously described (135). Briefly, the gene was amplified from the Mtb 
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H37Rv genome using PrpR_M1_Fw and PrpR_Rv primers. (All primers were 
synthesized by Integrated DNA Technologies, and are listed in Table 2.) The PCR 
product was treated with the BamHI and XhoI restriction enzymes (New England 
Biolabs) and cloned into a pET28a vector (Novagen). 
A re-annotation of Mtb ORF (152) suggested that the ninth amino acid valine 
might be the translational start site.  PrpR_V9 construct removing first eight amino acids 
from the N-terminus was subcloned into a pET28a vector between the BamHI and XhoI 
sites using PrpR_V9_Fw and PrpR_Rv primers. Both the MtPrpR_M1 and MtPrpR_V9 
were expressed in Escherichia coli BL21(DE3). The cells were grown in LB media 
supplemented with 50 μg/ml kanamycin to an OD600 of 0.8, induced with 0.08 mM 
IPTG, and shaken at 18 °C for another 12-16 hours before being pelleted. The cells were 
resuspended in Lysis Buffer (100 mM Na2HPO4/NaH2PO4 pH 7.5, 200 mM NaCl, 30 
mM imidazole), homogenized using a Microfluidizer M-100P (Microfluidics). Cell 
debris was clarified and the supernatant was applied to a Ni-NTA resin (Qiagen). The 
resin was washed with 20 column volumes of Wash Buffer (100 mM 
Na2HPO4/NaH2PO4 pH 7.5, 200 mM NaCl, 60 mM imidazole). An isocratic elution was 
performed using Elution Buffer (100 mM Na2HPO4/NaH2PO4 pH 7.5, 200 mM NaCl, 
300 mM imidazole).  
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Table 2. Primers used in this study 
Cloning 
PrpR_M1_Fw 5’-GGTCTAGAGGGATCCATGACGCGGAGTAATGTCTTA-3’ 
PrpR_V9_Fw 5’-CGCGGATCCGTGGCTAGGACGTATTCGAG-3’ 
PrpR_Rv 5’-GGGGTACCCTCGAGTCAAACCGATTGCTCGGTCGA-3’ 
PrpR_D81_Fw 5’-TACTTCCAATCCAATGCCGACGCACGGTTGGTGG-3’ 
PrpR_V486_Rv 5’-TTATCCACTTCCAATGTTAAACCGATTGCTCGGT-3’ 
PrpR_F155_Fw 5’-TACTTCCAATCCAATGCCTTCGAGGAGGTCCGCGAC-3’ 
PrpR_E440_Rv 5’-TTATCCACTTCCAATGTTACTCCGTGCTCGGGTCGTC-3’ 
PrpR_F240A_Fw 5’-CCCGGACAGCGCGCCGCCCAGATCGCCACCCAA-3’ 
PrpR_F240A_Rv 5’-TTGGGTGGCGATCTGGGCGGCGCGCTGTCCGGG-3’ 
PrpR_H319A_Fw 5’-TTCGAAACCGTCTGCGCCCGGCTCTCCACACTG-3’ 
PrpR_H319A_Rv 5’-CAGTGTGGAGAGCCGGGCGCAGACGGTTTCGAA-3’ 
PrpR_F155H_Fw 5’- GCGCGGCCGATGCCGCACGAGGAGGTCCGCGAC-3’ 
PrpR_F155H_Rv 5’-GTCGCGGACCTCCTCGTGCGGCATCGGCCGCGC-3’ 
PrpR_F155A_Fw 5’-GCGCGGCCGATGCCGGCCGAGGAGGTCCGCGAC-3’ 
PrpR_F155A_Rv 5’-GTCGCGGACCTCCTCGGCCGGCATCGGCCGCGC-3’ 
PrpR_F155W_Fw 5’-GCGCGGCCGATGCCGTGGGAGGAGGTCCGCGAC-3’ 
PrpR_F155W_Rv 5’-GTCGCGGACCTCCTCCCACGGCATCGGCCGCGC-3’ 
PrpR_F155Y_Fw 5’-GCGCGGCCGATGCCGTATGAGGAGGTCCGCGAC-3’ 
PrpR_F155Y_Rv 5’-GTCGCGGACCTCCTCATACGGCATCGGCCGCGC-3’ 
PrpR_C363A_Fw 5’-CGGGTCGGCGGCAGCGCCCCGCTGTGGGTGGTC-3’ 
PrpR_C363A_Rv 5’-GACCACCCACAGCGGGGCGCTGCCGCCGACCCG-3’ 
PrpR_C450A_Fw 5’-GCGGGCTGCAAGATCGCCAACCGAACGTCGTGC-3’ 
PrpR_C450A_Rv 5’-GCACGACGTTCGGTTGGCGATCTTGCAGCCCGC-3’ 
p1129c_Fw 5’-GACGTCAACCGGATCGGCAGC-3’ 
p1129c_Rv 5’-GGCACCGGAAAACGTCCTCGA-3’ 
RT-qPCR for M. tuberculosis 
prpR_Fw 5’-ATGTCAACCAGTTGGAGAATGA-3’ 
prpR_Rv 5’-CGGAATCCGAGGAGAAATACTG-3’ 
prpD_Fw 5’-TGACTTTCACGACACGTTTCTGGC-3’ 
prpD_Rv 5’-TGTGGATCTCATAGGCGGTTACCA-3’ 
icl1_Fw 5’-CAGCACATCCGCACTTTGAC-3’ 
icl1_Rv 5’-ATCACCACCGTGGGAACATC-3’ 
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Table 2. Continued 
RT-qPCR for M. tuberculosis 
ramB_Fw 5’-CCTGCCCGCTGTGGAA-3’ 
ramB_Rv 5’-GGCGATTTGCACCAAGATCT-3’ 
sigA_Fw 5’-CAAGTTCTCCACCTACGCTAC-3’ 
sigA_Rv 5’-GTTGATCACCTCGACCATGT-3’ 
RT-qPCR for M. smegmatis 
rv1129 _Fw 5’-GTTACGCTATGACATCGACCTG-3’ 
rv1129_Rv 5’-GAAGATGAACGGTATCCCTCG-3’ 
MsprpR_Fw 5’-CACCCAGTCAGAGCAGTTATC-3’ 
MsprpR_Rv 5’-CGAATAGATCAGCCGGTGAG-3’ 
MsprpD_Fw 5’-AACAAGTTCGTCACCCTGG-3’ 
MsprpD_Rv 5’-ACTTGTCCAACACCGTCTTG-3’ 
MsprpB_Fw 5’-AAGTCTTCGACGCTGGAAC-3’ 
MsprpB_Rv 5’-GAAGTTGTAGATGTCGGAGTCG-3’ 
MsprpC_Fw 5’-AGGAGAAGGTCATGGGATTTG-3’ 
MsprpC_Rv 5’-TTGTAGATGTCGAGCCAACG-3’ 
MssigA_Fw 5’-GACTACACCAAGGGCTACAAG-3’ 
MssigA_Rv 5’-TTGATCACCTCGACCATGTG-3’ 
Binding Oligos 
Pos_Pal30mer 5'-GCACATTTTGCAAATTTTGCGAACATGACG-3' 
Neg_Pal30mer 5'-CGTCATGTTCGCAAAATTTGCAAAATGTGC-3' 
Pos_HalfPal30mer 5'-GCACATTTTGCAAA T CCTGTGTACATGACG-3' 
Neg_HalfPal30mer 5’-CGTCATGTACACAGGATTTGCAAAATGTGC-3’ 
Pos_/Cy3/Pal30mer 5'-/Cy3/GCACATTTTGCAAATTTTGCGAACATGACG-3' 
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The protein truncations were determined by domain and secondary structure 
analysis. The domain annotation was performed in InterPro (145) 
(https://www.ebi.ac.uk/interpro/). Protein secondary structure was predicted by 
PSIPRED (153) (http://bioinf.cs.ucl.ac.uk/psipred/) 
PrpR81-486 truncating the N-terminal helix-turn-helix domain was subcloned into 
a ligation-independent cloning (LIC) vector pMCSG7 (154) with primers PrpR_D81_Fw 
and PrpR_V486_Rv. This construct contains a His6-tag and a TEV cleavage site to the 
N-terminus of the target protein. The plasmid was transformed into E. coli BL21(DE3) 
competent cells. The cells were grown at 37 °C in LB medium supplemented with 100 
μg/ml carbenicillin to an OD600 of 0.8. Protein expression was induced by 0.3 mM IPTG. 
Cells were grown at 18 °C for another 12-16 hours before being pelleted. Protein 
purification was analogous to that of the full-length proteins except that 20 mM Tris-HCl 
pH7.8 was used instead of 100 mM Na2HPO4/NaH2PO4 pH 7.5 in all the buffers. The 
salt and imidazole concentrations remained unchanged. PrpR81-486 was about 95% pure 
according to SDS-PAGE analysis.  
The protein was diluted in IEX Buffer A (20 mM Tris-HCl pH 7.8) until the 
NaCl concentration was below 100 mM and was loaded to an anion exchange HiTrap Q 
FF column (GE Healthcare). The column was washed by mixing the IEX Buffer A with 
ten column volumes of 20% IEX Buffer B (20 mM Tris-HCl pH 7.8, 1 M NaCl). An 
isocratic elution was performed with 30% IEX Buffer B. 
Protein was concentrated immediately to approximately 30 mg/ml and injected 
onto a HiLoad 26/600 Superdex-200 column (GE Healthcare) equilibrated with Gel 
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Filtration Buffer (20 mM Tris-HCl pH 7.8, 100 mM NaCl, 3 mM DTT). The majority of 
the protein appeared as a tetramer in solution. Peak fractions were pooled and 
concentrated to 24 mg/ml for crystallization trials. 
MtPrpR81-486 point mutations were introduced using the primers listed in Table 2 
and the QuikChange site-directed mutagenesis kit (Agilenet). The F155H variant was 
expressed and purified in particular following the same procedure for the wildtype 
protein.  
Selenomethionine-derived MtPrpR81-486 was expressed by growing the bacteria in 
M9 minimal salt media supplemented with 0.4% glucose, 2 mM MgSO4, 0.1 mM CaCl2, 
and 100 μg/ml carbenicillin. Cells were grown to an OD600 of 0.6 and chilled on ice. 100 
mg l
-1
 each of L-lysine, L-threonine, L-phenylalanine, 50 mg l
-1
 each of L-leucine, L-
isoleucine, L-valine, and 60 mg l
-1
 L-selenomethionine, were added before induction 
along with 100 mg/l ferrous ammonium sulfate. Cells were shaken at 18 °C for 15 min, 
and protein expression was induced with 0.3 mM IPTG for 12-16 hours. The 
selenomethionine-derived protein purification procedure was identical to that of the 
native protein and its behavior was also very similar to that of the native protein. 
The transition metal ion evaluations was performed by growing the E. coli cells 
in M9 minimal salt media supplemented with 0.4% glucose, 2 mM MgSO4, 0.1 mM 
CaCl2, and 100 μg/ml carbenicillin to an OD600 of 0.8. Each flask was supplied with 25 
μM one of the chloride salts of Fe3+, Co2+, Ni2+, Cu2+ and Zn2+ 15 min before induction. 
Protein expression was induced with 0.3 mM IPTG for 16 hrs at 18 °C. The total protein 
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expression in the whole cell lysate and the soluble protein in the supernatant were 
analyzed on a SDS PAGE. 
PrpR155-440 was subcloned into a pMCSG7 vector using primers PrpR_F155_Fw 
and PrpR_E440_Rv. Procedures for protein expression and affinity purification were 
similar to those of MtPrpR81-486 except that all purification buffers contain 500 mM 
NaCl. The protein was dialyzed overnight against 20 mM Tris-HCl pH7.8, 500 mM 
NaCl while the His6-tag was cleaved with TEV protease. The protein was reapplied to 
the Ni-NTA resin to remove the His6-tag and the residual impurities. The protein was 
concentrated to about 10 mg/ml and injected to a HiLoad 26/600 Superdex-75 column 
(GE Healthcare) pre-equilibrated with 20 mM Tris-HCl pH 7.8, and 400 mM NaCl. The 
protein appeared as a monomer in solution. The peak fractions were pooled and 
concentrated to approximately 10 mg/ml. 
Analytical size exclusion chromatography (SEC) for each protein construct was 
performed using the Superdex 200 10/300 GL (GE Healthcare). SEC buffer for each 
protein construct was identical to their preparative SEC buffer. 
 
II.2.3 Crystallization  
Freshly purified His-tagged MtPrpR81-486 or MtPrpR81-486_F155H variant proteins 
at 24 mg/ml was screened against over 900 crystallization conditions in sitting-drop 
vapor diffusion using a Mosquito Crystal liquid handler (TTP Labtech Inc). Protein was 
equilibrated with the crystallization conditions in 17 °C. Brown color crystals appeared 
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within two days. The best growth condition contained either 100 mM HEPES pH 7.5 or 
100 mM Bicine pH 9.5, 1 M sodium acetate, 0.08 mM Zwittergent 3-14. 
The MtPrpR155-440 protein was screened against over 900 conditions at about 10 
mg/ml in the presence and absence of 1 mM CoA. Crystals of identical morphology for 
both formulations appeared in about one week in 0.2 M CaCl2•2H2O, 0.1 M HEPES pH 
7.5, 28% v/v PEG 400. 
 
II.2.4 Data collection and structure determination 
Crystal X-ray diffraction data were collected at Beamline 19-ID, 19-BM, or 23-
ID at the Advance Photon Source, Argonne National Laboratory in Chicago. Anomalous 
scattering for selenomethionine derived MtPrpR81-486 was collected around the peak 
position at 0.97949 Å. (We planned for iron phasing and selenium phasing, but were 
informed that the beam at low energy was not stable at the time.) The crystal diffracted 
to approximately 2.7 Å resolution. Crystal symmetry and diffraction intensity were 
analyzed with Denzo in HKL2000, scaled and reduced with Scalepack in 
HKL2000(155). The selenomethionine derived crystal belonged to the P212121 space 
group with a = 96.19 Å, b = 142.37 Å, c = 145.97 Å, α = β = γ = 90°, and contained four 
molecules per asymmetric unit (ASU) in D2 symmetry. Experimental phasing was 
achieved using single-wavelength anomalous dispersion (SAD). Heavy atom sites were 
searched in SHELXD (156) (SHELXC/D/E pipeline in CCP4 (157)). Seventeen out of 
28 possible heavy atom sites were found, all of which were correct when compared to 
the final structure. The electron density map was calculated with SHELXE(158), 
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followed by density modification with Parrot (159) in CCP4 by applying non-
crystallographic symmetry (NCS) calculated from the heavy atom substructure. 
Automated initial model building plus refinement was conducted using Buccaneer (160) 
in CCP4. Manual model building was performed in Coot (161). The [4Fe4S] cluster and 
Coenzyme A were built into the electron density in all four chains in the ASU. 
The native PrpR81-486 crystal was collected to 2.5 Å and had slightly different unit 
cell dimensions. The crystal was indexed to a higher symmetry of the P41212 space 
group with a = b = 144.88 Å, c = 97.77 Å. In this case, a tetramer was formed with two 
molecules relating to the other two in twofold crystallographic symmetry. Since the 
native crystal is non-isomorphous to the heavy atom derived one, a molecular 
replacement search was performed in Phaser-MR (162) in PHENIX (163) using one 
polypeptide chain from the Se-PrpR81-486 tetramer. Refinement was carried out using 
phenix.refine (164), by randomizing the B-factor of the MR solution and applying 
simulated annealing to remove the trace of refinement of the initial model. Real space 
refinement was performed in phenix.refine and Coot. Fifteen TLS groups were defined 
by phenix.refine and applied in the refinement. X-ray/stereochemistry and X-ray/ADP 
weights were optimized in the final cycles of refinement to improve the refinement 
statistics. 
The MtPrpR81-486_F155H variant crystal diffracted to 2.7 Å, and the unit cell was 
isomorphous to the native PrpR81-486. The structure of the wildtype protein was directly 
refined against the mutant data by transferring the test set from the wildtype data. The 
process of refinement was analogous to that of the wildtype protein. 
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The MtPrpR155-440 crystal diffracted to about 1.8 Å and belonged to the I222 
space group with a = 75.03, b = 81.71, c = 95.37, α = β = γ = 90°. A molecular 
replacement search was performed in Phaser-MR using one molecule of MtPrpR81-486 
trimmed to appropriate positions as the search model. The manual model building and 
refinement were performed in Coot and phenix.refine analogous to that of the native 
MtPrpR81-486. 
The interface analysis was performed with PISA (165). The 3D structure 
similarity search was performed in Dali (165) 
(http://ekhidna2.biocenter.helsinki.fi/dali/). The structure figures were generated using 
UCSF Chimera (166) (http://www.rbvi.ucsf.edu/chimera). 
 
II.2.5 Iron-sulfur cluster identification and redox characterisation 
The iron-sulfur cluster was initially identified with the UV-visible spectroscopy. 
MtPrpR81-486 protein was diluted to 30 μM and transferred to a quartz cuvette of 1 cm 
path length. The UV-visible spectra were recorded from 200 nm to 800 nm using a Cary 
50 UV-Vis spectrophotometer (Varian/Agilent Technologies, Santa Clara, CA, USA). A 
single peak was observed at 410 nm, indicating the presence of the [4Fe-4S] cluster. 
Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) was 
conducted using an ELAN DRC II ICP Mass Spectrometer (Perkin Elmer) to further 
confirm the identity and the stoichiometry of the metal ion. Iron standard was diluted in 
1% HNO3 to 25, 50, 100, 150, 200, and 250 ppb, and plotted as the standard curve. The 
protein sample (10 mg/ml) was denatured and 200-fold and 400-fold diluted in 1% 
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HNO3 to around 1.04 and 0.52 μM and centrifuged to remove the protein and was 
subjected into the ICP-MS system. The iron concentration was calculated based on the 
standard curve. 
The H2O2 oxidation test was performed by mixing 20 µM of purified MtPrpR81-
486 with different concentrations of H2O2 (Sigma-Aldrich) in the SEC buffer. The 
property of iron-sulfur cluster was monitored optically using the UV-visible 
spectrometry at indicated time points. 
The NO response was performed as described before (167). Briefly, PROLI 
NONOate (Cayman Chemical), the NO donor compound, was dissolved in 25 mM 
NaOH. And it was introduced into 50 µM of MtPrpR81-486 in 20 mM Tris-HCl pH 7.8, 
300 mM NaCl at indicated concentrations. Each molecule of PROLI NONOate can 
release two molecules of NO (t1/2=13 s at 25 °C) (168). The UV-visible spectrum was 
measured after 10 min incubation. 
 
II.2.6 Coenzyme A derivative isolation and identification 
The CoA derivative isolation procedure was performed at 4 °C to maintain the 
integrity of the molecules. 100 mg of 25 mg/ml of the wildtype MtPrpR81-486 or the 
F155H variant was denatured in 10 volumes of 8 M urea acidified with 0.1 M formic 
acid to stabilize the potential thioester bond. The urea was freshly made and purified 
with mixed bed resin (Sigma Aldridge) to minimize the content of isocyanate and other 
ions. Denatured protein solution was passed through a 30 kDa cut-off concentrator to 
remove the protein. Flow-through was collected and loaded onto Q fast flow sepharose 
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anion exchange resin (GE Healthcare Life Sciences). The resin was washed with five 
column volumes of 0.1 M formic acid, and eluted with two column volumes of 2 M 
ammonium formate in 0.1 M formic acid. The eluate was lyophilized and dissolved in 
0.2 ml pure water for identification. The LC-MS analysis was adapted from previous 
research on CoA derivatives. Specifically, a 10 µL sample solution was injected into a 
Kinetex 2.6 µm EVO C18 100A LC column 100 x 4.6 mm and separated by a mobile 
phase gradient elution of 50 mM ammonium acetate (A) and acetonitrile + 0.1% formic 
acid (B) at a flow rate of 0.5 mL/min. An Agilent 1200 Series LC system was used to 
start (B) at 10% and increase linearly to 100% from 0 to 8 minutes, hold (B) at 100% 
from 8–12 minutes, decrease linearly from 100% to 10% from 12–14 minutes, and held 
at 10% for an additional three minutes (total run time 17 minutes). A Bruker Daltonics 
micrOTOF-Q II LC-MS with an electrospray ionization system was operated in positive 
mode, at a source temperature of 220 ˚C, dry nitrogen gas flow of 11 l/min and under 3.5 
bars of pressure. A 0.4 mg/ml sodium formate external calibration solution was directly 
injected at 13 minutes for post data analysis and calibration. Quantification was based on 
integrating peak area corresponding to the elution of the target compound in the 
extracted product ion chromatograms. Data was processed using Bruker Hystar Software 
4.1 and extracted ion chromatograms were created for each target compound. 
 
II.2.7 Protein sequence alignment and analysis 
MtPrpR and a group of representative homologous protein sequences were 
aligned in Clustal Omega (169) (https://www.ebi.ac.uk/Tools/msa/clustalo/). The output 
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alignment file was further analyzed and illustrated using ESPpript 3.0 (170) 
(http://espript.ibcp.fr/ESPript/ESPript/index.php). The proteins with names are those 
whose functions are either reported before, or recognizable based on the genome 
context. The proteins with question marks are those with unknown functions and 
adjacent to uncharacterized genes or operons. 
 
II.2.8 Transcription level quantification 
Quantification of gene expression was performed using reverse transcription, 
quantitative PCR (RT-qPCR) as describe previously (140). PrpR variant strains were 
grown to log phage in 7H9 complete media, spun down, and resuspended to an OD600 of 
0.1 in 10 ml of 7H12 media (7H9 salts, 0.2% glycerol, 0.1% casamino acids, and 0.05% 
tyloxapol) with 0.02% of the indicated short chain fatty acid. After two days of 
exposure, RNA was isolated using the Direct-Zol RNA miniprep kit (Zymo Research) 
and cDNA was generated using Superscript IV reverse transcriptase (Invitrogen) with 
200-300 ng of total RNA as a template. The transcription of prpD, prpR icl1, and sigA 
was measured with the primers included in Table 2. Transcriptional level of prpD, prpR, 
and icl1 was quantified using the delta-delta CT method using sigA as a housekeeping 
gene to normalize for input. Expression of the prpR wildtype complement in acetate was 
set to one in each case. 
In the ramB knockdown experiments, wildtype H37Rv and the H37RvΔprpR 
mutant strains transformed with ramB knockdown vector were cultured in acetate or 
propionate media as describe above simultaneously with 100ng/ml ATc where indicated 
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to induce knockdown. RNA was collected after 48 hours of media exposure and 
induction, and was quantified as described above. 
 
II.2.9 Recognition DNA preparation and DNA-binding assay 
The 30 bp duplex DNA pieces were prepared by annealing Pos_30mer with 
equal molar of Neg_30mer in a thermocycler. The oligo mixtures were heated to 95 °C 
for 10 min and slowly cooled down to 25 °C in 35 min. The quality of the duplex DNA 
was evaluated in pre-cast 8% TBE gel (ThermoFisher Scientific). 
The 260 pb promoter region of the prp operon were amplified as described in the 
literature(135) using primers p1129c_Fw and p1129c_Rv. 
The interaction between MtPrpR and the suggested recognition DNA was tested 
using eletrophoretic mobility shift assay (EMSA). MtPrpR_V9 construct was used in the 
assay. The purified protein was prepared in serial dilutions as indicated in figures. 
Protein-DNA mix were loaded to pre-cast 8% TBE gel and resolved at 4 °C. The binding 
buffer, loading dye and other reagents were used following the supplier’s manual 
(ThermoFisher Scientific). Small molecule ligands were added when indicated. 
 
II.3 Results 
II.3.1 Identification of an iron-sulfur cluster in MtPrpR 
To understand the transcription activation of MCC at the molecular level, we 
employed X-ray crystallography to study the structure and function of its transcriptional 
regulator MtPrpR. We generated a number of different recombinant protein constructs of 
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MtPrpR that were subsequently overexpressed in E. coli (Fig. 16a), and most of the 
resultant proteins were either insoluble or easily aggregated (Fig. 16b). However, when 
we truncated the first 80 residues that contained the N-terminal helix-turn-helix DNA-
binding domain (residues 20-76) and its flanking loops, the resultant MtPrpR81-486 
protein was both soluble and monodispersed even at > 20 mg/ml. 
 
 
Figure 16. Expression and purification of MtPrpR constructs 
a, Truncations of MtPrpR. Numbers indicate the of N- (above) and C-termini 
(below) of the constructs. Protein domains are illustrated as in Fig. 14. b, Affinity 
purification of each construct in a. (1. Lysate, 2. Supernatant, 3. Flow-through, 4. 
Wash, 5. Elution). 
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 The MtPrpR81-486 had a yellowish brown color, and showed an absorbance peak 
at 410 nm in UV-visible spectrometry (Fig. 17a). The extinction coefficient at 410 nm 
(ε410 nm) was approximately 13,700 cm
-1 
M
-1
, indicating the potential presence of the 
iron-sulfur cluster. Inductively coupled plasma mass spectrometry (ICP-MS) confirmed 
the identity of the metal as Fe, and each polypeptide chain contains approximately 3.8 Fe 
(data not shown). Iron-sulfur clusters are typically oxygen labile and require stringent 
anaerobic conditions for the protein purification or cluster reconstitution. However, 
aerobically and anaerobically purified MtPrpR81-486 showed no apparent difference in 
solubility or UV-visible spectra. Moreover, the iron-sulfur cluster could tolerate 0.01 % 
(approximately 3 mM) of H2O2 (Fig. 17c) or 16-fold molar excess of nitric oxide (Fig. 
17d) for hours without showing a decrease of the absorbance peak at 410 nm. The 
cluster could only be reduced by > 30-fold molar excess of dithionite ion (Fig. 17b). 
This high level of stability of the iron-sulfur cluster suggests that MtPrpR was unlikely 
to be an oxidation stress sensor. 
We then assessed the importance of iron to MtPrpR stability by expressing 
MtPrpR81-486 in M9-dextrose media supplemented with common transition metal (Fe, 
Co, Ni, Cu and Zn) ions and we could only observe soluble MtPrpR when iron was 
added to the media (Fig. 17e). 
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Figure 17. Characterization of the iron-sulfur cluster of MtPrpR81-486 
a, UV-visible spectrophotometry of MtPrpR81-486. A peak at ~410 nm was observed. 
b, Sodium dithionite reduction of the iron-sulfur cluster in MtPrpR81-486. The 
absorbance at 410 nm was bleached by 30 fold molar excess of sodium dithionite 
over the time indicated. No bleaching effect was observed for twofold to tenfold 
molar excess of sodium dithionite. c, H2O2 at ≤ 0.01% did not decrease the the 410 
nm absorption peak of MtPrpR. d. Nitric oxide up to 32 molar excess did not 
decrease the 410 nm absorption peak of MtPrpR. e, Several common transition 
metals were tested to substitute iron in MtPrpR81-486 expression. Only iron could 
yield soluble protein (L, lysate; S, supernatant). 
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II.3.2 Crystal structure of MtPrpR81-486 
To visualize the iron-sulfur cluster binding mode in MtPrpR, we conducted 
crystallization trials on several of the above mentioned protein constructs, and only the 
stable MtPrpR81-486 produced protein crystals. An X-ray diffraction dataset to 2.70 Å 
resolution was collected and phased using the selenium-single-wavelength anomalous 
diffraction (Se-SAD) methods (171, 172) with the selenomethionine-derived (Se-Met) 
protein crystals (Table 3). Interestingly, the Se-Met protein crystallized in the P212121 
space group with two axes of very similar lengths (a = 142.37 Å, b = 145.96 Å).  
However, the native protein crystallized in a similarly packed unit cell but in the higher 
symmetry space group P41212 with a = b = 144.87 Å. The asymmetric unit (ASU) of the 
P41212 crystal contained two protein molecules and was equivalent to half of the ASU of 
the P212121 crystal. Nevertheless, the overall crystal unit cell volumes and the structures 
of both forms were nearly identical. The biological assembly of MtPrpR81-486 in the 
crystals was a homotetramer suggested by PISA(173) (Fig. 18a), which was consistent 
with our size exclusion chromatography (SEC) results (Fig. 18b). The four polypeptide 
chains organized in D2 symmetry (Fig. 18a). The shared surface area of the interface on 
each chain were around 2,400 Å
2
 between Chain A and B, around 1,250 Å
2 
between 
Chain A and C, and around 340 Å
2
 between Chain A and D (Fig. 18b). Since the four 
chains in the Se-Met structure were virtually identical (Cα_RMSD < 0.3 Å), we focus on 
Chain A for subsequent depictions. 
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Table 3. Crystallographic data collection and refinement statistics 
 SeMet 
PrpR81-486 
Native 
PrpR81-486 
PrpR81-486 
_F155H 
PrpR155-440 
PDB code 6CZ6 6CYY 6CYJ 6D2S 
Data Collection     
Space Group P212121 P41212 P41212 I222 
Unit cell demensions  
 
  
 
 
 
a, b, c (Å) 96.19, 142.37, 
145.96 
144.87, 144.87, 
97.27 
144.49, 144.49, 
96.19 
75.00, 81.72, 95.36 
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Wavelength (Å) 0.97949 1.07507 1.03328 0.97935 
Resolution range (Å)  50.00-2.70 
(2.75-2.70) 
50.00-2.50 
(2.54-2.50) 
50.00-2.70 
(2.75-2.70) 
50.00-1.82 
(1.85-1.82) 
Unique reflections * 55,505 (2,747) 35,534 (1,773) 27,986 (1,414) 26,651 (1,274) 
Multiplicity * 7.4 (7.4) 21.2 (22.6) 17.0 (17.1) 9.5 (7.3) 
Completeness (%) * 100.0 (100.0) 98.4 (100.0) 97.8 (100.0) 99.8 (100) 
Rmerge 
* 0.108 (1.132) 0.059 (0.733) 0.078 (1.052) 0.043 (0.241) 
Rpim 
* 0.043 (0.446) 0.013 (0.157) 0.019 (0.258) 0.015 (0.095) 
I/σ (I) * 21.80 (1.38) 66.7 (3.77) 45.60 (2.44) 61.53 (10.11) 
Wilson B value (Å2) 65.88 70.26 78.74 20.30 
Refinement     
Resolution (Å) 45.56-2.70 (2.80-
2.70) 
46.10-2.51 (2.60-
2.51) 
45.63-2.70 (2.80-
2.70) 
32.09-1.82 (1.88-
1.82) 
Rwork/Rfree 
* 0.182/0.212 
(0.302/0.345) 
0.183/0.214 
(0.259/0.307) 
0.185/0.218 
(0.281/0.364) 
0.179/0.214 
(0.205/0.269) 
No. of atoms 10,515 5,288 5,286 2,484 
Protein 10,267 5,172 5,158 2,287 
Ligand 224 112 126 5 
Solvent 24 4 2 192 
Mean B factors (Å2) 67.29 77.75 85.96 27.72 
Protein 67.28 77.85 86.05 26.87 
Ligand 69.43 73.98 82.36 24.43 
Solvent 52.00 62.62 69.59 37.83 
Rmsd bond length (Å) 0.005 0.004 0.003 0.007 
Rmsd bond angle (°) 0.763 0.823 0.721 0.834 
Clashscore 5.90 3.55 6.15 5.67 
Number of TLS groups 28 15 15 2 
Ramachandran plot (%) 
(favored/allowed/outliers) 
97.69/2.31/0.00 97.87/2.13/0.00 98.47/1.53/0.00 97.79/2.21/0.00 
Rotamer outliers (%) 0.94 0.00 0.56 0.00 
* Values in parentheses indicate highest-resolution bin. 
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Figure 18. Structure of MtPrpR81-486 and analytical SEC of MtPrpR81-486 in solution  
a, Crystal structure of MtPrpR81-486 tetramer. The four chains are labeled and 
shown in different colors. Arrows and ellipse indicate the positions and directions 
of the two-fold rotation axes of the tetramer. b, Size exclusion chromatography 
analysis of MtPrpR81-486 with or without TCA and MCC intermediates citrate 
and methylcitrate. 
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Based on the visible part of the truncated protein structure, MtPrpR contains at 
least three domains (Fig. 20a), including the N-terminal DNA-binding domain (residues 
20-76) that was removed in our protein construct. A disordered region (residues 81-152) 
connected the DBD to the second domain (designated DII, residues 153-324). The 
electron density for the disordered region was not visible in our crustal structure, but 
based on the length of this region, it is likely to form a domain. Protein mass 
spectrometry confirmed that this region was present in the crystallized protein (Fig. 19). 
The DII domain is composed of a nine-helix bundle and a three-stranded β-sheet (Fig. 
20). A loop (residues 325-334) links the DII to a GAF-like (cGMP 
phosphodiesterase/adenylyl cyclase/FhlA) (174) domain (residues 335-419). 
 
 
Figure 19. Mass spectrometry of the His-tagged MtPrpR81-486 crystals  
Protein intact MS showed a de-convoluted peak with a [M+H]
+
 m/z of 47,743, 
indicating that no proteolysis had occurred. 
 
MtPrpR also contains a long C-terminal region (residues 420-486) consisting 
primarily of loops plus several fairly short secondary structure elements. The C-terminal 
region of Chain A interacts with the DII-GAF di-domain of Chain B (Fig. 18a, Fig. 20). 
The interaction is stabilized by an extended β-sheet formation between a short β-strand 
  
78 
 
at the end of the C-terminal region and the three β-strands in the DII domain of the 
neighboring chain (Fig. 20). 
 
Figure 20. Iron-sulfur cluster binding mode of MtPrpR81-486 
Chain A (color in pink) and Chain B (color as in the domain organization) are 
extracted from the tetramer. The iron-sulfur cluster binding site is zoomed in. 2Fo-
Fc electron density of iron-sulfur cluster is shown at a contour level of 1 σ. 
 
  
79 
 
The cubane-type [4Fe4S] cluster resides in the C-terminal region (Fig. 20) with 
three of the four irons ligated by Cys447, Cys450 and Cys455 in a C-X2-C-X4-C motif 
which appears to be conserved among all MtPrpR homologs (Fig. 21). Cys363 from the 
GAF-like domain of the same chain coordinates the fourth iron (Fig. 20). The loop 
harboring the C-X2-C-X4-C motif wraps around the iron-sulfur cluster and buries the 
majority of it inside the protein, which we postulate as the major contribution to the 
stability of the cluster when the protein was exposed to air. 
A 3D structure similarity search of the MtPrpR81-486 structure against the Protein 
Data Bank (PDB) (165) suggested that apart from the hits on the well-studied GAF 
domain, the only structure that showed significant similarity to MtPrpR81-486 was a 
Deinococcus deserti DNA damage repair regulator IrrE (146) (PDB code: 3DTI and 
related entries, Z-score 15.5, rmsd 5.0 Å, Fig. 22a, b). There were only around 240 
residues within the DII-GAF region of MtPrpR81-486 that could be structurally aligned to 
IrrE, and the sequence identity of the region was only 14%. IrrE was proposed as a 
metalloprotease with an HEXXH motif coordinating a Zn ion (146, 147) (Fig. 22b). 
However, those residues are not conserved in MtPrpR. 
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Figure 21. Sequence alignment of MtPrpR and homologs 
The CoA adenine group interacting residues are pointed with black triangles. The 
CoA hydrogen bonding residues are pointed with purple triangles. The CoA tail 
contacting residue is pointed with green triangle. The cysteinyl residues ligating the 
iron-sulfur cluster are pointed with yellow triangles. 
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Figure 22. Structure comparison between MtPrpR81-486 and D. deserti IrrE 
 a, Superposition of MtPrpR81-486 (colored by the domains as in Fig. 20) and IrrE 
from D. deserti (orange, PDB accession number: 3DTI). The RMSD of 160 aligned 
Cα of DII domain is 2.33 Å, and 7.79 Å over all 229 Cα pairs between the two 
proteins. b, Rotating (a) by 90 degree to show the ligand binding cavity in 
MtPrpR81-486 (dashed ellipse), and the zinc binding site of the putative 
metaloprotease domain in IrrE (square). A close-in view of the zinc-binding site 
shows that the residues are not conserved in MtPrpR. The IrrE residues are labeled 
in black; the MtPrpR residues are labeled in blue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
82 
 
II.3.3 Identification of Coenzyme A in MtPrpR 
After building and refining the protein atoms and the iron-sulfur clusters into the 
electron density map, we observed a large electron density blob in each polypeptide 
chain that could not be accounted for by protein. These electron density peaks were 
nearly identical in shape, and they were located in the cleft between the DII and GAF 
domains in both the Fo-Fc and 2Fo-Fc difference electron density maps (Fig. 23a), 
indicating a ligand molecule had been cocrystallized with the protein. To identify the 
ligand, MtPrpR81-486 was denatured, and the ligand was enriched by ion exchange resin 
and subjected to liquid chromatography-high resolution mass spectrometry (LC-MS). 
The [M+H]
+
 m/z value showed that the majority of the ligand was Coenzyme A (768.12) 
from protein expressed in LB media (Fig. 23b). When the protein was expressed in M9-
dextrose-iron media, acetyl-CoA ([M+H]
+
 m/z = 810.12) was also detected besides CoA 
(Fig. 23c). The ratio of acetyl-CoA to CoA was about 1:8 according to the HPLC UV 
chromatogram (data not shown). However, we did not observe well defined electron 
density of the acetyl group, although there was room for it in the binding cavity. 
Therefore, the predominant CoA was built into all protein chains, and the CoA 
molecules fit very nicely into the electron density map with occupancies of 1.0 and 
reasonable refined B-factors. 
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Figure 23. Identification of CoA in MtPrpR81-486 
a, Coenzyme A binding cavity in MtPrpR81-486; protein chain is colored in grey. The 
binding cavity is cooperatively formed by the DII (left, mainly helix bundles) and 
GAF (right, mainly β sheets) domains. Key interacting residues are labeled. CoA is 
shown in stick and ball; 2Fo-Fc map of CoA is contoured at 1 σ. Electron density of 
CoA is also displayed by a 90 degree rotation. b and c, Mass spectrum of CoA and 
its derivatives extracted from purified MtPrpR81-486 expressed in LB (b) or in M9-
dextrose (c) media. 
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Although the GAF-like domain in MtPrpR participated in the CoA binding, the 
binding mode was quite different from those found in typical GAF domain structures. 
The canonical GAF domain and the closely related PAS (Per-Arnt-Sim) domain have 
been reported to bind to a variety of signaling molecules (174-178) on the concave face 
of the central β-sheet of the GAF domain (Fig. 24). However, the CoA binding cavity in 
MtPrpR was cooperatively formed between the convex face of the central β-sheet of the 
GAF-like domain and the helix bundle of the DII domain (Fig. 23a, 24a, b). The CoA 
molecule embedded snugly in the cavity. The adenine group was sandwiched between 
Phe240 and His319, and was held in place by π-π interactions. The rest of CoA bound 
via 13 hydrogen bonds and electrostatic interactions contributed by the side chains or 
backbone atoms of seven amino acids in the DII and GAF domains (Fig. 25). The 
diphosphate group in particular was surrounded by four basic residues, Lys217, 347 and 
410 and Arg338. Phe155 located at the bottom of CoA binding cavity and contacted the 
cysteamine thiol through van der Waals interactions. The C-terminal loop region of the 
neighboring Chain B forms a hinged triangular lid that covers the CoA binding cavity of 
Chain A (Fig. 26c). 
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Figure 24. Structure and ligand binding mode comparisons between canonical GAF 
and MtPrpR GAF-like domains 
a, Topology diagrams of canonical GAF domain (left) and the GAF-like domain in 
MtPrpR (179) indicate the ligand binding modes are different. b, Comparison of 
the canonical cGMP bound GAF domain structure (magenta, PDB code: 1MC0) 
with the GAF-like domain in MtPrpR structure (protein colored in yellow and 
ligand colored in cyan). 
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Figure 25. Interactions between MtPrpR81-486 and CoA  
The residues contributing to π-π interactions are colored in green. The residues and 
hydrogen bonds between protein and CoA are colored in blue, and Glu315 which 
forms intramolecular hydrogen bonds to stabilize Arg348 and Lys347 is colored in 
magenta. The CoA tail contacting residue Phe155 is colored in orange. 
 
 
 The hinge region harbors the C-X2-C-X4-C motif where the iron-sulfur cluster is 
ligated. The bound of the iron-sulfur cluster appears to rigidify the hinge region, as 
indicated by the lower local b-factors (Fig. 26a, b). This makes it difficult for the lid to 
open, and therefore CoA appears to be locked inside the cavity (Fig. 26c). Common 
ligand stripping procedures such as dialysis failed to dissociate CoA from the protein. 
From the structural aspect, the integrity of the iron-sulfur cluster appears to be pivotal 
for protein oligomerization and the retention of CoA in the cavity. 
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Figure 26. Relationship between iron-sulfur cluster and CoA binding 
a, MtPrpR81-486 rendered by b-factor (Å
2
). b, A close-in view of a around the iron-
sulfur cluster. c, The hinged triangle lid (dark grey) that covers the CoA binding 
pocket of the neighboring chain (orange). The iron-sulfur cluster is located at the 
hinge region and stabilizes the hinge. 
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II.3.4 The iron-sulfur cluster is critical for CoA binding and transcription activation 
 To determine if the iron-sulfur cluster in the structure was important for 
transcriptional regulation, we picked two iron-coordinating cysteine residues, Cys363 in 
the GAF-like domain and Cys450 in the C-terminal C-X2-C-X4-C motif, and mutated 
them individually into alanine (C363A and C450A) in a prpR-containing shuttle vector 
(140). We chromosomally integrated the wildtype prpR, each mutant, or an empty vector 
into the prpR deleted M. tuberculosis laboratory strain H37Rv (H37RvΔprpR) (104). The 
upregulation of prp operon, represented by prpD, or prpR in response to propionate were 
completely abolished in the ΔprpR::C363A, ΔprpR::C450A, and ΔprpR::vector strains 
(Fig. 27). 
 We next sought to visualize the iron-sulfur free form of the protein. Since 
overexpressing MtPrpR81-486 in the iron-free M9-dextrose media failed to produce 
soluble protein, we truncated a large portion of the C-terminal region (residues 441-486) 
containing the C-X2-C-X4-C iron-sulfur cluster-binding motif. In addition, residues 81-
154, which were disordered and not visible in the MtPrpR81-486 structure, were also 
removed from the expression construct. The resultant prpR155-440 construct produced 
soluble protein with no color, and the MtPrpR155-440 protein was a monomer in solution 
as shown by the size exclusion chromatography (Fig. 28a). The crystal structure of 
MtPrpR155-440 showed that the protein retained the DII-GAF core structure of MtPrpR81-
486 and, as expected, had no bound iron-sulfur cluster (Fig. 28b). Interestingly, the CoA 
was also absent in the structure, even though 1 mM CoA was mixed with the protein 
during crystallization. The structure of the CoA binding cavity revealed a dramatic 
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conformational change of the protein (Fig. 28c). The loop between β7 and β8 of the 
GAF-like domain flipped back nearly 180 degrees, thereby blocking the CoA cavity 
entrance. A hydrophobic fragment of the loop with the amino acid sequence of 
G402L403G404Y405L406G407P408 inserts into the CoA binding cavity and interacts with 
Trp232, Phe240, 336, 412, and Val414, all within van der Waals distances to the loop 
(Fig. 28d). Gly404, Tyr405 and Leu406 at the tip of the loop occupy the space where the 
3’-phosphoadenosine diphosphate moiety of CoA resided in the CoA bound form of the 
protein (Fig. 28c). While in the tetrameric MtPrpR81-486 structure, the aromatic Tyr405 
and the aliphatic Leu403, 406 and Pro408 in the loop in Chain A were surrounded by the 
hydrophobic residues Leu365 and Ala456 in Chain B, and Leu305, Ile378, Val427 and 
Tyr428 in Chain C, all within 5 Å distances (Fig. 28e). In addition, Asp302 in Chain C 
hydrogen bonded (2.8 Å) to the backbone nitrogen of Tyr405 (Fig. 28e). These 
interactions would essentially hold the hydrophobic loop in an open conformation 
 
 
Figure 27. Transcription levels of prpD and prpR in MtPrpR variants under acetate 
or propionate conditions 
Values presented as mean ± SD (N=3 for wildtype and each variant, Data were 
analyzed with two-way ANOVA followed by Sidak’s test, **** p<0.0001). 
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Figure 28. Structural characterization of MtPrpR155-440 
a, Size exclusion chromatography analysis of MtPrpR155-400. b, Crystal structure of 
MtPrpR155-400. c, Conformational change of MtPrpR in the presence (green and 
grey for the two neighboring chains) or absence (180) of the iron-sulfur cluster 
binding region. The surface of CoA is shown in orange. Red arrow indicates the 
open and closed forms of the loop. Solid-line square is zoomed in (d) to show the 
hydrophobic interactions in the loop-closed conformation. Dashed-line square is 
zoomed in (e, Chain A in green, Chain B in violet, Chain C in grey) to show the 
interactions in the loop-open conformation. 
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allowing for CoA binding. Taken together, this conformational change of the protein, 
likely induced by the lack of the iron sulfur cluster, prevented CoA from binding. 
 
II.3.5 CoA derivatives control the MCC pathway activation 
 The π-π interactions between CoA adenine group and the residues Phe240 and 
His319 may play critical roles during CoA binding. These two residues appear to be 
invariable in most MtPrpR homologs (Fig. 21). To test the importance of these 
interactions, we complemented the H37RvΔprpR strain with each of the prpR_F240A, 
prpR_H319A single mutations or prpR_F204A/H319A double mutation. None of the 
resultant strains could upregulate prpD or prpR in response to propionate (Fig. 27). 
 There is good agreement between our studies (Fig. 27, 30, 32) and the literature 
(104, 135) on prpR that it activates the transcription of the prp operon only under 
propionate or cholesterol carbon utilization, where propionyl-CoA is the common 
metabolite. Therefore, we speculated that the CoA bound MtPrpR was not the active 
form, but that propionyl-CoA was the switch molecule used to activate the prp operon 
transcription. We tried to crystallize propionyl-CoA bound MtPrpR81-486 by mixing the 
protein with different concentrations of propionyl-CoA, or by purifying MtPrpR81-486 
expressed in M9-propionate media. Nonetheless, the desired propionyl group was not 
discernible in the electron density map. 
 We therefore virtually modeled propionyl-CoA into the MtPrpR81-486 structure by 
treating the protein as a rigid body (Fig. 29a, b). This led to steric clashes between the 
propionyl group and Phe155 (Fig. 29c). These clashes cannot be overcome by simply 
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changing the rotamer conformation of Phe155 (Fig. 29d). Instead, a roughly fifteen-
degree movement of the α-helix (α1, the first visible helix) where Phe155 locates is 
required for the protein to accommodate propionyl-CoA. This also implies that Phe155 
may directly participate in the ligand selection. 
 
 
Figure 29. MtPrpR81-486 with propionyl-CoA computationally modeled into the CoA 
binding cavity 
a, Propionyl-CoA was modeled into the MtPrpR81-486_WT structure. Electrostatic 
surface is shown (red, negative charge; blue, positive charge; unit kcal*mol
-1
*e
-1
). 
b, Close-in view of a. c, Propionyl-CoA clashes with protein chain. Atoms within 5 
Å to the C1 and C2 of the propionyl group are colored in pink. Distance between 
Phe155 and C1 is ~2.3 Å. Black wires represent the possible rotamers of Phe155. d, 
A roughly 15° movement of α1 (blue, new position) is required to overcome the 
clashes. 
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Through a structure guided sequence comparison, we noticed that Phe155 in 
MtPrpR is replaced by a histidine in its paralog MtRamB (Phe155His143, Fig. 30a), 
while other CoA contacting residues remains identical. Recall that MtRamB has been 
shown as a transcriptional repressor of icl1 in dextrose containing media (148). We 
hypothesized that the PheHis substitution would allow MtRamB to bind to a different 
CoA derivative, and that F155H mutation of MtPrpR would affect its ability to respond 
to propionyl-CoA. We therefore integrated a prpR_F155H mutant allele into the 
H37RvΔprpR genome. The ΔprpR::F155H retained no activity in response to propionate 
in two experimental runs (Fig.30b). Mutating Phe155 into alanine, which has an even 
smaller side chain, completely abrogated the upregulaiton of prpD and prpR. While 
mutating Phe155 into the bulky aromatic residues tryptophan or tyrosine restored the 
upregulation of prpD and prpR to the wildtype level (Fig 30b). In fact, these bulky 
aromatic residues naturally exist in MtPrpR homologs activating either the methylcitrate 
cycle (i.e. Ajs_1637 protein of Acidovorax sp. JS42 strain harbors a Tyr (181)) or the 
methylmalonyl pathway (i.e. the PccR protein of Rhodobacter sphaeroides harbors a Trp 
(150)) (Fig. 21). Notably, both pathways are used by bacteria to assimilate propionyl-
CoA. Therefore, it leads to the postulate that propionyl-CoA clashes with those aromatic 
residues and induces a similar conformational change of the proteins. 
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Figure 30. Study of the role of Phe155 in CoA derivative binding 
a, Sequence alignment of the helix α1 between MtPrpR and MtRamB, highlighting 
Phe155 in MtPrpR and its counterpart His143 in MtRamB. e, and f, Transcription 
level of prpD (N=3) and prpR (N=3) in MtPrpR_F155 variants under acetate or 
propionate conditions. Values presented as mean ± SD (Data were analyzed with 
two-way ANOVA followed by Sidak’s test, **** p<0.0001). 
 
II.3.6 MtRamB may recognise succinyl-CoA 
 We were particularly interested in the identity of the ligand recognized by 
MtRamB. However, the insolubility of the full-length MtRamB and the aggregation of 
MtRamB69-474 with the helix-turn-helix DNA-binding domain truncated similar to 
MtPrpR81-486 obstructed a direct study of MtRamB. We instead used MtPrpR81-
486_F155H as a mimic based on the fact that the other CoA binding residues in both 
proteins are identical. MtPrpR81-486_F155H remained a tetramer in solution as shown by 
the size exclusion chromatography (Fig. 31a) and crystallized in the same condition as 
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the wildtype protein. The overall structure of the polypeptide chain superimposed 
perfectly to the CoA-bound wildtype protein, including the helix α1 where residue 155 is 
located (Cα_RMSD = 0.314 Å, Fig. 31c). The 2Fo-Fc and Fo-Fc electron density maps 
showed that the ligand was longer than CoA (Fig. 31d), indicated a fatty acyl CoA 
derivative was bound to this mutant protein. The ligand was purified and identified using 
LC-MS. A monoisotopic molecular ion peak with a [M+H]
+
 m/z value of 868.12 was 
detected (Fig. 31b) besides CoA. The amount of CoA was less than a quarter of the new 
compound according to the UV chromatogram (data not shown). This mass corresponds 
to both epimers of methylmalonyl-CoA as well as succinyl-CoA, which share an 
identical chemical formula. Attempting to build (R)- or (S)- methylmalonyl-CoA into 
the electron density resulted in a strong negative electron density peak (> 4 σ) around the 
methyl branch in Fo-Fc map (Extended Data Fig. 31e). The methyl branch also caused 
steric clashes with adjacent residues His155 and Arg159, while succinyl-CoA nicely fit 
the electron density with no steric overlap (Fig. 31f). The terminal carboxyl group of the 
succinyl moiety interacts with His155 (~ 4 Å), Arg348, and Arg159 (~ 2.8-3.2 Å) (Fig. 
31g). 
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Figure 31. Characterization of MtPrpR81-486_F155H as a mimic of MtRamB 
a, Size exclusion chromatography of MtPrpR81-486 wildtype and F155H variant. b, 
Mass spectrum of the ligands. M/z and ligand identities are labeled (SCA for 
succinyl CoA; SCA+Na
+
 for the sodium adduct form of SCA). c, Structure 
comparison between MtPrpR81-486_WT and the F155H variant. The first visible 
helix α1 in the two neighboring chains, where residue 155 is located, are indicated 
with black arrows. d, 2Fo-Fc map (blue, contoured at 1.0 σ) and positive Fo-Fc map 
(green, contoured at 3.0 σ) of MtPrpR_F155H with CoA built into the electron 
density. e, 2Fo-Fc map (blue, contoured at 1.0 σ) and negative Fo-Fc map (green, 
contoured at 3.0 σ) of MtPrpR_F155H with (S)-methylmalonyl-CoA built into the 
electron density. f, 2Fo-Fc electron density of succinyl CoA bound by MtPrpR81-
486_F155H mutant, electron density contoured at 1 σ. g, Succinyl CoA binding 
environment. Dashed lines indicate the hydrogen bond and electrostatic 
interactions between protein and succinyl moiety. 
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Figure 31. Continued. 
 
II.3.7 PrpR and RamB cross-regulate icl1 but not MCC 
 Given that Mtb has two homologous regulators, crosstalk between prpR and 
ramB is very likely. To understand if this was the case, we incorporated a tunable ramB 
knockdown into both wildtype and the prpR deleted backgrounds using a CRISPR 
interference (CRISPRi) system optimized for Mtb (151). The knockdown of ramB was 
confirmed as measured by a depletion of 80 to 90 % of its transcription after anhydrous 
tetracycline (ATc) induction (Fig. 32a).  
 Our studies showed that icl1 transcription was controlled by both MtRamB and 
MtPrpR. MtRamB acted as a consistent repressor under all tested conditions and genetic 
backgrounds. By depleting ramB, icl1 was upregulated by at least three-fold compared 
to the wildtype background in acetate media and without ATc induction regardless of the 
carbon source (Fig. 32b). MtPrpR, on the other hand, could upregulated icl1 by about 
seven-fold, but the upregulation only occurred in response to propionate exposure, 
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irrespective of the level of ramB (Fig. 32b). This is because icl1 is also the MCL (25, 
127) in Mtb, it needs to be upregulated by MtPrpR during propionyl-CoA exposure. 
 Unlike icl1, prpD and prpR, which specifically participate in MCC, were only 
robustly upregulated by MtPrpR under propionate condition (Fig. 32c, d). Depleting 
ramB had no noticeable effect on the transcription level of prpD or prpR under either 
carbon sources. 
 
 
Figure 32. Cross-regulation of MCC and glyoxylate shunt by prpR and ramB  
a, Transcription level of ramB in Mtb H37Rv or ΔprpR strains with or without 
anhydrous tetracycline (ATc) induction and under acetate or propionate carbon 
sources. b, c, and d, Transcription levels of icl1, prpD, and prpR in the same 
situations as in a. Black bars are WT H37Rv transformed with ATc inducible 
vector. Red bars are H37RvΔprpR transformed with the same vector. N=2 for each 
strain, treatment and carbon source combination. Data were analyzed with two-
way ANOVA followed by Tukey’s test. *** p=0.0002. 
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II.3.8 MtPrpR may require propionyl-CoA to specifically bind to the promoter region of 
prp operon  
It has been shown that the recognition sites of both MtPrpR and MtRamB harbor 
tandem palindromic repeats TTCGCAAAATTTGCAAA (Fig. 14) (135, 148). Similar 
DNA sequences were also proposed as the operator sites of MtPrpR homologs in other 
organisms(150). To analyze the DNA binding by MtPrpR, the N-terminal His6-tagged 
MtPrpR_V9 recombinant protein was used throughout EMSAs, since Val9 was 
predicted to be the first amino acid of the ORF after genome re-annotation, and 
MtPrpR_V9 was more soluble than MtPrpR_M1 (Fig. 16b). But similar to MtPrpR_M1, 
MtPrpR_V9 was still not very stable. Therefore, we had to purify fresh proteins each 
time for EMSA, and this led to some level of variability in the experiments due to batch-
to-batch variability of the protein quality. We evaluated the binding between the purified 
MtPrpR_V9 and a 30 bp oligonucleotides of the prp operon promoter region centered by 
the tandem repeats (Fig. 33). EMSA showed that the affinity between MtPrpR_V9 and 
the tandem repeats was weak with a dissociation constant roughly estimated to > 800 nM 
based on the ratio of shifted and unshifted bands. In addition, the dual palindromic and 
half palindromic DNA pieces did not show noticeable difference in binding. When the 
sheared salmon sperm DNA (100 µg/ml) was added into the buffer to reduce nonspecific 
binding, the affinity became even weaker. This seems to indicate that the DNA binding 
in the tested condition was likely not specific, and thus was not physiologically relevant,. 
When the DNA length was extended to 260 bp to cover the promoter region (p_1129c), 
the binding seemed to be slightly improved (Fig. 34). However, the F155H mutant form 
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could also bind to p_1129c with similar affinity. Given that F155H does not bind to 
propionyl-CoA but preferentially binds to succinyl-CoA, we conclude that the poor 
binding that we observed was not relevant to the robust transcriptional activation 
induced by propionyl-CoA. In addition, MtPrpR could also bind to irrelevant DNA 
pieces under the experimental conditions (Fig. 35). 
 Next we investigated whether the small molecules that had been proposed as 
PrpR effector could affect the binding or not. The small molecules include 2-
methylcitrate and cAMP. We picked an intermediate protein concentration where both 
free and shifted DNA fragments were present. This would allow us to tell easily if the 
DNA binding was enhanced or disrupted in the presence of the small molecules. We did 
not notice obvious difference in the DNA binding with the addition of either small 
molecule, although the MCC intermediate 2-methylcitrate at 500 µM showed a more 
intense shifted band (Fig. 36). It is worth mentioning that the commercially available 2-
methylcitrate is a racemic mixture of diastereomers, which means the bioactive forms 
may be one half of the total concentration being used. 2-methylcitrate did not 
significantly affect the shape or oligomeric state of MtPrpR81-486 based on the SEC 
analysis (Fig. 18b). The effect of 2-methylcitrate may need further investigations. 
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Figure 33. Binding of MtPrpR_V9 to different forms of 30 bp DNA 
Binding between MtPrpR_V9 and the original dual palindrome DNA (left) was 
similar to binding between MtPrpR_V9 and the half palindrome DNA (middle). 
The DNA was stained with SYBR Green. When sheared salmon sperm DNA (sSSD) 
was added as competitor (right), the affinity appeared even lower. The intensities of 
the Cy3-Pal30mer bands were weak because we did not have a gel documentation 
instrument with light source or filter compatible with Cy3 dye, and staining with 
SYBR green gave too strong background due to sSSD. 
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Figure 34. Binding of wildtype and F155H variant MtPrpR_V9 to the260 bp 
promoter region of the prp operon 
 
 
Figure 35. Binding of MtPrpR_V9 to physiologically irrelevant DNA fragments of 
the Mtb embC gene 
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Figure 36. The effects of 2-methylcitrate and cAMP on the DNA affinity of 
MtPrpR_V9 
Neither molecule showed obvious trend of increased or decreased DNA affinity. 
 
 
II.4 Discussion 
II.4.1 Regulatory model of MCC and glyoxylate shunt by MtPrpR and MtRamB 
 Mtb’s dependence on lipid catabolism (22), especially cholesterol (34), is well 
documented, as is its reliance on MCC to assimilate propionyl-CoA and detoxify the 
metabolic intermediates (25, 129, 130). The local transcriptional regulator MtPrpR 
determines the on and off states of MCC (104, 135, 138). However, the triggering 
molecule that activates MCC has not been found yet, and consequently, the biochemical 
mechanism of the regulation has remained a mystery. In our studies, we showed that the 
major regulator of MCC, MtPrpR directly binds to CoA and three CoA derivatives, and 
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that the binding is under the control of an unexpectedly identified iron-sulfur cluster 
which was located at the C-terminal region of the protein. 
 All genetic studies so far pointed to propionyl-CoA as the triggering molecule of 
MCC since the pathway was only activated in propionyl-CoA producing conditions. 
However, our structure and LC-MS data showed that MtPrpR also readily bound to CoA 
and acetyl-CoA. This was not surprising because the CoA binding cavity of MtPrpR 
does not possess any dedicated feature, such as a potential hydrophobic pocket, to 
accommodate the extra propionyl group. Therefore, this strongly suggests that the 
selection of propionyl-CoA verse other CoA derivatives is a thermodynamic driven 
process mainly determined by the proportion of propionyl-CoA in the intracellular CoA 
pool. This explains the earlier finding that the relative balance, but not the absolute 
abundance, of the three- to two-carbon intermediates impacts the fitness of the bacilli 
(105). In addition, it becomes apparent that the transcription of all three MCC enzymes 
is controlled by the levels of intracellular short-chain fatty acyl-CoAs (SCFAs), 
especially propionyl- and acetyl-CoA (Fig. 32). We herein propose a regulatory model 
of the transcriptional regulation of MCC based on different carbon sources (Fig. 37). 
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Figure 37. Schematic of MtPrpR/MtRamB regulation mediated by short chain fatty 
acyl CoA molecules 
a, Under propionyl-CoA-producing conditions, the active form of MtPrpR 
(MtPrpRa, propionyl-CoA bound) dominates the transcription of the prp operon 
and icl1 to detoxify propionyl-CoA, regardless of the presence of MtRamB 
(succinyl-CoA or CoA bound) and inactive forms of MtPrpR (MtPrpRi, CoA or 
acetyl-CoA bound). b, Under acetate and even chain fatty acids conditions, acetyl-
CoA in large quantity would be produced. MtPrpRi cannot upregule prp operon or 
icl1, while MtRamB could still repress the transcription of icl1 to some extent. But 
since the glyoxylate shunt is required, the icl1 transcription needs to be maintained 
at a certain level. c, During dextrose utilization, succinyl-CoA is produced in TCA 
cycle. MtRamB with succinyl-CoA bound is expected to repress the transcription of 
icl1, which is not required in this case. 
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 One remaining question is what ratio of intracellular propionyl- to acetyl-CoA 
can turn on MCC. Although we were not able to investigate it biochemically, a previous 
icl1 deleted Mtb whole cell experiment showed that over 80-fold molar excess of acetate 
in the growth media of Mtb was required to remove the growth inhibition by propionate 
(105). As a comparison, each molecule of cholesterol, a prominent carbon source of Mtb 
in vivo (34), was predicted to produce four molecules each of acetyl- and propionyl-CoA 
(57, 71). In this case, the propionyl-CoA level would be much higher than the threshold 
to turn on MCC. This was recently demonstrated during macrophage infection (41). 
 An intriguing fact about Mtb is that the bacilli also possess a prpR paralog, 
ramB, whose protein product MtRamB is a transcriptional repressor of icl1 during 
dextrose utilization (148). Our experiments showed that MtRamB likely bound to 
succinyl-CoA, a TCA cycle intermediate. It is known that Mtb synthesizes succinyl-CoA 
from α-ketoglutarate (182) using both the KG dehydrogenase (KDH) (183, 184) and 
KG:ferrodoxin oxidoreductase (KOR) 
47
. We propose that an increased level of succinyl-
CoA may act as a permit for a temporary shutdown of glyoxylate shunt mediated by 
MtRamB. Furthermore, it was recently reported the detection of Icl1 lysine succinylation 
when Mtb was cultured in a rich medium with albumin-dextrose-catalase as the carbon 
source (185). The succinylation could potentially decrease the enzymatic activity of Icl1 
(185, 186). Taken together, it appears that an increased level of succinyl-CoA reduces 
the concentration of active icl1 at both the mRNA and the protein levels. Notably, 
succinyl-CoA is also produced during the breakdown of the C/D-ring of cholesterol. 
However, the MCC is enforced to be upregulated during cholesterol utilization 
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regardless of the presence of succinyl-CoA, indicating that the degradation and 
detoxification of propionyl-CoA is a higher priority for Mtb. 
II.4.2 The role of iron-sulfur cluster 
 A sequence based classification suggested that MtPrpR homologs form a distinct 
clade of the short-chain fatty acyl-CoA regulators (ScfRs) (150). MtPrpR contained an 
iron-sulfur cluster that was ligated by a featured C-X2-C-X4-C motif in the C-terminal 
region of the protein. The motif appears to be conserved among all MtPrpR homologs, 
which leads to the postulate that all members of this clade bind to the iron-sulfur cluster. 
We herein suggest the term iron-sulfur-dependent ScfR (IssR) for this clade of regulators 
in order to distinguish them from the other non-iron-sulfur ScfR clades (144, 181). We 
showed that without the iron-sulfur cluster, MtPrpR could not bind to CoA derivatives or 
activate MCC. This was supported by a recent Mtb transcriptome study (187). The 
transcription of prp operon showed strong positive correlation with the iron 
concentration (187). Since the cluster was extremely stable under air exposure, it is 
unlikely to respond to oxidation stress in the canonical manner. Stable iron-sulfur 
clusters have been previously reported in several proteins (188), among which a most 
well-studied case was the E. coli endonuclease III. The iron-sulfur cluster in 
endonuclease III is also completely ligated by cysteinyl sulfur. The cluster had been 
regarded as to serve structural role (189, 190) for more than a decade before the advent 
of DNA-mediated charge transport that demonstrated the cluster was to sense DNA 
lesion (191). Although MtPrpR does not seem to bear enzyme function, the role of the 
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iron-sulfur cluster is potentially not limited to structural. Its biochemical function 
remains to be learned. 
II.4.3 The protein folding of IssR in other proteins 
 Our structure of the MtPrpR represents a prototype of the IssR transcriptional 
regulators. Moreover, it shed light on the functions of other structurally related proteins. 
The 3D-folding of the combined DII-GAF di-domain was previously observed in the 
Deinococcus IrrE (146), a radiation responsive transcriptional regulator (192). So far no 
small molecule ligand has been reported to bind to IrrE. Notably, similar to the CoA 
binding cavity in the MtPrpR structure, IrrE structure shows a wide cleft between its 
proposed Zn-dependent metalloprotease domain (corresponding to DII in MtPrpR) and 
the GAF-like domain (Fig. 22a, b). Mutations in these domains sensitized the bacteria to 
irradiation. Implanting the structural information of MtPrpR into IrrE, it is likely that the 
cleft is the nest of a light sensing chromophore. Taken together, despite the sequence 
dissimilarity, the architecture of MtPrpR could be repurposed and may be widely used to 
harness different signaling pathways. 
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CHAPTER III 
 NATURAL PRODUCT MZ721 IS A POTENT PROTEASOME INHIBITOR 
 
 
III.1 Introduction 
III.1.1 The Ubiquitin-Proteasome Pathway 
For a very long time, intracellular proteins were largely believed to be long-lived 
and barely turned over, although the lysosome-dependent proteolysis could degrade a 
small portion of total proteins, typically exogenous proteins that are endocytosed into the 
cell (193, 194). This sacrosanct principle was barely challenged until the 1970s, when 
the ubiquitin-proteasome pathway was identified. In 1977, Etlinger and Goldberg 
observed that abnormal proteins containing valine and lysine analogs were degraded 
much faster than native proteins in rabbit reticulocytes and cell free systems. They also 
confirmed that the protein degradation was ATP-dependent (195). One year later, 
Ciechanover et al. fractionated the protein degradation system into a heat-stable fraction 
I and heat un-stable fraction II. Neither fraction had significant protein degradation 
activity. However, once they were combined, in the presence of ATP, the degradation 
system was restored (196). The heat-stable fraction I was therefore renamed ATP-
dependent proteolysis factor-1 (APF-1). APF-1 was later on confirmed to have the same 
identity as ubiquitin (197), which had been found earlier to covalently attached to the 
histone H2A protein (198), although the biological significance of this attachment was 
unknown. Ubiquitin is a 76-amino-acid polypeptide whose C-terminal carboxyl group 
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could be covalently conjugated to protein lysine residues via an isopeptide bond (198, 
199). Studies focusing on the fraction II further identified an ATP-dependent cascade 
including E1-E2- E3 ligases that conjugate ubiquitin molecules to the target proteins 
(199-203). In fraction II, there was another ATP-dependent component which exhibited 
protease activity, and it was later known as the 26S proteasome (204-210). The process 
of the ubiquitinated protein degradation is summarized in Fig. 38. Specifically, the C-
terminal carboxyl group of ubiquitin is first adenylated consuming an ATP molecule and 
forms an acyl-AMP. The phospho-carboxylic anhydride bond is then substituted by a 
thioester bond between the C-terminal carboxyl group of ubiquitin and a cysteinyl 
thiolate of the E1 ligase (199, 200, 202). The ubiquitin is then passed onto a cysteinyl 
residue of the E2 ligase to form the second thioester bond. This step does not consume 
ATP (203). The E3 ligase conjugates the ubiquitin from the E2 to the ε-amino groups of 
lysine residues of the target proteins, and this step is also ATP-independent (203, 205). 
Subsequent ubiquitinations occur through the Lys48-Gly76 isopeptide bond between 
two ubiquitin molecules (211). Proteins are successively ubiquinated to reach a 
minimum of tetraubiquitin for efficient proteasomal targeting (212). The poly-
ubiquitinated proteins will then be recognized by the proteasome 19S regulatory particle 
(19S RP, also termed 19S proteasome) in an ATP-dependent manner (213). The protein 
is then deubiquinated, unfolded and shuttled into the lumen of the proteasome 20S core 
particle (20S CP, also termed 20S proteasome), where they are degraded into peptides 
ranging from 3 to 25 amino acids (214, 215). 
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Figure 38. Schematic of the ubiquitin-proteasome system 
 
III.1.2 Structure and Function of Proteasome 
The 26S proteasome holoenzyme is a protease complex of approximately 2,000 
kDa (206-210). The holoenzyme consists of a cylindrical 20S CP with 19S RPs capping 
at each end (216). The 19S RP can be subdivided into a lid and a base. The lid is 
responsible for poly-ubiquitinated substrate recognition and ubiquitin removal. The base 
is attached to the CP (216), and contains multiple ATPases for ATP-dependent opening 
of the channel in the α-ring of the 20S proteasome. The target proteins are translocated 
into the CP for breakdown (217). The 20S CP is composed of two sets of 14 individual 
proteins stacked into four heptameric rings under the assembly of α7β7β7α7 (209, 218, 
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219). The eukaryotic 20S CP harbors three types of proteolytic activity on each β-ring, 
designated as postglutamyl-peptide hydrolyzing (PGPH, also termed caspase-like, C-L) 
activity for β1 subunits, trypsin-like (T-L) activity for β2 subunits, and chymotrypsin-
like (CT-L) activity for β5 subunits. They are named for their preferential cleavage sites 
immediately after acidic, basic, and hydrophobic residues respectively, resembling their 
serine protease counterparts (204, 219-222). Unlike serine proteases, all three active sites 
of the proteasome employ the hydroxyl group of N-terminal threonines (Thr1) as their 
catalytic nucleophile, likely because the secondary hydroxyl group of Thr1 allows for 
more efficient proteolysis than the primary alcohol group of serine (223). Serine 
proteases use the catalytic triad including serine, histidine and aspartate to catalyze the 
hydrolosis, whereas proteasomes use the catalytic diad consisting of the side chain 
hydroxyl group of the Thr1 and the N-terminal amine (Fig. 39). 
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Figure 39. Mechanism of proteolysis catalyzed by proteasome Thr 1 
Proteasome Thr1 is colored is black. Protein or peptide substrate is colored in 
orange. State I: the N-terminal amine abstracts the proton of the Thr1 side chain 
hydroxyl group, and generates the hydryoxylate nucleophile; State II: formation of 
the enzyme-substrate tetrahedral intermediate; State III: cleavage of the 
downstream peptide substrate, leaving the acyl-enzyme intermediate; State IV: 
hydrolysis of the acyl-enzyme intermediate and formation of the hydroxylated 
tetrahedral intermediate; State V: release of the upstream peptide substrate and 
regeneration of the free enzyme for another round of proteolysis. 
 
 
 
III.1.3 UPS Functions in Tumorigenesis 
Proteasome has been considered as an important anti-cancer drug target. 
Inhibition of proteasome kills multiple cancer cell lines and rescues mice from various 
tumors (224). The mechanisms of why tumor cells are more susceptible to proteasome 
inhibitors are not fully understood, but it has been well accepted that tumor cells have a 
faster compound uptake, and inhibiting the proteasome activity could arrest the cell 
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cycle and induce apoptosis (224). At cell cycle checkpoints, positive regulators such as 
cyclin proteins, and negative regulators, p27 and p21
WAF1/CIP1
, need to be degraded to 
drive the cell proliferation forward. Digestion of these proteins is executed by the 
proteasome (224-226). On the other hand, for apoptosis, the proteasome also plays the 
crucial role by activating the transcription factor NF-κB (Nuclear Factor-κB). NF-κB, a 
heterodimer consisting of p65 and RelA, is deactivated in normal situations by forming a 
complex with its inhibitory protein IκBα (Inhibitory κ-B chain α) via its p65 subunit 
(227-230). In tumor cells, extracellular stimuli such as TNF-α (Tumor Necrosis Factor 
α) trigger IκBα phosphorylation catalyzed by IκB kinases (IKKs). The phosphorylated 
IκBα (pIκBα) is a substrate of E3 ubiquitin ligase. pIκBα is poly-ubiquitinated for 
concomitant proteasome-dependent degradation (231-233). Therefore, by hydrolyzing 
IκBα, NF-κB is free from inhibition and exposes its nuclear localization signal peptide 
(234). NF-κB then migrates into the nucleus and acts as a transcription factor activating 
anti-apoptosis gene, primarily the gene encoding Bcl-2 (B-cell lymphoma-2) anti-
apoptotic protein. By inhibiting the proteasome, IκBα eludes proteolysis, preventing NF-
κB from being activated (235-237). 
The site specific inhibitors of the proteasome have shown distinct cytotoxicity 
profile in cancer and normal cells, thus revealing the importance of the individual active 
site. CT-L activity was proposed to be rate-limiting for protein degradation, and its 
inactivation caused severe growth deficiency in a yeast model (238).  
 
 
  
115 
 
III.1.4 Proteasome Inhibitors 
There have been numerous proteasome inhibitors identified, which were either 
extracted from natural sources or chemically synthesized in the laboratory. Most 
proteasome inhibitors form covalent adduct with the side chain hydroxyl group of the 
Thr1. The reactive moieties of the inhibitors are known as the warheads. The common 
warheads include aldehyde (i.e. MG132, fellutamide B), boronate (i.e. bortezomib), α, β-
epoxyketone (i.e. epoxomicin, carfilzomib), β-lactone (i.e. lactacystin (needs to be 
activated), salinosporamide A), and Michael acceptors including vinyl sulfone and enone 
(also termed α, β-unsaturated carbonyl, i.e. Syringolin A, Glidobactin) (224) (Fig. 40, 
41).  
One of the early proteasome inhibitors, MG132, a tripeptide aldehyde 
synthesized by MyoGenics (MG, later renamed to ProScript, PS) (239), is now widely 
used in research. MG132 attacks all three active sites by mimicking the acyl-enzyme 
transition state. MG132 preferentially blocks the CT-L site with high affinity (Ki=4 nM) 
(240). However, there are several drawbacks for these aldehyde containing inhibitors to 
become drugs. The aldehyde moiety can be easily oxidized to acid form and lose the 
activity. The hemiacetal formed with Thr 1 is readily reversible. The aldehyde can also 
be nucleophilically attacked by cysteine proteases and serine proteases, thus weak target 
specificity (241).  
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Figure 40. Major categories of covalent inhibitors and the corresponding adducts 
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Figure 41. Examples of the covalent proteasome inhibitors 
a and b, aldehyde; c, boronate; d and e, α’, β’-epoxyketone; f and g, β-lactone; h 
and i, α,β-unsaturated carbonyl; j, vinyl sulfone. Reactive moieties are colored red. 
 
 
A group of boronic acids was also synthesized (224), and one of these 
compounds, bortezomib (242) (PS-341, marketed as Velcade) is now widely used in 
cancer chemotherapy. Bortezomib has a target priority of CT-L > C-L >> T-L, with the 
CT-L most selective and T-L barely touched (240). Bortezomib targets the CT-L site 
with affinity comparable to MG132. The crystal structure of bortezomib with the yeast 
20S proteasome showed that the boronic acid moiety of the compound covalently 
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attached to the hydroxyl group of the catalytic Thr 1 of all active sites, possibly due to 
the high concentration of the inhibitor used for crystal soaking (243). It has also been 
reported that bortezomib inhibits NF-κB activation and induces caspase-dependent 
apoptosis in a variety of cell lines. Bortezomib exhibits a remarkable efficacy for 
treating multiple myeloma (MM) (237, 244-247). As a result, bortezomib became the 
first-in-class therapeutic proteasome inhibitor tested in humans (248, 249), and the first 
FDA approved drug targeting proteasome for treating MM (250). However, the 
compound causes a number of toxic side effects including fatigue, peripheral 
neuropathy, thrombocytopenia, and heart problems. 
(http://www.velcade.com/Treatment-with-velcade/Possible-side-effects) The toxicity 
was likely due to the promiscuous activity on other proteases.  
To reduce the toxicity, compounds displaying higher target specificity against the 
proteasome were exploited, and these include the α’,β’-epoxyketone peptides (241, 251). 
A natural product epoxomicin is a representative of this class, and it reacts primarily 
with the CT-L site. The crystal structure of the yeast 20S proteasome-epoxomicin 
complex revealed that besides forming an expected ether adduct between the Thr1 
hydroxyl group and the β’ carbon (Fig. 41), the epoxyketone moiety also unexpectedly 
formed a morpholino adduct with the hydroxyl and amino groups of Thr 1 (252) (Fig. 
41). Carfilzomib, a synthetic analog of epoxomicin that is more potent than bortezomib 
(253), was approved by the FDA in 2012 to treat MM patients that are resistant to 
bortezomib (http://www.cancer.gov/cancertopics/druginfo/fda-carfilzomib). Despite of 
the great efficacy of bortezomib and carfilzomib, only 25% response was seen for both 
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drugs as a single agent treating relapsed and refractory MMs.  These results indicated an 
innate or acquired resistance to the drugs has emerged (254). Since drug dosage 
currently is still empirically based on the patient population response, personalized, or 
precision, medicine is difficult to achieve (255), new drugs with higher therapeutic 
indeces are desirable. 
TMC-95A and its diastereomers TMC-95B, C and D are a series of natural cyclic 
tripeptides (Fig. 42) (256, 257). TMC-95 series specifically inhibit the proteasome rather 
than non-proteasomal proteases. The inhibition exhibited strong stereoselectivity. In 
particular, TMC-95A was more potent than TMC-95B, and TMC-95C and D had much 
weaker activity compared to the former two. TMC-95A showed high potency and 
versatility against all three active sites of the proteasome with IC50 values ranging from 
low to mid nanomolar (5.4 nM for CT-L site, 60 nM for C-L site, and 200 nM for T-L 
site) in the presence of 0.03% SDS (256, 257).  The crystal structure of TMC-95A with 
the yeast 20S proteasome revealed that the compound is a non-covalent inhibitor 
residing in the pockets of all three active sites (258). The high affinity binding is likely 
achieved by the constrained conformation of the cyclic peptide backbone and the 
formation of a host of hydrogen bonds between the inhibitor and the main chain atoms of 
the protein. The binding is entropically favored since it neither rearranged the ligand nor 
significantly changed the conformation of the protein (258, 259). Currently, the total 
synthesis of TMC-95A/B is available but not commercially practicable (260-262). Since 
TMC-95A is such an informative lead compound and a promising anti-tumor candidate, 
modifications have been made based on the cyclic backbone scaffold. However, the total 
  
120 
 
synthesis of TMC-95A was so challenging that it hindered the structure-activity 
relationship (SAR) studies. As a result, simple chemical modifications were only 
incorporated during the final steps of the synthesis, particularly around the P1 position 
(R1 group in Table 4) (262-264). Therefore, the diversity of the compounds was very 
limited. To simplify the synthesis, especially the Suzuki coupling reaction to form the 
biaryl linkage, biphenyl ether linkage was instead used to cyclize the backbone (259, 
265). Although in this case, the P1 and P3 sites were able to be modified with higher 
diversity (R1 and R2 in Table 5), the potency of the modified compounds dramatically 
decreased. This loss of potency could be attributed to the lower rigidity of the biphenyl 
ether bond than the biaryl clamp (265). So far, none of the TMC-95A synthetic 
derivatives improved the potency against the three catalytic sites (Tables 4 and 5) (262-
268). 
 
 
Figure 42. Structures of TMC-95A—D, adapted from (269) with permission 
Copyright (2004) National Academy of Sciences.
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Table 4. Structure-activity relationship of TMC-95A based on previous literatures 
 
Compound R1 R2 R3 R4 R5 R6 
Ki or IC50 for CTL, TL, PGPH 
(nM) 
TMC-95A 
 
OH OH 
 
OH 
 
5.4; 200; 60 (256) 
1.1; 800; 29 (262) 
1  OH OH 
 
OH 
 
1.9; 1,200; 23 (262) 
2  OH OH 
 
OH 
 
24; 13,000; 110 (262) 
3  H H 
 
 
 
8,000; 106,000; 7,400 (263) 
2,400; 55,000; N/A (264) 
550; 150; 90,000 (266) 
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Table 4. Continued 
Compound R1 R2 R3 R4 R5 R6 
Ki or IC50 for CTL, TL, PGPH 
(nM) 
4 
 
H H 
  
 
9,100; 60,000; N/A (264) 
5 
 
H H 
  
 
2,400; 22,000; N/A (266) 
N/A: ≥ 2,000,000 
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Table 5. Structure-activity relationship of a backbone modified TMC-95A analog 
 
Compounds R1 R2 R3 R4 Ki or IC50 for CTL, TL, PGPH (nM) 
1  
 
NO2 
 
5,500; 74,000; ≥ 2,000,000 (265) 
2 
  
NO2 
 
65,000; ≥ 2,000,000; ≥ 2,000,000 (265) 
3 
  
NH2 
 
N/R (267) 
4 
  
NO2 
 
N/R (267) 
5 
  
NH2 
 
N/R (267) 
N/R: not reported.
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In this study, we identified a natural product from the fungus Auxarthron 
umbrinum (originally named strain F01804) that could strongly inhibit the 20S 
proteasome. The compound has a [M+H]
+
 m/z value of 721.33 in ESI positive mode 
mass spectrometry (tentatively named Mz721). The crystal structure of yeast 20S 
proteasome in complex with Mz721 showed that Mz721 possesses a peptide backbone 
that was cyclized via a biaryl linkage similar to TMC-95 series. The major difference 
between Mz721 and the TMC-95 series was at the P3 position, where Mz721 had a 
longer side chain. By comparing the proteasome-Mz721 complex structure with the 
published proteasome-TMC-95A structure, we found some alterations of hydrogen 
bonds between Mz721 and the protein active sites. In vitro bioactivity assays showed 
that Mz721 preferentially inhibits the T-L activity with below five nanomolar IC50. 
Mz721 exerts markedly lower cytotoxicity than TMC-95A and bortezomib on human 
dermal fibroblasts (HDF). The discovery of this new natural product is highly significant 
in that the inhibitor has a potentially larger therapeutic window, and the unique 
modification at P3 position is informative in guiding the synthesis of more potent and 
active site-selective analogs. 
 
III.2 Materials and methods 
III.2.1 Proteasome inhibitors and fungal strain acquisition 
A high-throughput screening against a library of 105,500 crude extracts to look 
for proteasome inhibitors was previously performed by the scientists in the 
biotechnology company Cetek Corporation in Marlborough, Massachusetts. 
  
125 
 
Fungal strain with the code name F01804 showed up as a hit, and was isolated by the 
scientists at the Cetek Corporation and had been identified to produce secondary 
metabolites that inhibited the 20S proteasome. When Cetek was closed, Ohr 
Pharmaceuticals acquired the assets of Cetek and licensed the intellectual property 
around some bioactive metabolites to Texas A&M University (AgriLife Research) for 
possible development. Small amount of the metabolites were semi-purified and were 
predicted to be structural analogs of the known proteasome inhibitor TMC-95 series 
(256, 257). Before that research was completed, Ohr Pharmaceuticals sold the natural 
product assets of Cetek to Dow AgroSciences LLC, and the fungal strain was acquired 
for metabolite production purposes under a material transfer agreement (MTA) 
negotiated with Dow AgroSciences. 
Since a major metabolite showed a mass to charge ratio of 721, it was tentatively 
named Mz721 during the following research. 
 
III.2.2 Taxonomy, strain identification 
The mycelial suspensions of the F01804 was inoculated into a 200 ml erlenmeyer 
flask containing 30 ml PYG medium (0.125 % (w/v) of soybean peptone, 0.125 % (w/v) 
of yeast extract, and 0.5 % (w/v) of dextrose) with or without 0.4 % of calcium 
carbonate to neutralize the produced acids during growth. The culture was incubated at 
26 ° C for one week with gentle shaking at < 100 rpm. 
An estimate of three grams of the fungus was collected by centrifuging at 2,000 
rpm for 20 min. The medium was aspirated. The pellet was washed with 20 mM Tris-
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HCl pH 7.5, transferred into a sterilized mortar, and flash frozen with liquid nitrogen. 
The fungus was ground into powder with a sterilized pestle to disrupt the cell wall and 
membrane. The powder was resuspended with 10 ml of the buffer containing 50 mM 
Tris-HCl pH 7.5, 10 mM EDTA, 0.3 % SDS, and the cell debris was pelleted by 
centrifugation. The supernatant was transferred to clean tube for genomic DNA 
extraction. 
The genomic DNA extraction of F01804 followed a general protein denaturation 
and DNA precipitation procedure (270). Basically, 600 µl of the above supernatant was 
mixed with 200 µl of 5 M NaCl. 160 µl of CTAB solution was preheated at 65 °C and 
added to the above mixture. After that, one volume of 24:1 chloroform/isoamyl alcohol 
solution was added and vigorously mixed. The mixture was centrifuged at 13,000 rpm 
for 5 min to separate the phase. About 900 µl of the upper aqueous phase was transferred 
to a fresh tube and the extraction was repeated again. About 800 µl of the aqueous phase 
was transferred to a fresh tube and 560 µl of isopropyl alcohol was added to precipitate 
the genomic DNA. The tube was placed at 4 °C for five minutes to accelerate the 
precipitation procedure. The DNA was pelleted by centrifugation at 13,000 rpm for 10 
min. The solution was aspirated and the DNA pellet was washed with 1 ml of 70 % 
ethanol and centrifuged again. The supernatant was removed and the DNA was air dried. 
50 µl of DNase free pure water was used to dissolve the DNA pellet. 
Around 40 ng/µl final concentration of the extracted genomic DNA was used as 
the template for PCR reactions. The fungal conserved primers were used (listed in Table 
6) to amplify the ribosomal DNA (rDNA). Primers 5.8SR+LR7 and LROR+LR7 were 
  
127 
 
used to amplify the large subunit (LSU) 28S rDNA and the PCR products were 
sequenced with LROR, LR3R, LR6 and LR7. The sequencing results were compared 
against the sequences from the type material of the Targeted Loci Nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=T
argLociBlast), a curated database, to find the genus information. To obtain more 
information of the species, the 28s rDNA sequence was also compared with the entire 
GenBank database 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearc
h&LINK_LOC=blasthome) to potentially find more hits with higher matching scores. 
Phylogenetic trees were generated in NCBI BLAST tree view based on the BLAST 
results. The 28S rDNA sequences of the representative organisms were retrieved from 
GenBank and a customized phylogenetic tree was generated using the  Phylogeny.fr 
(271, 272) http://www.phylogeny.fr/. 
 
Table 6. Fungal 28S universal primers used in this research 
Primer name Sequence 
5.8SR 5’-TCGATGAAGAACGCAGCG-3’ 
LROR 5’-ACCCGCTGAACTTAAGC-3’ 
LR3R 5’-GTCTTGAAACACGGACC-3’ 
LR5 5’-TCCTGAGGGAAACTTCG-3’ 
LR16 5’-TTCCACCCAAACACTCG-3’ 
LR6 5’-CGCCAGTTCTGCTTACC-3’ 
LR7 5’-TACTACCACCAAGATCT-3’ 
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III.2.3 Fermentation 
Secondary metabolites production from fungal strain F01804 was undertaken 
using solid state fermentation. Brown rice was used as the solid substrate, and a broth 
solution composed of yeast extract (0.2 % (w/v)), glucose (0.2 % (w/v)) and tryptonized 
casein (0.2 % (w/v)) was added into a 100 ml bottle prior to autoclaving at a ratio of 6 g 
brown rice and 20 mL of broth. Mycelial suspensions of the fungus were inoculated onto 
the rice medium and incubated at room temperature for 4 to 10 weeks. 
 
III.2.4 Natural product extraction and purification 
Each bottle of the rice medium with F01804 growing was mixed with 15 ml of 
methanol, acetone or ethyl acetate and was left static for an overnight extraction. Since 
acetone gave the best extraction results with respect of the yield and initial purity, it was 
used for later batches of the extractions. The extracts were passed through a filter paper 
to remove the rice and insoluble materials in the solvents prior to evaporating the 
solvents in a centrifugal evaporator (Genevac Ltd.) or a rotary evaporator. The dried 
materials were redissolved in a smaller volume of dimethylformamide for preparative 
HPLC purification using (see below for details). The target compound in the HPLC 
fractions was tracked with both the analytical HPLC-mass spectrometry (LC-MS) signal 
(see below for details) and the yeast 20S proteasome bioactivity (see below for details). 
The fractions containing the bioactive metabolites were pooled and lyophilized. 
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III.2.5 HPLC and mass spectrometry 
For the preparative HPLC experiment, one milliliter of crude extract was injected 
into a Kromasil 100-5-C18 column 150 × 21.2 mm and was separated on a PerSeptive 
Biosystem BioCad HPLC by a mobile phase gradient elution of water (A) and 
acetonitrile (B) both acidified with 0.1% formic acid at a flow rate of 20 ml/min. The 
gradient was performed starting from 5-10% B over the first 3 min, followed by 10-35% 
B from 3 to 15 min, and 35-100% from 15 to 18 min. 10 ml per fraction was collected 
using an ADVANTEC SF-3120 fraction collector. 
For the analytical HPLC, 30 µl of the sample was injected into a 
PrincetonSPHER-100 C18 50 × 4.6 mm column and was separated on a Shimadzu 
Prominence HPLC System by a mobile phase gradient elution of  water (A) and 
acetonitrile (B) both acidified with 0.1% formic acid at a flow rate of 1.2 ml/min. For 
initial analysis of the crude extraction, a steep gradient of 5% to 95% B over 5 min was 
performed (Method I). For further analysis, a slower gradient was used starting from 0% 
to 20% B over the first 2 min, and 20% to 50% B from 2 min to 8 min (Method II). For 
mass spectrometry analysis, the A Shimadzu LCMS-2010 EV with an electrospray 
ionization system was operated in positive mode. 
 
III.2.6 Yeast and human cell line 
Saccharomyces cerevisiae strain MBY1202 was provided as a courtesy from Dr. 
Mary Bryk’s lab. Human cell lines were purchased from ATCC, Manassas, Virginia. 
Chemical sources are indicated in the context. 
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III.2.7 Yeast 20S proteasome Cloning, Protein Purification and Crystallography 
The yeast 20S proteasome was chosen as the model to elucidate the structural 
basis of inhibition. The yeast strain MBY1327 expressing a protein-A (ProA) tag fused 
proteasome was cloned by a former lab member Michael Schneider. Briefly, a ProA tag 
was cloned to the C-terminus of the PUP1 (β 2) subunit linked by a tobacco etch virus 
(TEV) protease cleavage site as described previously (273). The modified yeast strain 
was cultivated in YPDt media (1 % yeast extract, 2 % peptone, 2 % dextrose, 0.4 mM 
tryptophan) because the parental strain MBY1202 was tryptophan auxotroph. 
The yeast 20S proteasome was purified with IgG resin (GE healthcare) and was 
polished with the size exclusion chromatography (SEC) HiPrep Sephacryl S-500 HR 
column (GE healthcare) as described previously (273). The purified recombinant 20S 
proteasome was concentrated for the biochemical assays (1 mg/ml stock) and the 
crystallographic studies (30 mg/ml). The crystallization conditions were slightly 
modified around the reported condition (243) 28 mM Mg(CH3COO)2, 100 mM MES pH 
7.2, and 10% 2-methyl-2,4-pentanediol (MPD). The proteasome and the crystallization 
buffer were mixed in a 1:1 or 2:1 ratio for the hanging drop vapor diffusion 
crystallization. Rod shaped crystals appeared after 2 days at 16 ˚C. The proteasome 
crystals were then soaked for 3 h with Mz721 dissolved in the crystallization condition 
to a final concentration of around 1 mM to obtain the protein-inhibitor complex. Crystals 
were picked up and soaked into the cryoprotectant (20 mM Mg(CH3COO)2, 100 mM 
MES pH6.9, 30% MPD) before being flash frozen in the liquid nitrogen.  
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III.2.8 X-ray diffraction data collection and processing 
The crystals were shipped to the synchrotron beamlines 19-ID or 23-ID of the 
Advanced Photon Source (Argonne National Laboratory, Illinois). X-ray diffraction data 
were collected using the oscillation method at the wavelength of 0.97949 Å. 
The 20S proteasome crystal was diffracted to an overall resolution of  2.8Å. X-ray 
intensity evaluation and data reduction were performed with HKL2000 (155). The 
crystal unit cell was isomorphous to the reported yeast 20S proteasome structures (219, 
243, 258). Therefore, an isomorphous replacement was performed by omitting the ligand 
from the template model, randomizing the b-factors of the protein atoms and performing 
the simulated annealing (163). The Mz721 compound geometry library file was 
generated by modifying the TMC-95A in JLigand (274) and in PHENIX.elbow (163) by 
providing a modified TMC-95A atomic coordinates. Mz721 was manually placed into 
the electron density in Coot. Structure refinement was performed in PHENIX.refine or 
Refmac5 and rounds of manual refinement were performed in Coot (157, 275, 276). 
Data collection and refinement statistics were listed in Table 2. 
The structure was analyzed and the figures were generated using UCSF Chimera 
(166).  
 
III.2.9 Yeast Proteasome Bioactivity Assay 
Bioactivity of Mz721 was tested with the purified recombinant yeast 20S 
proteasome. The substrates used for the three active sites were succinyl-Leu-Leu-Val-
Tyr-AMC (Suc-LLVY-AMC) for CT-L activity, aceto-Arg-Leu-Arg-AMC (Ac-RLR-
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AMC) for T-L activity, and carboxybenzyl- Leu-Leu-Glu-AMC (Z-LLE-AMC) for post-
glutamyl peptidyl hydrolase activity (all substrate were purchased from Boston 
Biochem). The Km values for the three substrates were determined in the buffer 
containing 50 mM Tris-HCl pH 7.4, 1 mM EDTA. Yeast 20S proteasome was used at a 
final concentration of 2 nM, and the substrates were serially diluted. Km value for Suc-
LLVY-AMC substrate was approximately 50 µM, and for the other two substrates were 
around 100 µM. 
The inhibition assays were performed in 384-well microtiter plates (Greiner) at a 
total volume of 50 μl/well containing 29 μl assay buffer (50mM Tris-HCl pH 7.4, 1 mM 
EDTA), 10 μl yeast 20S proteasome (2 nM final concentration), 10 μL of the peptide 
mimic substrates (100 μM final concentration), and 1 μl DMSO or inhibitors (dissolved 
in 100% DMSO). Bortezomib was used as the control inhibitor if indicated in this assay 
at concentrations ranging from 100 nM to 0.78 nM by serial dilutions. DMSO was kept 
at 2 % throughout the assay. A time-course fluorescence intensity of the AMC cleavage 
was measured by exciting at 380 nm and recorded at 460 nM with a microtiter plate 
reader (Omega). 
 
III.2.10 Cell Culture and Treatments 
Mz721 was tested on multiple tumor cell lines to assess the activity and 
specificity. Four tumor cell lines, MOLT-4 (leukemia), OVCAR-8 (ovarian cancer), 
Toledo (lymphoma), and SNU-398 (liver cancer), were selected for this batch of tests. 
The cells were cultivated at 37 ˚C in RPMI-1640 medium supplemented with 10% fetal 
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calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. During treatment, the 
cells were grown to optimal drug-test density (9×10
4
 cells/ml for MOLT4, 2.5×10
4
 
cells/ml for OVCAR-8, 6.4×10
4
 cells for 2631, and 3×10
4
 cells/ml for SNU-398), and 
aliquoted into a 384-well microtiter plate in triplicates. Mz721 was added in 2-fold serial 
dilutions ranging from 20 µM to 2.4 nM. The cells were incubated with the compound at 
37 ˚C. Resazurin, a dye measuring aerobic respiration and commonly used as an 
indicator of cell viability, was applied 2 days after the compound treatment. The plate 
was read on a microtiter plate reader 24 h after the addition of the dye. The intensity of 
the fluorescence at 590 nm is proportional to the number of live cells. IC50 values were 
calculated accordingly. Doxorubicin, a DNA intercalating agent and an anti-cancer drug, 
was set in 2-fold serial dilutions from 10 µM to 0.3125 µM as a control compound 
throughout the experiment. Mz721 was also tested upon human dermal fibroblasts 
(HDF) to assess the cytotoxicity against normal cells. 
 
III.3 Results 
III.3.1 Identification and taxonomy study of the fungal strain F01804 
Mz721 was a hit originated from a high throughput capillary electrophoresis 
screening against a library containing 105,500 crude extract samples. The crude extract 
was then tracked back to a fungal strain with the code name F01804. The genomic DNA 
of F01804 was extracted and its 28s ribosomal DNA (rDNA) was amplified and 
sequenced. A sequence alignment against the curated database of fungal 28s rDNA at 
the National Center for Biotechnology Information (NCBI) suggested that it was closest 
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to the genus of Auxarthron (Fig. 43). The hit with the highest score (A. californiense) 
showed a sequence identity of approximately 97%. In order to potentially obtain more 
taxonomic information, the sequence was tentatively searched against the GenBank at 
NCBI which includes many more entries although about 20% of the fungal sequences in 
GenBank were potentially misannotated (277). The query sequence was 100% covered 
and 100% matched to A. umbrinum (Fig. 44), in agreement in the genus annotation with 
the preceding search against the curated database. Therefore, we are more confident to 
conclude that the fungal strain F01804 belongs to Auxarthon spp. 
 According to the previous owner of the fungus and metabolites assets, the novel 
proteasome inhibitors produced by F01804 were presumably analogs of the TMC-95 
series. Recall that the TMC-95 series was produced by Apiospora montagnei (256). 
Although causing confusion, the same fungi species could have multiple names 
describing their sexual morph and asexual morph. This also applies to A. montagnei, 
whose asexual morph is Arthrinium arundinis according to (278) and the NCBI 
Taxonomy Browser (https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi). 
We compared the 28s rDNA sequences between A. arundinis and our target fungal strain 
Auxarthon spp. F01804. The identity between the partial 28s rDNA sequences was only 
78 %. As references, some other fungal representatives from the previous searches were 
included in Fig. 45. Clearly, the genetic relationship between F01804 and A. arundinis 
was farther than that between F01804 and the farthest hit in the preceding searches in 
Fig. 43 and Fig. 44. The results indicated that the biosynthetic pathway of TMC-95 
analogs may exist in many genera. 
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Figure 43. Taxonomy study of fungal strain F01804 (Part 1)  
A phylogenetic tree of the hits from a search against a curated database of the 
targeted loci of the fungal 28s rDNA in NCBI. Some farther related genera were 
collapsed. The target fungus was highlighted in yellow. Green shades represent the 
sequences from type material (type material is the taxonomic device that ties 
formal names to the physical specimens that serve as exemplars for the species) 
(279). 
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Figure 44. Taxonomy study of fungal strain F01804 (Part 2) 
A phylogenetic tree of the hits from a search against an uncurated database of the 
GenBank in NCBI. Some farther related genera were collapsed. The target fungus 
was highlighted in yellow. Green shades represent the sequences from type 
material. 
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Figure 45. Taxonomy study of fungal strain F01804 (Part 3) 
A phylogenetic tree of the target sequence (blue) and some representative sequences 
including A. arundinis (A. montagnei, magenta), the fungal strain that produced 
TMC-95 series of compounds. 
 
III.3.2 Fermentation and extraction of the novel secondary metabolites 
After identifying the fungal strain F01804 as A. umbrinum, we sought to confirm 
that it could produce the desired secondary metabolites which inhibit the 20S 
proteasome. Upon receiving the materials from Ohr Pharmaceuticals, we were informed 
that a particular metabolite of interest had a [M+H]
+
 m/z value of 721 (designated 
Mz721), and a vial containing the purified fraction of Mz721was included in the assets. 
We assessed the quality of Mz721. The purity was around 90 % assuming the major UV 
absorption peak was Mz721 (Fig. 46a), which was very probable because the peak 
showed a clean [M+H]
+
 molecular ion peak of 721.30 on the mass spectrometry (Fig. 
46b). High resolution mass spectrometry showed that the accurate m/z value to the 
second decimal was 721.33 (Fig. 46c), and a clear isotopic pattern was observed. The 
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group of peaks centered at 725.0618 came from the residual contamination on the 
column, which was also observed in blank runs before sample injection (data not 
shown). Therefore, we used the purified fraction as the standard to track our 
fermentation extract using a combination of HPLC-MS and the bioactivity again the CT-
L site of the yeast 20S proteasome. The production of the metabolites was assessed in 
different time points from four to ten weeks post inoculation. The production of Mz721 
started to appear after about five weeks and accumulated. We initially used fungus 
grown for five weeks to evaluate three different extraction solvents, including methanol, 
acetone and ethyl acetate. While the total extraction efficiency of the Mz721 was similar, 
acetone seemed to extract less unwanted metabolites (Fig. 47). Therefore, we used 
acetone for a larger scale extraction of F01804 grown for ten weeks. 
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Figure 46. HPLC-MS of the Mz721 standard fraction 
a, The UV chromatogram of Mz721 (280). The major peak with the retention time 
of 2.9 min (indicated by red arrowhead) corresponds to the Mz721. b, Mass 
spectrometry analysis of the center of the UV peak showed a clean molecular ion 
peak with the m/z value of 721. c, The high resolution mass spectrometry of Mz721 
showed the accurate m/z was equal to 721.33. 
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Figure 47. HPLC-MS of extraction with different solvents 
a, Methanol; b,  Acetone; c, Ethyl acetate. LC elution at 2.9 min was subjected to 
MS. (The highest peak at 2.8 min was not Mz721, but a mixture of [M/z]
+
 355 and 
409) 
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Figure 47. Continued. 
 
 
Since the total yield of Mz721 was still very low comparing to other extracted 
metabolites (much less than 1%), and was too dilute, the HPLC fractions had to be dried 
and redissolved in smaller volumes of DMSO for enzyme activity test. The bioactivity 
profile of the fractions indicated that there seemed to be more than one proteasome 
inhibitor (Fig. 48). The fractionation ended at Fraction 42, and the later elution was 
unfortunately not collected. High resolution mass spectrometry showed that the activity 
around Fraction 33 was likely because of Mz721 (Fig. 49), and Fraction 42 appears to 
contain another active compound probably with an [M/z]
+
 of 705 or 679 (Fig. 50). The 
mass spectrometry signal for Mz705 was stronger and more consistant than Mz679. We 
tentatively named it Mz705-mix for easier clarification throughout this research. 
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Nevertheless, we were not certain that the active ingredient was the Mz705, given that 
[M/z]
+
 of 679 happened to match TMC-95A. 
 
 
Figure 48. Inhibition profile of the preparative HPLC fractions 
The 1X dilution was too concentrated and all showed strong inhibition. 0.1X 
dilution suggested there were multiple proteasome inhibitory compounds which 
were not well-separated on the HPLC column. 
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Figure 49. LC-MS of Fraction 33 in Fig. 48 
The analytical HPLC of the Fraction 33 (280), and the high resolution mass 
spectrometry of the peak (281). 
 
 
 
Due to the low fermentation scale and the low abundance of the metabolites, we 
could not further enrich Mz721 or Mz705-mix. Therefore, we conducted the following 
crystallography and biochemical assays using either the standard sample obtained from 
Ohr Pharmaceuticals or the mixture after the crude purification.  
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Figure 50. LC-MS of Fraction 42 in Fig. 48 
Analytical HPLC (280) suggested the fraction still contains multiple components. 
The peak indicated by the arrow was subjected to MS. Mz705 was the most 
consistant peak in MS based on its detection in multiple time frames (represented 
by two here). 
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III.3.3 Mz721 preferentially inhibits the Trypsin-like activity of the yeast 20S proteasome 
Both Mz721 standard and Mz705-mix were tested against the three types of the 
catalytic sites of the yeast 20S proteasome. While most other known proteasome 
inhibitors, including TMC-95series, preferentially hit the CT-L activity, Mz721 showed 
more than ten-fold higher potency against the T-L activity than the CT-L activity (Fig. 
51a). In particular, the IC50 values for the T-L and CT-L activities were 3.2 and 46.8 nM, 
respectively. It had been reported previously that the addition of 0.03% SDS can activate 
the proteasome and also increase the apparent potency of an inhibitor. Therefore, the 
effect of SDS on the potency of Mz721 against CT-L activity was assessed, and the IC50 
decreased to 32.9 nM in the presence of SDS (Fig. 51b). The IC50 values of Mz721 and 
the TMC-95 series were listed in Table 7. 
The peak fraction containing Mz705-mix had an inhibition profile similar to the 
known inhibitors, and showed approximately three-fold higher potency for the CT-L 
sites than for the T-L sites (Fig. 52). 
Both Mz721 and Mz705-mix showed weakest potency against the PGPH site. 
Interestingly, both compounds activated the PGPH activity by around 50 % at low 
concentrations. This was not reported in the TMC-95 series of compounds, we do not 
know if similar effect was also observed. 
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Figure 51. Yeast 20S proteasome inhibition test of Mz721  
a. IC50 on the three active sites of the yeast 20S proteasome. b. The effect of SDS on 
the CT-L site 
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Table 7. Inhibitory activities of Mz721 and the TMC-95 series against CT-L, T-L 
and PGPH active sites of the 20S proteasome. 
(The data for TMC-95 series were reported in (256).) 
 
Compounds SDS 
IC50 (nM) 
CT-L T-L PGPH 
Mz721 
- 46.8 3.2 ~ 4,800
A
 
+ 32.9 N/A N/A 
TMC-95A 
- 12
B
 1,500
B
 6,700
B
 
+ 5.4
B
 200
B
 60
B
 
TMC-95B + 8.7
B
 490
B
 60
B
 
TMC-95C + 360
B
 14,000
B
 8,700
B
 
TMC-95D + 270
B
 9,300
B
 3,300
B
 
 
N/A: the activity was not assessed. 
A : the IC50 value was inaccurate because the data points could not be fit into a sigmoid 
curve. 
B: tested on human 20S proteasome 
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Figure 52. Yeast 20S proteasome inhibition profile of Mz705-mix 
 
III.3.4 Mz721 binds to the active sites of the 20S proteasome 
We employed X-ray crystallography to understand the high potency of Mz721 
against the T-L activity. The yeast 20S proteasome crystal was soaked with Mz721 to 
obtain the complex crystal. The crystal diffracted X-ray to an overall resolution of 
approximately 2.8Å. The crystal belonged to P21 space group, and the unit cell was 
isomorphous to the available structures of yeast 20S proteasome with a = 135.92, b = 
299.99, c = 143.63, β = 112.99 ° (data collection and refinement statistics are listed in 
Table 8). The electron density was well-defined for the protein and the compound. 
Mz721 bound to all three active sites similar to the structurally elucidated TMC-95A 
(258). The electron density of the catalytic Thr1 Oγ of all three active sites was clearly 
disconnected from the electron density of the inhibitors, indicating Mz721 was a non-
covalent inhibitor.  
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Table 8. Crystallography data collection and refinement statistics 
Data Collection Yeast 20S proteasome-Mz721 
Space Group P21 
Unit cell demensions 
a, b, c (Å) 
α, β, γ (°) 
 
a = 135.92, b = 299.99, c = 143.63 
90.00, 112.99, 90.00 
Wavelength (Å) 0.97949 
Resolution range (Å) * 
50.00-2.80 
(2.85-2.80) 
Unique reflections * 259,599 (13,021) 
Multiplicity * 4.3 (4.3) 
Completeness (%) * 99.8 (100.0) 
Rmerge * 0.098 (0.634) 
Rpim * 0.054 (0.347) 
I/σ (I) * 19.68 (2.76) 
Wilson B value (Å
2
) 56.59 
Refinement  
Resolution (Å) * 34.45-2.79 (2.86-2.79) 
Rwork/Rfree * 0.175/0.232 (0.29/0.38) 
No. of atoms 49,902 
Protein 49,586 
Ligand 313 
Solvent 3 
Mean B factors (Å
2
) 72.69 
Protein 72.77 
Ligand 60.71 
Solvent 55.55 
Rmsd bond length (Å) 0.009 
Rmsd bond angle (°) 1.40 
Clashscore 12.7 
Number of TLS groups 1 
Ramachandran plot (%) 
(favored/allowed/outliers) 
93.31/5.66/1.03 
Rotamer outliers (%) 0.11 
* Values in parentheses indicate highest-resolution bin. 
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When we tentatively built TMC-95A into the electron density of Mz721 at all 
three active sites, we noticed a major difference at the P3 position between the two 
inhibitors (Fig. 53a). Mz721 possesses a longer P3 side chain. Based on the 42 Da mass 
difference between TMC-95A ([M/z]
+ 
= 679, exact mass 678.26 Da) and Mz721, we 
suggest that the P3 site of Mz721 is an arginine substituting an asparagine in TMC-95A, 
and the arginine side chain could perfectly fit into the electron density. In addition, the 
calculated exact mass (721.33) also precisely matches the high-resolution mass 
spectrometry data (Fig. 46c, 54). 
Although peptide inhibitors commonly contain two to four residues to occupy the 
S1 to S4 substrate binding pockets, only the S1 and S3 pockets are practically used for 
inhibitor binding. This is because the S2 and S4 pockets face the lumen of the 
proteasome and do not form deep and well-structured pockets. The S1 pockets of all 
three active sites are solely formed by the catalytic subunits, while the S3 pockets are 
cooperatively formed by the catalytic subunits and the neighboring subunits. For 
example, the S1 pocket of the T-L site is formed by β2 subunit, and the S3 pocket is 
formed by β2 and β3 subunits. Notably, most of the known proteasome inhibitors, 
including the covalent ones bortezomib and epoxomicin and the non-covalent TMC-
95A, barely touch the β3 portion of the S3 sub-pocket (Fig. 53c) (243, 252, 258). 
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Figure 53. T-L site bound by Mz721 
a, The electron density of the ligand showed that there was a major difference at 
the P3 position between Mz721 and TMC-95A. b, The longer P3-Arg side chain 
interacted with β2-Gln22 and β3-Asp131. c, Comparison with the TMC-95A bound 
T-L site clearly showed that the P3-Arg induced the rotamer conformational 
change of β2-Gln22 and β3-Asp131. d, P3-Arg inserted deep into the S3 pocket and 
contacted with the S3 sub-pocket. 
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Figure 54. The comparison of TMC-95A with Mz721 
 
 
When scrutinizing the Mz721 binding mode, we found that the P3-arginine 
inserted deep into the S3 sub-pocket and interacted strongly with the acidic residues 
(Fig. 53c, d). Furthermore, the P3-arginine induced side chain conformational change of 
the β3 subunit (Fig. 53b, c). The β3-Asp131 in other structures (243, 252, 258) faced 
away from the inhibitors and could not form hydrogen bond with the P3 side chain, 
while in the Mz721-bound structure, β3-Asp131 rotated nearly 180 ° to interact with the 
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P3-arginine, and a very strong hydrogen bond with a bond length of around 2.2 Å was 
formed. In addition, the P3-arginine also forced β2-Gln22 to adopt another side-chain 
conformation to prevent steric clashes. The new rotamer resulted in the formation of an 
additional set of hydrogen bonds between β2-Gln22 and P3-arginine (2.6 Å), and 
between β2-Gln22 and the backbone ketoamide moiety (3.1 and 3.5 Å, respectively) of 
Mz721 (Fig. 53b). In the TMC-95A bound structure, the ketoamide moiety was 
proposed to have little contribution to the protein-inhibitor interactions (258). Since the 
other interactions between Mz721 and the proteasome T-L site were very similar to 
those between TMC-95A and the proteasome, we conclude that the unique interactions 
contributed by the P3-arginine gave rise to the high potency of Mz721 against the T-L 
activity. The interactions between the T-L site amino acid residues and Mz721 is 
illustrated in Fig. 55. 
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Figure 55. Mz721 forms a host of hydrogen bonds with the proteasome T-L active 
site 
The hydrogen bonds include those formed between the inhibitor and the protein 
main-chain atoms (a), and those formed between the inhibitor and the side-chain 
groups of the protein (b). 
 
 
In addition to the T-L activity, Mz721 also strongly inhibited the CT-L activity. 
Similar to that of the T-L site, CT-L site ligand binding pocket was also composed by 
two subunits, the β5 baring the catalytic Thr1 and β6 without catalytic role. The P3-
arginine did not form hydrogen bonds with the protein. Although the S3 sub-pocket of 
CT-L site was also very acidic, the distances between the protein residues and the P3-
arginine were all above 4 Å, indicating the interactions were likely electrostatic. In the 
TMC-95A-bound structure (258), the P3-Asn interacted with Asp145 and Ser149 of β6 
subunit with hydrogen bonds (Fig. 56a). However, in the Mz721-bound structure, the 
P3-Arg could not form these two hydrogen bonds. This potentially explains why 
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substitution of the P3 position of Mz721 decreased the potency of the inhibitor against 
CT-L activity by nearly one order of magnitude compared to TMC-95A. 
The PGPH activity was inhibited by Mz721 with an IC50 value in the low 
micromolar range without SDS supplementation into the assay buffer. This was in the 
same concentration range as the TMC-95A. In both TMC-95A-bound and Mz721-bound 
proteasome structures, only the protein backbone of the PGPH site formed hydrogen 
bonds with the inhibitors. Because major interactions between TMC-95A and the protein 
are conserved among all three active sites, the weak inhibition of TMC-95A against 
PGPH site was previously ascribed to the P3 asparagine side chain which might not be 
optimal for PGPH site binding pocket (258). We noticed that the P3 arginine of Mz721 
is also not optimal. P3-arginine induced a partial conformational change of β2-His114. 
Around 50% of the β2-His114 in the whole protein population adopted an alternative 
conformation (Fig. 56b) as analyzed by the electron density map (data not shown). 
Notably, the S3 sub-pocket of PGPH site is more basic than those of the CT-L and T-L 
sites. This was largely because of the His114 residue, and it can cause some level of 
electrostatic repulsion between the positively charged guanidino group of P3-arginine 
and the positively charged imidazole group of His114 (Fig.56b).  
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Figure 56. Binding mode of Mz721 in CT-L and PGPH sites 
a, The Mz721 binding environment in CT-L site. The β5 subunit baring the CT-L 
activity is colored in orange. The β6 subunit contributing the S3 sub-pocket is 
colored in grey. Electrostatic surface for the S3 sub-pocket is shown. b, The Mz721 
binding environment in PGPH site. The β1 subunit baring the PGPH activity is 
colored in blue, and the β2 subunit which both contributes the S3 sub-pocket to the 
PGPH site and bares the T-L activity is colored in yellow. 
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We also soaked the crude Mz705-mix into the yeast 20S proteasome crystals and 
solved the structure. Electron density showed that Mz705 mix has a shorter P3 side chain 
when we placed Mz721 into the electron density map (Fig. 57). Combining its inhibition 
profile, it may possess an asparagine at the P3 position. More work is required to 
identify this potent compound. 
 
 
 
Figure 57. Electron density of Mz705-mix overlaid with Mz721 coordinates at the 
T-L site. 
The 2Fo-Fc (blue) and Fo-Fc (green) electron density maps of the Mz705-mix in 
complex with yeast 20S proteasome were shown in 1.5 σ and 3.0 σ, respectively. The 
coordinates of Mz721 (yellow and by elements) was overlaid with the electron 
density of Mz705-mix. Mz721 clearly possessed a longer P3 side chain. 
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III.3.5 Mz721 showed cytotoxicity on several cancer cell lines 
Mz721 was tested on four different tumor cell lines to assess its whole cell 
activity. Growth of SNU-398, a liver cancer cell line, and MOLT-4, a leukemia cell line, 
was inhibited by Mz721with IC50 values of around 15 and 22 µM, respectively (Fig. 
58a). While the growth of two other cell lines Toledo (also named CRL-2631), a 
lymphoma cell line, and OVCAR-8, an ovarian carcinoma cell line, were not affected by 
Mz721 under tested concentration range. These results suggest that certain cell lines are 
more susceptible to Mz721. The cytotoxicity of Mz721 against normal cells was tested 
on human dermal fibroblast. Mz721 was not toxic even treated at 50 μM (Fig.58b). 
TMC-95A, however, started to shown toxicity above 10 μM, and an IC50 of around 40 
µM. Although Mz721 showed less cytotoxicity in normal cells, its potency on the cancer 
cells, especially the drug-resistant cell lines, was not improved. We ascribe this mainly 
as the amino acid sequence differences of the β2 subunit between the human proteasome 
and the yeast proteasome. Although Mz721 showed high potency against the T-L site of 
the yeast proteasome, the amino acids β2-Gln22 and β3-Asp131 which formed unique 
interactions with the P3-arginine are not conserved in the human proteasome (Fig. 59). 
The amino acids at equivalent positions in human proteasome are glutamate and 
methionine, respectively. The latter may even clash with the P3-arginine. Another 
possibility for the reduced potency is that the positively charged guanidino group on the 
P3-arginine side chain may impair the compound uptake by the cells, resulting in low 
intracellular concentrations of the drug, and therefore lower cytotoxicity for both normal 
and cancer cells.  
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Figure 58. Effects of Mz721 on tumor cell lines and human dermal fibroblasts 
a, MOLT-4 (leukemia, red square), OVCAR-8 (ovarian cancer, green triangle), 
SNU-398 (liver cancer, purple diamond), Toledo (lymphoma, blue asterisk) were 
tested for Mz721 dose-response assay. MOLT-4 and SNU-398 showed response to 
Mz721, with the apparent IC50 values of approximately 25 and 15 μM respectively. 
b, Mz721 (red square), TMC-95A (blue diamond), bortezomib (green triangle) 
were tested against the HDF. The bortezomib curve was expanded five times along 
the concentration axis. Therefore, the concentrations of the data points for 
bortezomib are virtually one-fifth of the indicated concentrations. Bortezomib and 
TMC-95A are cytotoxic against the HDF with apparent IC50 values of 
approximately 3 and 40 μM respectively. 
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Figure 59. Sequence alignment of selected subunits between the yeast and human 
proteasome 
a, β2, T-L subunit. b, β3, the subunit that contributes the S3-subpocket to the T-L 
site. c, β5, CT-L subunit. d, β6, the subunit that contributes the S3-subpocket to the 
CT-L site. The interactions between the inhibitor and the main-chain atoms of the 
protein are indicated with blue triangles, and the interactions between the inhibitor 
and the side-chain groups of the proteins are indicated with yellow triangles. 
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III.4 Discussion 
In this study we report the discovery of a non-covalent proteasome inhibitor 
Mz721 that is naturally produced by the fungus strain A. umbrinum F01804. Moreover, 
the fungus seems to produce a series of the analogs that all inhibit the 20S proteasome 
with different selectivity. At least two compounds were observed or semi-purified in our 
studies. Mz721 showed superb potency against the T-L activity when tested on the 
purified yeast 20S proteasome, while Mz705-mix preferentially inhibits the CT-L 
activity. The crystal structure of Mz721 in complex with the yeast 20S proteasome 
revealed that the inhibitor interacts with the active sites via a host of hydrogen bonds. 
Similar to TMC-95A, most of these hydrogen bonds are formed between the inhibitor 
and the main-chain atoms of the protein. Given that the overall scaffold of the 
proteasome from different organisms are more or less identical, these cyclic peptides 
may potently inhibit proteasome regardless of the origin. A unique feature of Mz721 is 
that the molecule has a long P3 side chain, which protrudes deep into the S3 sub-pocket, 
particularly that of the T-L site, and specifically interacts with the amino acid side chains 
of the protein. Based on the electron density map and the precise molecular mass of 
Mz721, and the acidic environment of the S3 sub-pocket of T-L and CT-L sites, we 
propose that the amino acid in the P3 position of Mz721 is an arginine. The P3 position 
makes Mz721 a potent inhibitor of the T-L activity of the yeast 20S proteasome. 
Although TMC-95A has been chemically synthesized, the challenging total 
synthesis and the limited choice of the building blocks of the P1 position restricted the 
structure-activity relationship (SAR) studies. For the P3 site, only asparagine, valine and 
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leucine were tried without altering the cyclic peptide backbone, and the potency for the 
T-L site was not improved (256, 262-264, 266). In another study, the P3 site was 
changed to arginine but the biaryl linkage was also substituted by a biphenyl-ether 
linkage. Although this linkage was aimed to mimic the strained backbone conformation 
of TMC-95A and meanwhile simplify the synthesis, the potency of the inhibitor was also 
dramatically compromised (259, 266). This was either because the loss of backbone 
rigidity cost more entropy during binding, or because substituting the oxindole ring also 
removed the critical hydrogen bond between the carbonyl on the oxindole ring and the 
backbone NH of Gly23. Taken together, none of the modifications to date have 
improved the potency of TMC-95A against any of the three activities (Table 4, 5). Our 
studies of Mz721 proved the concept that in order to further potentiate the inhibitor 
against a particular active site, modification of the P3 position is a practical route. 
Moreover, the S3 sub-pocket contributed by the adjacent subunit should be utilized but 
with caution during inhibitor development because of the amino acid sequence 
differences between different organisms. In the Mz721 example, the P3-arginine 
strongly interacted with the β2-Gln22 and β3-Asp131. However, in the human 
proteasome, these residues are substituted by glutamate and methionine. This might be 
the part of the reason why the whole cell activity of Mz721 was not so impressive, 
although the charged side-chain of P3-arginine could also be a liability in drug uptake. 
Similar to the TMC-95 series compounds (258)(259)(258)(257), the (Z)-propyl-
1-enyl of the P1 position barely interacts with the reactive nucleophile of Thr1O
γ
 or 
other residues in the S1 pocket of all three active sites. So far, the (Z)-propyl-1-enyl 
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group has only been modified into propyl, (Z)-propyl-2-enyl, norleucine-NH2 and a 
longer ketomethylene containing group (262-264). Apart from (Z)-propyl-2-enyl 
substitution which showed similar potency to TMC-95A, the others all lost hundreds to 
thousands-fold of the potency especially against the CT-L site. These suggest that the 
double bond which stabilizes the P1 group is essential and should be maintained in 
future SAR studies. Notably, in the proteasome-TMC-95A complex structure reported in 
(258), the amide of the P1 position of TMC-95A adopted a cis configuration, which is 
rare in the natural peptide bonds except for proline. This may need re-examination. In 
the Mz721 bound structure, the amide adopted a more common trans configuration. 
In the enzyme activity assay, we observed that Mz721 below 1 µM enhanced 
PGPH activity (Fig. 51). It has been shown that CT-L site substrates allosterically 
activated PGPH activity (282). Since Mz721 is also a peptide which can mimic a 
substrate, it is likely that by binding to the CT-L site, Mz721 allosterically activates the 
PGPH site. In agreement with this hypothesis, our data showed that Mz721 started to 
exhibit inhibitory effect on PGPH site after CT-L activity is fully inhibited (Fig. 51). 
In summary, Mz721 is a potent proteasome inhibitor as well as an informative 
lead compound in guiding the design of cyclic peptide proteasome inhibitors. 
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CHAPTER IV  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
IV.1 MtPrpR and the MCC transcriptional regulation 
 MCC is a critical pathway of Mtb, even though its in vivo essentiality remains to 
be learned. We showed that MCC is transcriptionally regulated by MtPrpR through 
direct binding to CoA derivatives and an iron-sulfur cluster. There are several major 
questions to be answered in order to fully understand the regulatory mechanisms of 
MCC and potentially the glyoxylate shunt in Mtb. The questions and future directions 
are listed below. 
 
IV.1.1 Propionyl-CoA bound MtPrpR structure 
So far, we still do not know the actual structure of MtPrpR when it has 
propionyl-CoA bound, although our modeling suggested that the helix α1 is expected to 
move by approximately 15°. It will be very desirable to confirm this potential 
conformational change and to see what follows, particularly the positions of the HTH 
DNA-binding domains. We have already tried heterologous expression of the 
recombinant MtPrpR81-486 in E. coli using the M9-propionate media but did not see 
propionyl-CoA bound in the structure. One experiment that might be done in the future 
is to express MtPrpR in mycobacteria, i.e. M. smegmatis, a non-pathogenic fast growing 
surrogate of M. tuberculosis. However, there is another potential problem that may 
account for our current and future failure to visualize propionyl-CoA. The crystal 
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structure is a representation of the ensemble of proteins. If the vast majority of the 
protein molecules bind to CoA, the feature of propionyl-CoA will be averaged and thus 
may never be discerned. Moreover, we do not know whether all four chains in the 
MtPrpR tetramer bind to propionyl-CoA or only a subset bind, because physiologically 
it will be difficult for all four chains to bind propionyl-CoA simultaneously. Therefore, it 
is likely that the transcription can be activated when one or two subunits have propionyl-
CoA bound. This can bring severe homogeneity problem in crystal packing. So far, the 
main stream structural biology techniques cannot overcome this problem. Single particle 
CryoEM, for example, uses similar concept of classifying and averaging particles. 
Unless the conformational change is significant enough, it may not be visualized. In this 
case, it may be helpful to include the HTH domain to potentially see a more remarkable 
conformational change, and also introduce the recognition DNA to stabilize a potential 
propionyl-CoA bound protein. 
 
IV.1.2 MtPrpR tetramer mystery 
If the recognition operator of MtPrpR is a 17 bp DNA, why would MtPrpR be a 
tetramer? Typically, the tetrameric transcriptional regulators can bend DNA operators. 
However, this requires the operators being separated by hundreds of base pairs in order 
not to generate too much strain. Footprinting experiments may be carried out to confirm 
the DNA binding region. Although DNase I footprinting of MtPrpR-DNA complex has 
been reported before, the result was very ambiguous (135). In a tetrameric photoreceptor 
transcriptional regulator CarH structure, the four HTH domains followed an unusual 
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organization with three involved in binding to a 26-bp DNA segment and the fourth one 
was disordered (283). It will be interesting to see how the four HTH domains in MtPrpR 
arrange. Single particle CryoEM may be the technique to resort to especially if longer 
DNA fragment is required for protein binding, because long piece of DNA will make 
crystallization much more difficult. 
 
IV.1.3 Signaling molecules that may induce CoA derivative exchange 
Based on our experiences of MtPrpR, the protein binds to CoA with very high 
affinity, and we were not able to release CoA unless we destroyed the protein. This does 
not seem to be the case in vivo, because it will be very uneconomic not to recycle 
transcriptional regulators, especially for bacteria that survive in nutrient restricted 
environment. Ideally, there should be certain signal that can open the lid of the CoA 
binding pocket and allow CoA exchange. The signal may be related to the iron-sulfur 
cluster or MCC intermediates. It will be very challenging but of great significance to 
identify the factor required for CoA release so that MtPrpR could be manipulated. 
 
IV.2 Mz721 purification, identification and characterization 
 Mz721 potently inhibits the yeast 20S proteasome, particularly the T-L activity. 
The structure of the inhibitor has been proposed based on the high-resolution mass 
spectrometry data and its binding mode on the proteasome active sites. The structures of 
Mz721 and its analogs, including the TMC-95 series, are very unique, and it will be of 
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great value to identify its biosynthetic pathway and characterize the natural product 
assembly lines. The remaining questions and future directions are listed below. 
 
IV.2.1 Genome sequencing and mining of the biosynthetic pathways of Mz721 and 
analogs 
So far, we have identified the genus and species information of the fungus as A. 
umbrinum. However, apart from the rDNA region, the genome information of A. 
umbrinum is barely available. This complicates further investigation of the biosynthetic 
pathway of Mz721 and analogs. Thereby, the whole genome sequencing and the gene 
annotation of A. umbrinum need to be conducted. Provided that the whole genome of A. 
umbrinum was sequenced and annotated, we need to determine which genes should be 
targeted. Clearly, Mz721 and its analogs are peptide based natural products, but it is not 
clear whether they are ribosomal peptides (RP) or non-ribosomal peptides (NRP) just 
based on the structure. Both RP and NRP synthetic systems can produce peptides with 
extensive “posttranslational” modifications, and the same type of peptides could be 
synthesized using either system in different organisms (284). Although it will be 
extremely challenging to unravel the biosynthetic pathway of the natural products, the 
structure of Mz721 provides some information that may guide the genome mining. 
Typically, genes for both RP and NRP synthetic pathways are clustered. This 
prerequisite should simplify the search. The structure of Mz721 showed it is a tripeptide. 
However, it is likely that the precursor of Mz721 contains at least four amino acids Ile-
Tyr-Arg-Trp (Fig. 60), and the isoleucine is deaminated during Mz721 biosynthesis 
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(green shade). Therefore, we should anticipate a deaminase-encoding gene in the cluster. 
Mz721 contains a unique C-C biaryl linkage between the oxindole and phenol. This type 
of reactions during natural product syntheses involves cytochrome P450 monoxygenase, 
such as OxyC in vancomycin biosynthesis (285) and ComI in complestatin biosynthesis 
(286). Furthermore, the tryptophan residue is hyperoxidized (blue shades). The 3-
hydroxy 2-oxindole type of modification was also observed on several other natural 
products including maremycin A, welwitindolinone C, donaxaridine, etc (287). In the 
maremycin A, the 2-oxo group was added by MarE, a non-canonical tryptophan 
dioxygenase (TDO), which is a heme-containing enzyme (288). Although the 
modifications on the indole ring may be catalyzed by enzyme other than a dioxygenase, 
we may expect multiple metalloenzymes in the cluster such as cytochrome P450 
oxygenases. Mz721 also contains an n-propylene group ((Z)-propyl-1-enyl group, grey 
shade), which is potentially reduced from n-propyl. So we may expect an alkyl 
transferase and a reductase in the gene cluster. 
The NRP synthetic systems are pipelines containing different modules. A 
majority of NRPs contain D-amino acids, most of which are converted from L-amino 
acids by epimerase domains (E domain) in the synthetic modules (289). However, there 
is no D-amino acid in Mz721, which means if the compound is synthesized by NRP 
synthase, E domains are not expected in any modules of the synthetic pipeline. 
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Figure 60. Retro-biosynthesis analysis of Mz721 
The modification sites of Mz721 are shaded. Mz721 is first linearized and then the 
modifications are removed to potentially reveal its original amino acid sequence. 
The precursor is likely to contain Ile-Tyr-Arg-Trp tetrapeptide.  
 
 
IV.2.2 Mz721 extraction and purification 
If the identification of the biosynthetic pathway eventually becomes possible, the 
synthetic gene cluster may be cloned and overexpressed heterologously to improve the 
yield of the natural products. If that is not practical, the fungal growth condition needs to 
be optimized to enhance Mz721 production. In addition, the purification methods also 
need to be improved. For large scale purification, preparative HPLC may not be suitable 
for the initial steps of crude extract separation, provided that the percentage of Mz721 in 
the crude extract is extremely low. Therefore, separating the metabolites based on their 
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partition in different solvents can be used in the preliminary purification before the 
chromatography-based polishing purification. In addition, since Mz721 is likely to 
contain a positively charged arginine side chain, ion exchange chromatography may be 
used. 
 
IV.2.3 Mz721 accurate structure identification 
Natural product structure identification has always been a challenging task. So 
far, we do not have pure enough compound to perform NMR. If we were able to obtain 
sufficient amount of Mz721, we may purify the compound by crystallization, or even 
solve the structure using small molecule X-ray crystallography. X-ray diffraction (XRD) 
is a powerful technique in elucidating the structures of natural products, and in 
determining the absolute configuration of the chiral centers when a reference chiral 
center is available to solve the X-ray phase ambiguity (290). Fortunately, since we 
already know from the structure of proteasome-Mz721 complex that the amino acids in 
Mz721 are in L- form, these Cα chiral centers can serve as internal references for the rest 
of the chiral centers in the molecule. 
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